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ABSTRACT 
Most uncomplicated urinary tract infections (UTIs) are caused by uropathogenic 
Escherichia coli (UPEC). Both motility and adherence are integral to UTI pathogenesis, 
yet they represent opposing forces. Therefore it is logical to reciprocally regulate these 
functions. PapX, a non-structural protein encoded by the pheV- but not pheU-associated 
pap operon encoding the P fimbria adherence factor of E. coli CFT073, represses 
flagella-mediated motility and belongs to a highly conserved family of winged-helix 
transcription factors. Thus, when P fimbriae are synthesized for adherence, synthesis of 
flagella is repressed.  The mechanism of this repression, however, is not understood. 
papX is found preferentially in more virulent UPEC isolates, being significantly more 
prevalent in pyelonephritis strains (53% of isolates) than in asymptomatic bacteriuria 
(32%) or fecal/commensal (12.5%) strains.  To examine PapX structure-function, we 
generated papX linker-insertion and site-directed mutants, which identified two key 
residues for PapX function (Lys
54
 and Arg
127
) within domains predicted by modeling 
with I-TASSER software to be important for dimerization and DNA binding, 
respectively. SELEX in conjunction with high-throughput sequencing was utilized for the 
first time to determine the unique binding site for the bacterial transcription factor PapX 
in E. coli CFT073.  It was necessary to write and implement novel software for the 
analysis of the results from this technique.  The software, TFAST, is freely available 
(Appendix C) and has near-perfect agreement ( =
xii 
 
0.89) to a gold standard in peak-finding software, MACS.  Analysis of TFAST indicates 
that it correctly stratifies data to generate meaningful results, and successfully identified a 
29 bp binding site within the flhDC promoter 
(TTACGGTGAGTTATTTTAACTGTGCGCAA), centered 410 bp upstream of the flhD 
translational start site. PapX bound the flhD promoter in gel shift experiments, which was 
reversible with the 29 bp sequence, indicating that PapX binds directly to this site to 
repress transcription of flagellar genes. Microarray, qPCR and promoter fusions indicate 
that PapX is not transcriptionally regulated itself. Co-precipitation studies indicate that 
PapX likely requires at least one cofactor for its repressive activity, and OmpA was 
identified as a promising candidate. 
1 
 
CHAPTER 1 
INTRODUCTION 
 
Urinary tract infections 
The urinary tract consists of kidneys and ureters, referred to as the upper urinary 
tract, and bladder and urethra, referred to as the lower urinary tract. The kidneys filter 
blood and produce urine, which is transmitted via the ureters to the bladder. The bladder 
stores urine until it can be released from the body via the urethra [1]. Urinary tract 
infections (UTIs) occur when the upper or lower urinary tract is colonized by pathogenic 
bacteria, typically when a reservoir of a bacterial pathogen residing within the 
gastrointestinal tract [2-4] gains access to the urethra and ascends to the bladder [5]. 
Lower UTI, also called cystitis, is usually self-limiting [6] and rarely leads to severe 
complications. Upper UTI, also called pyelonephritis, attends greater severity and can 
lead to renal dysfunction, bacteremia or potentially fatal sepsis [7, 8]. Access of bacteria 
to the bloodstream is facilitated because there are only two layers of cells between the 
kidney tubules and host blood supply, the epithelial cells of the proximal tubule and the 
endothelial cells of the capillaries. UTI is a costly and potentially dangerous malady in 
the United States, associated with an estimated healthcare cost of $3.5 billion in 2000 [9] 
and 479,000 hospitalizations in 2006 [10]. 
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Clinical diagnosis of bacterial UTI is frequently based on signs, symptoms and 
analysis of urine. Symptoms of lower UTI may include urinary urgency and pain 
associated with voiding. However, UTI can be asymptomatic in certain patients, either 
due to impaired sensory apparatus or due to infection with a strain of bacteria that causes 
asymptomatic bacteriuria (ABU). Signs of lower UTI may include frequent urination and 
altered urine characteristics, such as odor, color, or visible texture due to presence of 
blood or high concentrations of bacteria [11]. The signs and symptoms of UTI can vary; 
therefore, diagnosis is often heavily dependent on urinalysis or urine culture, and a 
diagnosis of UTI can be made based on the presence of ≥103 bacteria/ml in a midstream 
clean-catch urine sample from a patient [7, 12]. The most common cause of upper UTI is 
lower UTI [5]. Upper UTI can present with all of the above signs, symptoms, and lab 
values, but additionally presents with flank pain or costovertebral tenderness, fever, 
chills, nausea and vomiting [13] as well as renal function impairment. 
Microscopically, urine from a patient with UTI may reveal leukocytes and 
bacteria. Renal tubular casts consisting of cellular debris and leukocytes are diagnostic 
for upper urinary tract involvement [14]. Other laboratory values may indicate reduced 
ability of the kidneys to concentrate urine and general systemic inflammatory markers, 
including elevated leukocytes in the bloodstream, elevated erythrocyte sedimentation 
rate, and elevated C-reactive protein [15]. Histological examination of the urinary tract 
during pyelonephritis may reveal polymorphonuclear leukocytes (PMNs, also called 
neutrophils) extending from the renal papillae to the cortex, tubules filled with PMNs, 
and necrosis of proximal tubular epithelial cells. Glomeruli are frequently spared, even 
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when renal inflammation is severe [16]. The infection may spread beyond the kidneys, 
and bacteremia develops secondarily in 12% of cases of pyelonephritis [7, 8]. 
Uncomplicated UTI occurs in the setting of a healthy, non-pregnant adult woman 
with no urinary tract abnormalities, such as anatomical defects, impaired immune 
function, presence of devices, or obstructions [5]. 75-95% of all uncomplicated urinary 
tract infections are caused by Escherichia coli, specifically uropathogenic E. coli (UPEC) 
[17-27]. UTI-causing bacteria are studied using a combination of basic microbial 
techniques, murine, primate and canid animal models [28], and epidemiological and 
molecular analysis of samples derived from patients. 
UPEC makes use of specialized virulence traits to cause UTI (Figure 1-1). Iron is 
scarce in the urinary tract [29], so UPEC encodes numerous iron receptors and has 
developed multiple strategies for mediating iron acquisition [30] by encoding iron 
salvage and sequestration systems such as hemophores ChuA and Hma [31] and 
siderophores such as aerobactin, enterobactin, and salmochelin [32]. Extracellular 
polysaccharides may confer serum resistance or resistance to phagocytosis [33, 34], and 
disruption in synthesis of O4, K54, and K2 antigens led to fitness defects relative to 
parental strains in a murine model of UTI [35-38]. UPEC may also encode secreted 
toxins. -hemolysin, encoded on the hly operon, causes enhanced damage and 
hemorrhaging in the uroepithelium and bladder, potentially liberating nutrients to expand 
UPEC’s environmental niche within the urinary tract [39-41]. A related protein, TosA, is 
found much more commonly in UPEC compared to commensal strains of E. coli, acts as 
an adhesin, and is associated with persistence during bacteremia [42, 43]. Cytotoxic 
necrotizing factor 1 (CNF1) mediates changes in the cytoskeleton of neutrophils [44] and  
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Figure 1-1. UPEC virulence factors. UPEC strains encode numerous virulence 
factors that contribute to urovirulence. Shown are examples of adherence organelles 
(Type 1, P, S, and F1C fimbriae), motility apparatus (flagella), toxins (Hly, CNF1, 
TosA), extracellular polysaccharides (O4/K54, K2) and iron acquisition systems (Hma, 
ChuA, IreA). Insets show TEM images of flagellated and fimbriated bacteria. 
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may reduce chemotaxis and antimicrobial activity in host phagocytes [44, 45].  Lateral 
gene transfer suggested by the existence of pathogenicity-associated islands (PAIs) 
suggests that many virulence traits may be shared, such as specific fimbriae, other 
adhesins, secreted toxins [46] and iron acquisition systems [47]. 
Ascension is the most common route of UTI [5]. To ascend, UPEC depends 
primarily on flagella [48-50], complex membrane-bound extracellular organelles that 
consist of a basal body, a hook, and a filament that propel the bacterium upwards through 
the urinary tract. UPEC strains unable to produce flagella are out-competed by parental 
strains in a mouse model of UTI [49, 50]. To resist being expelled from the urinary tract, 
bacteria are dependent on adherence. The presence of Type 1 fimbriae, which bind 
glycoproteins containing mannosides found in the lumen of the human urinary tract, is 
necessary for the development of UTI in a mouse model of infection [51-54]. P fimbriae 
are epidemiologically associated with UPEC strains relative to commensal strains [55, 
56], and bind the -D-Gal-(14)--D-Gal digalactoside moiety of the P blood group 
antigen, found on both erythrocytes [57] and uroepithelial cells [58]. 
Motility is the force that causes UPEC to move up the urinary tract, while 
adherence factors resist expulsion by the flow of urine. Thus, these forces should 
antagonize one another. Yet both are demonstrably important for urovirulence. Therefore, 
it would make sense that the expression of these features would be temporally 
coordinated during UTI. Biophotonic imaging studies indicate that flagellar expression is 
highly coordinated during UTI, with peak flagellar expression appearing during 
ascension of the ureters to the kidneys [59]. The plausibility of reciprocal control between 
these factors is underscored in work on Type 1 fimbria. When the genes for Type 1 
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fimbria are constitutively expressed, motility is greatly reduced, even if no functional 
Type 1 fimbria are produced on the surface of the bacterium [60]. The question of the 
underlying mechanisms mediating reciprocal control between the pathogenicity factors of 
motility and adherence in UPEC is central to understanding UPEC pathogenesis. 
 
Adherence 
UPEC strains can encode up to 15 epidemiologically and genetically distinct 
clusters of fimbriae, proteinaceous organelles primarily implicated in adherence; 
individual strains have been observed to encode up to 11 distinct fimbriae. Fimbriae 
project from the surface of bacteria and can be directly observed by transmission electron 
microscopy (Figure 1-1). Recent studies of fimbriae in UPEC support the model that 
adherence is an important component in UTI pathogenesis [61]. In these studies, the 
genomes of 303 E. coli strains were analyzed by multiplex PCR to assay for the presence 
of fimbrial operons. A bimodal distribution of fimbriae is encoded by uropathogenic and 
non-pathogenic E. coli: UPEC strains carry a high number and diverse array of fimbrial 
operons, whereas non-pathogenic E. coli tend to carry only a few. This suggests that 
acquiring or encoding a diverse array of fimbriae is an important characteristic of UPEC. 
Adherence is known to be important to prevent the flushing mechanism of voiding, and 
specific adherence organelles have been implicated in eliciting protective immune 
responses and are part of vaccine development [62, 63], highlighting their importance in 
the pathogenesis and study of uropathogenic bacteria. While UPEC strains can encode an 
array of distinct fimbriae, certain fimbriae have been identified as critical to the 
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development of a UTI. Among the best characterized fimbriae are P, Type 1, S and F1C 
fimbria. 
Early studies of fimbriae originated with examination of whole bacteria and their 
ability to agglutinate erythrocytes [64, 65]. Cross-linking of cells was used as a proxy for 
adherence, because bacteria binding to a given receptor should be able to bind to 
receptors expressed on the surface of multiple eukaryotic cells, bringing them into close 
proximity. Hemagglutination is still useful as a technique for assaying the phenotypic 
adherence properties of whole bacteria, as well as whole-cell agglutination and binding 
assays in general [56]. The use of different eukaryotic cells to assess adherence of 
bacteria is helpful in illuminating binding and substrate specificity [66-68]. In parallel to 
whole-cell phenotypic assays, electron microscopy techniques were employed to reveal 
the morphologic characteristics of adherent bacteria. Close examination of adherent 
bacteria revealed hair-like projections of cells, and the association of these extracellular 
structures, as well as the intuitive consistency that extracellular structures could be 
responsible for adherence, led investigators to posit that these structures, later identified 
as fimbria, were the factor mediating adherence of bacteria [69, 70]. 
The earliest virulence trait established for UPEC was P fimbria. In 1976, 
Svanborg-Eden et al. [56] made use of a whole-cell adherence assay with voided 
uroepithelial cells instead of erythrocytes, and discovered that pyelonephritis isolates of 
UPEC adhered to cells in greater numbers than did cystitis or fecal isolates. The 
adherence phenotype of those isolates was subsequently correlated with expression of 
fimbriae as assessed by transmission electron microscopy and hemagglutination [55]. 
These structures were ultimately designated P fimbriae because they adhered to the P 
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blood group antigen, common among most humans. Preparations of purified P fimbriae 
selectively adhered to uroepithelial cells [71] and mediated mannose-resistant 
hemagglutination (MRHA) of human type O erythrocytes [72]. Using erythrocytes, 
Svenson et al. [73] identified the receptor for P fimbria as the Gal(14)Gal moiety 
of the glycosphingolipid component of the P blood group antigen, a glycosphingolipid 
anchored in the cell membrane of erythrocytes and uroepithelial cells. Indeed, the free 
disaccharide is capable of inhibiting P fimbria from binding to its receptor on both 
erythrocytes [57] and uroepithelial cells [58]. In 1985, Uhlin et al. demonstrated that it 
was specifically the adhesive tip of P fimbria, PapG, that mediates binding to its substrate 
[74]. Parallel findings have since been repeated for other adherence systems, where only 
the terminal tip of a fimbria provides substrate binding specificity. The presence of P1 
and P2 phenotypes of the P blood group antigen, which bind pyelonephritogenic E. coli 
[58], is elevated in women prone to UTI [75, 76] compared to non-UTI prone women, 
suggesting a causal link between carrier state of P blood group antigen and development 
of UTI. 
Since its initial discovery, the association of P fimbria with virulent uropathogenic 
strains has been confirmed by many investigators [61, 67, 72, 77-86]. In a meta-analysis 
of prevalence studies, Welch and Donnenberg reported that UPEC isolates from 
otherwise healthy patients with pyelonephritis have a six-fold elevated relative risk of 
encoding P fimbriae compared to E. coli fecal isolates, which translates to roughly 80% 
of pyelonephritogenic UPEC strains (compared to a mere 16% of fecal/commensal E. 
coli isolates). In humans, expression of P fimbriae by UPEC in the urine [87] and  
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Figure 1-2. The pap operon and flagellar synthesis cascade. The pap operon encodes 9 
genes necessary for synthesis of intact, functional fimbriae (papAHCDJKEFG). Fimbaie 
are assembled via the chaperone-usher pathway, and many thousands of units of PapA 
oligomerize to form the shaft of the fimbria. Several hundreds of units of PapE are 
incorporated near the tip, and PapG provides substrate specificity of binding, and is 
essential for the ability of P fimbriae to adhere. The transcript for papX is encoded on the 
the pheV- but not pheU-associated pap operon in E. coli CFT073. PapX is a member of 
the 17kDa protein family and represses transcription of flhD and flhC by binding to the 
flhDC promoter. flhD and flhC encode the master regulators of motility in E. coli, and 
their transcription and activation initiates a cascade that results in the synthesis of 
functional flagella. Many factors are known to bind the flhD promoter to regulate 
flagellar synthesis and thus to control motility. PapX may serve to communicate between 
adherence and motility so that they may be reciprocally controlled in E. coli CFT073.  
11 
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antibodies to P fimbriae in the serum [88] suggest that E. coli produce and display P 
fimbria in vivo in infected patients. 
In 1981, Hull et al. [89] isolated a cosmid clone carrying the genes that encode P 
fimbria. Subcloning revealed that a minimal operon of 11 genes was necessary and 
sufficient to generate functional P fimbriae. The pap (pyelonephritis-associated pilus) 
operon (Figure 1-2) was crucial in the subsequent discovery and characterization of the 
chaperone-usher pathway for assembly of fimbria elucidated by Normark and Hultgren, a 
pathway of fimbrial biogenesis that is broadly applicable to a wide range of 
enterobacterial fimbriae [66, 74, 90-96] (Figure 1-2). Thus, P fimbriae represented not 
only a UPEC-specific virulence determinant but also served as the cornerstone for 
understanding adherence in the Enterobacteriaciae. P fimbriae consist of a composite 
fiber coupled to a tip adhesin. P fimbriae fibers are primarily composed of PapA subunits, 
and the adhesive tip fibrillum is composed of repeated PapE subunits that terminate in 
PapG, the component of P fimbria responsible for specific binding to its receptor [92, 
97]. P fimbriae bind the -D-Gal-(14)--D-Gal digalactoside moiety of the P blood 
group antigen. Indeed, the free disaccharide can inhibit P fimbria binding to its receptor 
on both erythrocytes [57] and uroepithelial cells [58]. Binding studies of PapG identified 
p-methoxyphenyl galabioside [98] and heavily modified galactopyranoside derivatives 
[99] as inhibitors of substrate binding for P fimbria. Structural studies of PapG in 
complex with receptor homologs have refined and supported these findings [100]. 
Another E. coli fimbria, encoded by the prs (pap related sequence) operon, is 
serologically identical to P fimbriae, but the two do not share virulence characteristics as 
the tip adhesin, PrsG, is antigentically distinct from PapG and binds the Forssman antigen 
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at GalNAc--(1-3)-GalNAc moieties [101]. The comparison between prs and pap 
fimbriae highlights the essential nature of specificity in adherence as it relates to 
pathogenesis. That is, adherence factors with highly similar or even identical nucleotide 
sequences may have vastly different functional effects on bacterial morphology, 
phenotype, and urovirulence, and especially careful attention must be paid to the tip 
adhesin of an adherence factor. The functional significance of sequence similarity must 
always be investigated experimentally. Conversely, dissimilar sequences may exhibit 
functional complementation. 
Expression of the pap operon is phase variable and regulated by a Dam-
methylation system [102, 103]. PapB and PapI act in concert with Lrp to control the 
methylation state and binding of two GATC sites, GATC1128 and GATC1130, located in 
the pap regulator region located between papI and papB [104]. When GATC1128 is 
methylated, the operon is in the OFF state, whereas methylation of GATC1130 is 
required for the ON state. PapB also appears to repress expression of Type 1 fimbriae, 
and deletion of pap-like gene clusters (including sfa) in E. coli strain 536 increased fim 
expression [105]. Several environmental conditions alter pap expression. P fimbrial 
expression in vivo in mice is down-regulated as determined by microarray analysis when 
compared to static growth in LB [38]. However, pap expression does not appear to be up-
regulated in vivo in humans [106]. In addition, the pap operon expressed in E. coli strain 
K12 is primarily phase-off in static liquid culture compared to growth on plates [107]. In 
contrast, Type 1 fimbrial expression is induced in static liquid broth culture compared to 
growth on plates [68]. 
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In animal models, demonstrating the direct contribution of P fimbria to infection 
has proven elusive. Two P-fimbrial isogenic deletion mutants of clinical isolates have 
been tested for virulence, in CBA/J mice [108] and in cynomologus monkeys [109, 110]. 
In work done by Mobley et al., [108] CBA/J mice were challenged with strain CFT073 or 
its P fimbria-negative mutant (both pap operons were disrupted by allelic exchange). At 
the end of a week-long infection using a wide range of infectious doses, no significant 
difference in pathogen concentration or histological findings were found between the 
parent and mutant strains in urine, bladder or kidney. Due to technical limitations at the 
time of the experiment, only discrete, cross-sectional data are available for those 
infections. 
Continuous data ware recently collected in a study by Melican et al. [111] which 
used GFP-expressing E. coli and multiphoton-based live-animal imaging during 
ascending and descending UTI in a mouse model of infection. The purpose of the study 
was to identify phenotypes of P fimbrial and Type 1 fimbrial mutants during infection of 
kidney tubules and glomeruli. A pap knockout strain of CFT073 caused tubular infection 
in the kidney at one-third the rate of the parental strain. They also observed that E. coli 
strain K12 transformed with a plasmid encoding the pap operon achieved visible growth 
more rapidly in the kidney tubules than did a strain containing vector [112]. Together 
these studies suggested that P fimbriae play a subtle role in the pathogenesis of 
pyelonephritis in the CBA/J mouse model of UTI. The complex role of P fimbria in 
urovirulence has been supported in later work in which P fimbrial knockouts did not 
affect urovirulence in a Type 1 fimbria-negative background in UPEC [113]. It was 
found, however, that synthesis of the P fimbria-related F1C fimbriae was up-regulated in 
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P fimbrial knockouts, hinting that some complementation or functional compensation 
between fimbrial organelles may be possible. Roberts et al. [109, 110] studied the effects 
of a papG mutation on colonization of the bladder and development of pyelonephritis in a 
primate model. No difference was observed by analysis of the primate urine (which 
gauged leukocyte esterase and analysis of bacteria/ml, by culture, in the urine of infected 
monkeys) between parent and mutant strain after bladder inoculation, although it was 
found that the parent strain persisted longer than the mutant strain in the urinary tract, and 
only animals infected with the parent strain showed evidence of impaired renal function 
and decreased renal mass. However, in both studies the mutant strain was still capable of 
infecting the kidneys. Together with epidemiological data, these studies suggest that 
while P fimbriae are associated with and probably contribute to virulence in the urinary 
tract, the murine model may not be the optimal setting in which to test the role of P 
fimbria in urovirulence. 
Nearly all E. coli strains including UPEC strains express the mannose-sensitive 
adhesin Type 1 fimbria [114, 115]. Type 1 fimbria has been well established as a 
virulence factor in the mouse model of UTI [51-54]. Type 1 fimbriae are encoded by a 
cluster of nine genes, fimBEAICDFGH, which are expressed from at least three 
transcripts [89, 116, 117]. One transcript encodes the main structural component of Type 
1 fimbria, FimA. Two transcripts encode FimH, the tip adhesin for Type 1 fimbria, and 
accessory proteins for assembly of the fimbrial stalk [118]. FimA forms the principal 
component of the fimbrial shaft [64] serving as the chief structural subunit of Type 1 
fimbriae. FimG and FimF form a complex with FimH to produce the tip adhesin, with 
FimH providing receptor binding specificity to glycolipids and glycoproteins containing 
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mannosides, such as uroplakin Ia. This receptor lines the interface between the luminal 
urothelium and urine within the urinary tract [119-128]. The binding and adherence 
function of Type 1 fimbriae, mediated by FimH, appears to be an essential factor in 
urovirulence. Point mutations altering the binding characteristics of FimH impacted 
urovirulence of select UPEC strains [129]. In addition, vaccine studies using FimH as the 
primary antigen demonstrated protection against UTI in mice [62] as well as in 
cynomologus monkeys [63]. 
Epidemiological data suggest that the adherence factors S and F1C fimbriae are 
associated with urovirulent strains. S and F1C fimbriae are nearly identical in their 
biogenesis, structure, and sequence, but possess distinct adhesive tips and thus differ in 
their substrate specificity. Pooled data suggest that F1C fimbriae are more common 
among pyelonephritis and cystitis isolates than among fecal strains of E. coli [130]. The 
presence of F1C fimbriae is especially common in O6-antigen serotypes of UPEC, which 
themselves are associated with pyelonephritis isolates and UPEC strains that encode P 
fimbriae and hemolysin [131-133]. Interestingly, FocB, a regulatory protein of the operon 
encoding F1C fimbriae, also appears capable of regulating both Pap and Type 1 fimbriae, 
indicating that F1C is involved in a complex genetic regulatory network with other 
fimbriae directly tied to urovirulence [134]. F1C fimbrial expression has also been 
observed to be elevated when Type 1 fimbriae and P fimbriae are deleted from the 
chromosome in UPEC, supporting the notion of coordinated regulation [113]. 
Mechanistically, F1C fimbriae could contribute to urovirulence by facilitating adherence 
to human distal tubular and collecting duct epithelial cells and vascular endothelial cells 
in kidney cross-sections by histology [135], and expression of F1C fimbriae in vivo has 
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been demonstrated using monoclonal antibodies to F1C in the urine of patients with 
UPEC UTI [136]. Using force-measuring optical tweezers, F1C fimbriae were shown 
microscopically to have a Young’s modulus (stretch-to-strain ratio) similar to that of P 
fimbriae and Type 1 fimbriae, a range which has been proposed to be important in the 
urinary tract to suitably resist flushing by urine flow [137]. Though F1C fimbriae do not 
agglutinate erythrocytes, they bind to galactosylceramide and globotriaosylceramide 
[138], and this binding can be inhibited by GalNAc14Gal and 
GalNAcb1414Glc [139]. The observed difference between whole-cell binding and 
substrate affinity may offer a clue to the mechanism by which F1C fimbriae bind to 
human epithelial and endothelial cells. 
 
Regulation of flagellar synthesis 
The pathogenesis of most UTIs proceeds via an ascending route [5]. Bacteria gain 
access to the urethra and ascend to the bladder and then to the kidneys. In E. coli, motility 
is primarily dependent on flagella [48] (Figure 1-2). Flagella are complex membrane-
bound extracellular organelles that consist of a basal body, a hook, and a filament. 
Synthesis proceeds in an “inside-out” manner, so that the basal body is constructed first, 
then the hook, and finally the filament [140]. Synthesis of flagella proceeds in a highly 
ordered hierarchical manner and is dependent on proper coordination of three classes of 
genes: class 1, class 2 and class 3 (Figure 1-2) [141-146]. Class 1 genes include 
primarily transcription of flhD and flhC, whose gene products form the FlhD4C2 complex 
that acts as a transcription factor to activate transcription of class 2 genes. flhD and flhC 
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are located on a single operon and their expression is highly regulated by numerous 
factors [147]. Several transcription factors regulate flhD expression by binding to the 
flhDC promoter, such as DnaA [148], the CAP-cAMP complex [149], OmpR (which 
binds in a phosphorylation-dependent manner) [150], and the two-component QseBC 
system [151]. Other factors regulate transcription in more subtle ways, such as H-NS 
which binds the flhDC promoter to alter DNA topology, reversing the binding of HdfR, a 
transcriptional repressor of flhD [152]. Still other regulators act post-translationally. 
DnaK, DnaJ, and GrpE appear to act together to enhance the transcription-factor activity 
of FlhD4C2 by enhancing functional folding [153, 154]. 
Thus flhD and flhC act as a central point of regulation of motility for many 
systems and pathways, leading to their designation as the master regulators of motility. 
The multi-faceted regulation of the class 1 genes equips bacteria to regulate motility in 
response to a host of environmental factors. Subsequently activated class 2 gene products 
are responsible for assembly of the basal body and hook, and expression of FliA (sigma 
28) and FlgM (anti-sigma 28) [142]. Once the basal body and hook structures are 
assembled, FlgM diffuses out of the bacterium [155], allowing activation of FliA. Active 
FliA is required for the transcription of the class 3 genes [156, 157]. Class 3 genes encode 
hook-associated proteins including FliC (flagellin), required to complete construction of 
functional flagella, and motility-associated proteins MotA, MotB, CheW and CheY 
[142]. 
Bacterial dependence on flagella-mediated motility in the pathogenesis of UTI has 
been illustrated in multiple experimental studies. UPEC fliC mutants are defective in 
motility but able to cause UTI in independent challenge in mice. However, the fliC 
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mutant was at a disadvantage relative to the motile parental strains in competition assays 
[49, 50]. In another study, non-motile mutants were highly attenuated for colonization of 
the kidneys even in independent challenge [59]. Interestingly, transcriptomic data from 
UPEC collected from the urine of mice with experimental UTI showed low levels of 
flagellar expression [38], suggesting that overall flagellar expression is repressed in the 
general population of E. coli infecting the urinary tract. Flagellar repression during UTI 
was confirmed in a study of human UTI, in which UPEC isolates collected directly from 
the urine of human subjects were subjected to transcriptional profiling by microarray. In 
general, the ranking of motility-related genes trended toward a lower-level of expression 
during human UTI [106]. Low ranking of motility genes may occur because flagellar 
expression is highly coordinated during UTI depending on location within the urinary 
tract, as has been shown by biophotonic imaging studies [59], or because UPEC shed in 
urine are not highly flagellated. Flagella are highly immunogenic in pathogenic E. coli, 
and are recognized by toll-like receptor 5 and induce IL-8 expression [158]. This may 
help to explain why UPEC tightly regulates expression of flagella to prevent excessive 
immune activation. 
 
Reciprocal control 
Ascension of the urinary tract by UPEC is an essential component of 
uropathogenesis to establish an infection of the bladder or kidneys during UTI.  To 
ascend, however, bacteria must use adherence to resist being expelled by the flushing 
mechanism of voiding, while simultaneously engaging in upward motility. Motility, 
mediated by flagella, and adherence, mediated by fimbriae, are inherently antagonistic 
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forces.  The immobilizing effect of fimbriae would limit the motility of flagella, and 
increased motility by flagella would reduce the ability of bacteria to adhere at one site, 
yet both motility and adherence contribute significantly to the development of UTI.  
Thus, it is logical that bacteria would have in place a mechanism to reciprocally control 
motility and adherence. 
Hints at a mechanism of reciprocal control of motility by adherence arose in 
studies of a UPEC-related gram-negative enteric uropathogen, Proteus mirabilis strain 
HI4320. This strain encodes the mannose-resistant Proteus-like (MR/P) fimbria, which is 
a typical chaperone-usher fimbria similar in structure to P fimbria of E. coli. Indeed, 
MrpA shares homology with PapA, the major structural subunit of P fimbria [159]. 
Phenotypically, MR/P fimbriae also agglutinate erythrocytes in a mannose-resistant 
manner [159-161], although the precise receptor has not been identified. 
Epidemiologically, P. mirabilis strains that cause pyelonephritis tend to be enriched for 
MR/P fimbriae compared to cystitis isolates and controls [162]. MR/P fimbriae have been 
shown genetically to contribute to virulence in a murine model of UTI but are not 
required to cause UTI [161, 163, 164]. Like P fimbriae, MR/P fimbriae induce a strong 
immune response [159], and recent vaccine trials indicate that either MrpH or MrpA is 
protective against UTI in the mouse model of infection [165-167]. 
The last gene of the MR/P fimbrial operon is mrpJ, which encodes a transcription 
factor predicted to employ a winged-helix DNA-binding motif. MrpJ represses 
swimming and swarming motility by binding to the flhD promoter and repressing 
transcription of the flagellar master regulator, as shown by expression studies and 
electrophoretic mobility shift assays [168]. P. mirabilis HI4320 has 14 paralogues of 
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mrpJ, 12 of which also repress motility and 10 of which are encoded at the end of 
fimbrial-encoding operons [168]. Studies in UPEC demonstrated that PapX, a non-
structural 183 amino-acid protein of the highly conserved 17 kDa family, is encoded as 
the last member of the PAI-CFT073pheV but not PAI-CFT073pheU –associated pap operon, 
down-regulates motility by repressing the expression of flagella [169]. Interestingly, there 
is up to 45% amino-acid identity between PapX and MrpJ in some of their domains, and 
papX functionally complements swimming and swarming phenotypes in isogenic mrpJ 
deletion mutants of P. mirabilis [170]. PapX also represses swimming motility in E. coli 
strain CFT073 (121). Both papX and mrpJ encode non-structural components of their 
respective fimbriae and are not required for fimbrial synthesis. Direct evidence in UPEC 
exists that PapX plays an integral role in reciprocal control of motility by adherence. In a 
series of studies investigating motility under conditions that affect adherence in E. coli 
strain CFT073, when the adherence factor Type 1 fimbria was constitutively expressed, 
motility was reduced. However, this repression of motility was partially reversed in papX 
deletion mutants [60, 169, 171]. Additionally, microarray and real-time PCR data 
indicate that the effect is mediated by repression of expression of flhD and flhC. Together 
with the homology to, and parallels with, mrpJ, these findings strongly support the model 
that papX encodes a transcription factor that plays an integral role in the regulation of 
motility by adherence in UPEC. 
 
Methods for assessment 
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Transcription factors and their binding sites may be studied by a three-pronged 
approach: predictors of function, transcriptional profiling, and direct binding assays. 
Predictors of function are often dependent on associative measures and computations. For 
example, structural prediction and homology modeling software such as PHYRE [172] 
and I-TASSER [173, 174] can predict the behavior of a protein based on sequence 
similarity and integrated predictors of protein folding. Putative annotations (i.e., in 
Pubmed or Genbank) serve much the same purpose. PapX is predicted to belong to the 
MarR-family of transcription factors, dimeric DNA binding proteins that alter 
downstream transcription. MarR family members typically bind to DNA using a winged-
helix motif, in which a turn region flanked by short beta-pleated sheets (“wings”) and a 
helix interact non-covalently with the major and minor grooves of the DNA helix to 
produce binding [175-179]. It varies by family member whether or not this interaction is 
dependent on cofactors, and whether the helix or the loop provides the sequence-
specificity of binding. Frequently, though not universally, MarR-family proteins act near 
the -10 and -35 sequences of promoters to sterically regulate gene expression by altering 
DNA helix topology, typically binding a sequence motif between 21 and 45 bases in 
length [180]. 
Transcriptional profiling broadly describes techniques that uncover factor-
dependent changes in transcription. This includes microarray, qPCR, and promoter-
reporter fusions. The weakness of transcriptional profiling techniques is that they are 
heavily inductive. That is, limited inferences about the mechanism of transcriptional 
effect may be drawn when only transcriptional data are available, because a 
transcriptional effect may be the result of intermediate or dependent events. For this 
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reason, identification of a protein as a transcription factor typically requires direct 
evidence of protein:DNA interaction. This approach includes techniques in which the 
output is influenced by or dependent on the factor interacting persistently and 
meaningfully with fragments of DNA of specific sequence. Examples of this type of 
approach are DNase footprinting assays, electrophoretic motility shift assays (EMSA), 
co-precipitation techniques (such as ChIP-seq [181] and protein-binding arrays [182]), 
computationally intensive techniques such as SELEX and SELEX-seq [183-189], and 
screening techniques such as bacterial 1-hybrid systems [190]. In each of these 
techniques, proteins of interests are exposed to DNA fragments and changes in species 
behavior are used to gauge interactions. 
Currently, programs exist to analyze high-throughput data from SELEX-seq, 
ChIP-seq and protein-binding arrays [186, 191]. All transcription factor binding-site 
prediction software requires substantially advanced knowledge of personal computing 
and tends to make heavy use of the command line or intermediary scripting languages 
and programs such as R or Matlab. The output of these techniques is frequently a list of 
sequences that were enriched against a target protein, ranging from a few sequences to 
thousands. Downstream analysis of these sequences can reveal binding motifs. The 
MEME suite of programs [192], for instance, can generate positional-weight matrices 
from a list of sequences. Positional-weight matrices are generated by aligning all similar 
sequences and quantifying how conserved a given nucleic acid is at any site within the 
sequence. These can be extremely useful for predicting likely binding sites and for 
directing downstream experiments to verify a candidate site. 
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Each of these techniques can be used to discover transcription factors, to 
determine whether or not a given protein is a transcription factor, and to identify the most 
likely site of interaction between a transcription factor and a genome. However, none of 
the techniques mentioned can identify the specific mechanism of protein:DNA 
interaction, though computational modeling may be useful for generating hypotheses. To 
explore mechanisms of DNA binding by proteins, biochemical and genetic techniques are 
essential, and a working knowledge of transcription-factor motifs and historical precedent 
for inferred mechanism are extremely useful. Biochemical and genetic techniques include 
making select mutations to a gene encoding the binding protein and assaying for binding 
capacity, solving the structure of the protein in the presence and absence of its DNA 
ligand (such as with crystallography or NMR), or activity assays under variable 
conditions. Currently, no technique allows an investigator to scrutinize DNA binding 
events and effects in real-time, so even direct techniques are inductive, though they are 
considered to be more reliable measures of protein function. 
 
Statement of the problem 
Although it was known that PapX regulates motility in UPEC, the precise 
mechanism of this control was unknown. There is a need to better understand the nuances 
of reciprocal control of adherence and motility in UPEC, and we reasoned that the study 
of PapX would be an excellent and useful lens through which to scrutinize the 
phenomenon. 
 
25 
 
Hypothesis 1: PapX is a transcription factor that regulates motility by 
repressing master regulator genes flhD and flhC. Determining the mechanism of 
action and binding site of this protein will shed light on a broad class of UPEC 
transcription factors. 
Previous work by EMSA and transcriptional profiling has shown that PapX binds 
somewhere within the flhD promoter and that flhD undergoes a papX-dependent 
repression of expression. This led us to formulate the model that PapX is a transcription 
factor that represses motility in UPEC by repressing flhD expression. We wanted to 
elucidate the precise mechanism by which PapX exerts its effect, including investigation 
of the specific target binding site sequence and biochemical mechanism. Prior work with 
the functional PapX homolog, MrpJ, had shown that using linker-insertional mutagenesis 
could reveal active domains of the protein [168]. We reasoned that subjecting PapX to a 
similar approach would identify domains necessary for full function of the protein, and 
would lend insight into the mechanism of action and class of the PapX protein. We also 
reasoned that, as PapX binds to the flhD promoter, we could identify the specific 
sequence of interaction using unbiased techniques. Because PapX belongs to a broadly 
conserved family of proteins within UPEC, we anticipated that our work would shed light 
on the mechanism of control of motility across many uropathogens. We hypothesized that 
this information would give us crucial insight into the specific mechanism of reciprocal 
control in UPEC. 
 
Hypothesis 2: papX is transcriptionally regulated by the pap operon 
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We were interested in the mechanism by which papX and its family members are 
regulated in UPEC. Prior work had demonstrated that papX is encoded on the pap operon 
[169], and that it is involved in reciprocal control of adherence and motility [60]. This led 
us to the simple model that PapX activity should be coeval (i.e., co-regulated) with the 
transcriptional activity of the pap operon, so that when expression of the adherence factor 
P fimbria is increased, papX expression is increased and thus the activity of PapX is 
increased in the bacterium. This would provide a simple model of reciprocal control and 
an explanation of how adherence may reciprocally repress motility in UPEC. When the 
pap operon is phase off, both P fimbria (the adherence factor) and PapX are not 
synthesized. Flagellar synthesis is not repressed, flagella are assembled and the bacterium 
is motile. When the pap operon is phase on, both P fimbria and PapX are synthesized. 
Flagellar synthesis is repressed and the bacteria are not motile. Thus, the bacterium is 
either motile or adherent, but not both. 
 
By testing these hypotheses, I will contribute to our understanding of the role of 
PapX in reciprocal control, the mechanism by which PapX suppresses motility, and the 
mechanism by which PapX activity is regulated. Because PapX and its homologs appear 
in many uropathogens, these studies will help to illuminate the pathways of reciprocal 
control of adherence and motility across a broad range of bacteria. The knowledge gained 
in this way could inform methods for disruption of this important pathway. 
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CHAPTER 2 
DETERMINATION OF THE TARGET SEQUENCE BOUND BY PAPX, A 
REPRESSOR OF BACTERIAL MOTILITY, IN THE FLHD PROMOTER USING 
SELEX AND HIGH-THROUGHPUT SEQUENCING
*
 
*
Published in modified form in the Journal of Biological Chemistry, 286(52):44726-38 (2011) 
 
Introduction 
papX represses motility by inhibiting expression of flhD [169], but the mechanism 
remains unknown. We reasoned that a multi-pronged approach to studying papX action 
would yield productive insight into the structure, function and the specific nature of its 
interaction with flhD. We first wanted to determine whether the mechanism of papX 
action was virulence-specific, or more broadly effective. To examine this question, we 
carried out studies of the effect of papX expression on pathogenic and non-pathogenic 
strains of E. coli, reasoning that a difference in effect would suggest a specific 
relationship to virulence while a lack of difference would suggest that the role of papX 
may be broad and not limited to only uropathogenesis. We supported the results of these 
studies using molecular epidemiology to analyze the distribution of papX within a large 
E. coli strain collection. We hypothesized that if papX was found more commonly in 
strains of increased urovirulence as compared to strains of diminished urovirulence, such 
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as commensal strains, that would be suggestive of a specific role in uropathogenesis for 
papX. 
To examine PapX mechanism directly, we designed molecular-genetic studies to 
uncover regions of PapX crucial for function. Homology modeling and mutagenesis 
approaches in the study of mrpJ have been informative for understanding the mechanism 
of its action [168], and because papX is a functional homolog of mrpJ, we concluded that 
this approach could be similarly useful in uncovering key regions and residues of the 
PapX protein. To further our understanding of the interaction between PapX and flhDC 
expression, we used systematic evolution of ligands by exponential enrichment (SELEX) 
in conjunction with high-throughput sequencing technology to identify a novel DNA 
binding site for PapX within the flhDC promoter.  To the best of our knowledge, this is 
the first description of aptamer-free SELEX in conjunction with high-throughput 
sequencing technology in bacteria to study DNA binding proteins, and the first time these 
techniques have been used to identify a novel binding site instead of to confirm or refine 
known binding sites.  Our application of SELEX with high-throughput sequencing 
provides for novel advantages over previous techniques for identifying bacterial 
transcription-factor binding sites, and may serve as the paradigm for future high-
throughput screens.  Because the 17 kDa family of genes is highly conserved, by 
elucidating the mechanisms underlying reciprocal control of motility by PapX in UPEC, 
we will be better equipped to manipulate and disrupt this important regulatory cascade 
and virulence property of a pathogenic microbe. 
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Results 
 
PapX has homologs in Extraintestinal Pathogenic E. coli (ExPEC) 
To assess the distribution and conservation of PapX, we compared the amino acid 
sequence of PapX homologs using Clustal-W.  PapX has six closely related homologs of 
the 17 kDa protein family among strains of UPEC and meningitis-associated E. coli, with 
over 93% amino acid identity between them (Figure 2-1).  Three of the ten non-identical 
residues are substitutions between Ala and Val or Ile and Val.  Four non-identical sites 
contain either Ala or Thr.  These features result in pairs of PapX homologs sharing up to 
99% amino acid sequence identity. 
 
Prevalence of PapX homologs among UPEC 
To assess the prevalence of papX in UPEC strains, a collection of 294 E. coli 
strains representing a range of isolates from fecal/commensal strains (n=88) to strains 
isolated from clinical cases of asymptomatic bacteriuria (ABU) (n=54), complicated UTI 
(n=39), uncomplicated cystitis (n=37), and acute pyelonephritis (n=76), was examined 
by multiplex PCR for the presence of papX homologs.  Primers were designed to unique 
flanking sequences of papX and focX, and to common regions of both to amplify 
fragments of specific size (Figure 2-2A, Table 2-1).  Within this collection, 53% of 
pyelonephritogenic strains of E. coli contained at least one copy of papX, the highest 
prevalence within the strain collection and significantly more prevalent than the 32% of  
30 
 
 
 
 
Figure 2-1. Alignment of PapX homologs in the 17 kDa family. PapX homologs of the 
17 kDa protein family were aligned using Clustal-W using Megalign.  Perfect consensus 
is shown above.  Positions with imperfect amino acid identity between homologs are 
shown as “.”.  Amino acid residues that represented the minority for that position are 
shaded in black within each homolog’s amino acid sequence.  The 7 family members are 
≥ 93% identical to one another at the amino-acid level past residue 17. N-terminal start-
site annotation in homologs (boxed) is the result of in silico analysis and has not been 
experimentally verified (using i.e. primer extension).  
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Figure 2-2. Multiplex PCR to analyze a 294 member library of UPEC and 
fecal/commensal isolates for the presence of papX, focX and non-specific 17 kDa 
family genes. (A) Three primer sets were designed to amplify a 607 bp fragment of papX 
and flanking region, a 449 bp fragment of focX and flanking region, and a 249 bp region 
common to all papX homologs. All primer sets shared a common reverse primer (Table 
2-1, papXMltplxRev) with a unique forward primer (Table 2-1, papXMltPlxfwd, 
focXMltPlxfwd, XMltPlxfwd). papX and focX contain nearly identical nucleotide 
sequence, so unique primers for each originated in the sequence flanking each gene. 
Fragments were sequenced to confirm their composition. Each fragment was generated 
from extracted, pooled CFT073 WT genomic DNA and separated on 2% agarose gel. The 
prevalence of (B) papX and (C) focX within the library was scored by the appearance of 
their respective amplicon during multiplex PCR within each strain type.  The percentage 
of (D) papX- or (E) focX-containing strains within papG- or focH-containing strains, 
respectively, is shown.  
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Table 2-1. Primers used in this study. 
Primer  Sequence (5’ 3’)  Function  
papXH1P1  ...TGCCTGAAGCTATCCGGCATACTCAGGCATTTCACGCTTTGTGTAGGCTGGAGCTGCTTC red mutants  
papXH2P2  ..AGAAATCAGGCAGGAATAAATTGTAGTGGAAAGTCGATGTATGGGAATTAGCCATGGTCC   red mutants  
lacZH1P1  …………………………………………..TTACGCGAAATACGGGCAGACATAGCCTGCCCGGTTATTA   red mutants  
lacZH2P2  …………………………………………..ATGACTATGATTACGGATTCTCTGGCCGTCGTATTACAAC   red mutants  
focXH1P1 …………..ATGCGCGCTTGTACACAGACAGTGTGTTTCAGTAAGTGTAGGCTGGAGCTGCTTC  red mutants
focXH2P2 ………….AATGACTTCAAACAGTTCCTGTTCATCATGGGTCAATGGGAATTAGCCATGGTCC  red mutants
gapA 29bp fwd  ………………………………………………………………….ACTCCACTCACGGCCGTTTCGACGGTACCG  Gel shift  
gapA 29bp rev  …………………………………………………………………CGGTACCGTCGAAACGGCCGTGAGTGGAGT  Gel shift  
papX 29bp fwd  ………………………………………………………………...TTACGGTGAGTTATTTTAACTGTGCGCAAC  Gel shift  
papX 29bp rev  ………………………………………………………………...GTTGCGCACAGTTAAAATAACTCACCGTAA  Gel shift  
EMSA154_F  ……………………………………………………………………………..……….TCGCTACACTGGCAAGCAAA  Gel shift  
EMSA154_R  ……………………………………………………………………………..……….GTTGTGCGGTAAGTGTTTGT  Gel shift  
papXRTfwd  ……………………………………………………………………………...CGCATATCCCTTTCGGGAGCATTT  qPCR  
papXRTrev  ……………………………………………………………………………..TCCGCTGCGAATAATGTGGTGAGA  qPCR  
gapARTfwd  ………………………………………………………………………………………CGTTAAAGGCGCTAACTTCG  qPCR  
gapARTrev  ………………………………………………………………………………………ACGGTGGTCATCAGACCTTC  qPCR  
flhDRTfwd  ………………………………………………………………………………TCCGCTATGTTTCGTCTCGGCATA  qPCR  
flhDRTrev  ……………………………………………………………………………...ACCAGTTGATTGGTTTCTGCCAGC  qPCR  
flhCRTfwd  ……………………………………………………………………………..AAACTGGCTTGTGTAATGGCGTCG  qPCR  
flhCRTrev  ……………………………………………………………………………...TCAACAAACCGCACCAATGTCCAG  qPCR  
T21Afwd  …GTAATATGGAGAATAATGAAATGAATAACGCAGACACATTAGAAAAAATAATCAGACAC  Site-directed mutant  
T21Arev  ……CATTATACCTCTTATTACTTTACTTATTGCGTCTGTGTAATCTTTTTTATTAGTCTGTG  Site-directed mutant  
R51Afwd  ………………………..GGAGCATTTGTTGATGCAACTCTGTATTGCCACAAATAAAAGAATGCAG  Site-directed mutant  
R51Arev  …………………………CTGCATTCTTTTATTTGTGGCAATACAGAGTTGCATCAACAAATGCTCC  Site-directed mutant  
K54Nfwd  …………………………….AGATATATTATCCTGCATTCTGTTATTTGTGCGAATACAGAGTTGCA  Site-directed mutant  
K54Nrev  …………………………….TGCAACTCTGTATTCGCACAAATAACAGAATGCAGGATAATATATCT  Site-directed mutant  
R55Gfwd  ……………………………….AGATATATTATCCTGCATTCCTTTATTTGTGCGAATACAGAGTTGC  Site-directed mutant  
R55Grev  ………………………………GCAACTCTGTATTCGCACAAATAAAGGAATGCAGGATAATATATCT  Site-directed mutant  
H71Afwd  ………………………..CTGAATTTCTGGGGGTGTATGGAATAAATGCCTCAGTATATATGGTTCT  Site-directed mutant  
H71Arev  ………………………...AGAACCATATATACTGAGGCATTTATTCCATACACCCCCAGAAATTCAG  Site-directed mutant  
R101Afwd  …………………………..TAAGCCAGAAACTTCAGTTTACCGCAACTAATATTACCCGCATTACAG  Site-directed mutant  
R101Arev  ………………………….CTGTAATGCGGGTAATATTAGTTGCGGTAAACTGAAGTTTCTGGCTTA  Site-directed mutant  
R106Afwd  ………………….TCAGTTTACCAGAACTAATATTACCGCCATTACAGATTTTTTAGAAAAAGCC  Site-directed mutant  
R106Arev  …………………GGCTTTTTCTAAAAAATCTGTAATGGCGGTAATATTAGTTCTGGTAAACTGA  Site-directed mutant  
K113Nfwd  ……………………TAATATTACCCGCATTACAGATTTTTTAGAAAACGCCGGATATGTAAAAAG  Site-directed mutant  
K113Nrev  ……………………CTTTTTACATATCCGGCGTTTTCTAAAAAATCTGTAATGCGGGTAATATTA  Site-directed mutant  
K118Afwd  …………………...TTACAGATTTTTTAGAAAAAGCCGGATATGTAGCAAGGATGGATAGCAGGG  Site-directed mutant  
K118Arev  ……………………..CCCTGCTATCCATCCTTGCTACATATCCGGCTTTTTCTAAAAAATCTGTAA  Site-directed mutant  
R119Afwd  …………………….AGATTTTTTAGAAAAAGCCGGATATGTAAAAGCGATGGATAGCAGGGAGG  Site-directed mutant  
R119Arev  ………………………..CCTCCCTGCTATCCATCGCTTTTACATATCCGGCTTTTTCTAAAAAATCT  Site-directed mutant  
R123Afwd  …………………………………………….…GTAAAAAGGATGGATAGCGCGGAGGATCGCCGTGCTAA  Site-directed mutant  
R123Afwd  …………………………………………………TTAGCACGGCGATCCTCCGCGCTATCCATCCTTTTTAC  Site-directed mutant  
R126Afwd  …………………………………………..AAAAAGGATGGATAGCAGGGAGGATGCCCGTGCTAAAAAA  Site-directed mutant  
R126Arev  ……………………………………………..TTTTTTAGCACGGGCATCCTCCCTGCTATCCATCCTTTTT  Site-directed mutant  
R127Gfwd  ………………………………………………………..TAGCAGGGAGGATCGCGGTGCTAAAAAAATCAGT  Site-directed mutant  
R127Grev  …………………………………………………………ATCGTCCCTCCTAGCGCCACGATTTTTTTAGTCA  Site-directed mutant  
R127Kfwd  ……………………………GATGGATAGCAGGGAGGATCGCAAGGCTAAAAAAATCAGTCTGACAT  Site-directed mutant  
R127Krev  ……………………………..ATGTCAGACTGATTTTTTTAGCCTTGCGATCCTCCCTGCTATCCATC  Site-directed mutant  
K129Afwd  …………………………………………CAGGGAGGATCGCCGTGCTGCAAAAATCAGTCTGACATCTG  Site-directed mutant  
K129Arev  ………………………………………….CAGATGTCAGACTGATTTTTGCAGCACGGCGATCCTCCCTG  Site-directed mutant  
K130Afwd  …………………………………………GGGAGGATCGCCGTGCTAAAGCAATCAGTCTGACATCTGAA  Site-directed mutant  
K130Arev  ………………………………………….TTCAGATGTCAGACTGATTGCTTTAGCACGGCGATCCTCCC  Site-directed mutant  
papXMltplxRev  ……………………………………………………………………………..TCCGCTGCGAATAATGTGGTGAGA  Multiplex PCR  
XMltPlxfwd  ……………………………………………………………………………...GCGCGCTTGTACACAGACAGTGTG  Multiplex PCR  
focXMltPlxfwd  ……………………………………………………………………………………...CAGGCGTGTGGAAGCTGATG  Multiplex PCR  
papXMltPlxfwd  ………………………………………………………………………………….CCTGACCATCGGCAGTCGCCTC  Multiplex PCR  
DNaseflhDrev  ……………………………………………………………………………………..TCAGCAACTCGGAGGTATGC  DNase protect assay  
DNaseflhDAfwd  ……………………………………………………………………………………...ACCAAAAAGGTGGGTCTGCT  DNase protect assay  
DNaseflhDBfwd  ………………………………………………………………………………………AAAATCGCAGCCCCCCTCCG  DNase protect assay  
DNaseflhDCfwd  ………………………………………………………………………………………TTTGCTTGCCAGTGTAGCGA  DNase protect assay  
DNaseflhDDfwd  ……………………………………………………………………………………...GTTGTGCGGTAAGTGTTTGT  DNase protect assay  
DNasegapAfwd  ………………………………………………………………………………………………..ACGTGACTGATTCTA  DNase protect assay  
DNasegapArev  ………………………………………………………………………………………………CAGCTATTTGTTAGTG  DNase protect assay  
flhDEHrev  ……………………………………………………………………………………...TCAGCAACTCGGAGGTATGC  lacZ-fusions  
flhDAfwd  ……………………………………………………………………………………...ACCAAAAAGGTGGGTCTGCT  lacZ-fusions  
flhDBfwd  ………………………………………………………………………………………AAAATCGCAGCCCCCCTCCG  lacZ-fusions  
flhDCfwd  ……………………………………………………………………………………..TTTGCTTGCCAGTGTAGCGA  lacZ-fusions  
flhDDfwd  ……………………………………………………………………………………..GTTGTGCGGTAAGTGTTTGT  lacZ-fusions  
flhDEfwd  ………………………………………………………………………………………ATGTACTGATTTCCCATATT  lacZ-fusions  
flhDFfwd  ……………………………………..………………………………………………TGGAGAAACGACGCAATCCC  lacZ-fusions  
papGX_Eco_fwd ………………………………………………………………...CCGGAATTCATGGTTTATCCGGAGCCGGAT lacZ-fusions 
PapGX_BamHI_rev ………………………………………………………………CGCGGATCCCAGTCATCCGGTAAACATCGAC lacZ-fusions 
papBA_Eco_fwd ……………………………………………..CCGGAATTCCGCTTTATTTGTTCAATTTAGTGAATTTGC lacZ-fusions 
papBA_BamHI_rev ……………………………………………………………..CGCGGATCCGCGCCTTGTTTCCCCCTTCTGTC lacZ-fusions 
 
  
33 
 
ABU strains (P = 0.0192).  Only 12.5% of fecal/commensal E. coli contained at least one 
copy of papX, the lowest prevalence within the strain collection and significantly less 
prevalent than in ABU strains (P = 0.0081) (Figure 2-2B).  focX, a close homolog of 
papX, did not significantly vary in prevalence within the UPEC strain collection (P = 
0.7927) (Figure 2-2C).  This was not surprising as focX is closely associated with genes 
encoding F1C fimbria, which appears more closely associated with meningitis-associated 
strains than with UTI-associated strains [193]. 
The association of the pap operon, which encodes P-fimbriae, with 
pyelonephritogenic strains of UPEC is well documented, with 77% of pyelonephritogenic 
isolates containing P fimbriae, as compared to only 23% of cystitis, 20% of ABU, and 
16% of fecal/commensal isolates [73, 75].  59% of all strains tested carrying at least one 
copy of papG also carried at least one copy of papX.  Therefore, to differentiate the 
influence of the increased representation of the pap operon in UTI-causing UPEC from 
the role of papX alone, we quantified the prevalence of papX in strains containing pap 
operons for each type of strain within the collection, using the prevalence of papG as a 
proxy for the prevalence of the pap operon [194]. 
Within strains that contained both the pap operon and papX, the relative 
prevalence of papX compared to papG was significantly higher in cystitis-causing strains 
of E. coli as compared to fecal/commensal strains (P =0.0165)  (Figure 2-2D).  The 
prevalence of strains containing both focX and focH, a proxy for the presence of F1C 
fimbriae, was not significantly different between UTI-causing strains of E. coli and 
fecal/commensal strains of E. coli (P = 0.2222) (Figure 2-2E). These data indicate that 
the presence of papX, but not focX, is strongly associated with UPEC.  Taken together 
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with the highly conserved nature of the protein sequence between PapX homologs, these 
data suggest that PapX contributes to UPEC virulence, but that encoding papX alone is 
not sufficient to convey virulence to E. coli strains. 
 
Functional characterization of PapX 
We previously demonstrated that PapX down-regulates motility [60, 169].  In 
strain CFT073, deletion of the single copy of papX, which resides on the PAI-CFT073pheV 
but not PAI-CFT073pheU-associated pap operons [169], results in increased motility as 
compared to wild-type.  On the contrary, over-expressing papX from the leaky, inducible 
plasmid pPxWT repressed motility.  papX overexpression in CFT073 (pPxWT) has a 
specific transcriptional effect, with 38 of 42 differentially expressed genes being 
associated with motility and the downstream effects of flhD and flhC regulation, the 
master regulator of motility [169].  Coupling this finding with the discovery that papX 
appears to be strongly associated with uropathogens, we introduced papX, carried on 
pPxWT, into strain CFT073 and the prototypical non-pathogenic fecal/commensal E. coli 
K12 strain MG1655.  Motility assays, performed on the resulting transformants, 
demonstrated that CFT073 had reduced motility in the presence of papX when compared 
to vector control (Figure 2-3A), but that papX had no effect on the motility of the non-
pathogenic K12 strain MG1655 (Figure 2-3B).  This informed us that the role of papX is 
pathogen-specific. 
To investigate structure-function relationships within PapX, we constructed a 
library of linker insertion mutations within papX in pPxWT.  15-nucleotide insertions 
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Figure 2-3. Effect of papX and papX_Arg
127
Gly mutant on motility of UPEC and a 
non-pathogenic E. coli. E. coli CFT073 and K12 MG1655 were transformed with 
pPxWT (WT papX), pR127G (papX Arg
127
Gly mutant) or pT21A (papX Thr
21
Ala 
mutant). Constructs were then stabbed into soft-agar plates and incubated at 30
o
C. 
Diameter of swimming motility was recorded after 16 hours.  For each construct, assays 
were performed on four biological replicates in triplicate.  (A) Compared to vector 
control (dashed line) in CFT073, pPxWT and pT21A reduced motility significantly, but 
pR127G did not. (B) None of the three constructs influenced motility significantly 
differently from vector control in K12 MG1655.  
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were randomly introduced along the coding sequence of papX.  Thirty unique in-frame 
insertions were generated, corresponding to amino acid residues 15-162 of PapX.  Each 
of the 30 insertional mutations was electroporated into CFT073 papX.  The growth rates 
of the  transformants were not significantly different from CFT073 papX complemented 
with either wild-type papX or vector control (Supplementary Figure 2-1).  Motility 
conferred by each construct was measured in soft agar, side-by-side with motility assays 
of CFT073 papX complemented with either pPxWT (encodes papX) or pVector (vector 
control) (Figure 2-4A).  We found that mutations in two regions of papX (encoding 
residues 51-74 and 103-133) produced constructs no longer able to repress motility 
(boxes, Figure 2-4A).  Insertions into either of these regions abolished PapX activity, 
resulting in motility similar to that observed for the CFT073 papX construct containing 
vector alone.  The motility results indicated that these two regions were critical for PapX 
function. 
We reasoned that structural modeling would provide insight into the structure and 
function of this DNA binding protein.  Indeed, structural models of PapX generated using 
I-TASSER [173, 174] and PHYRE [172] suggested that PapX is likely to be a member of 
the MarR-family of helix-wing-helix homodimeric transcriptional regulators (Figure 2-
4B).  Size-exclusion chromatography and semi-native SDS-PAGE confirmed that PapX 
is a dimer (Supplementary Figure 2-2). The MarR family of transcription factors tends 
to rely on specific positively charged residues, often Arg, to mediate DNA binding 
interactions [175-178, 180] and dimerization.  When the predicted structure is compared 
to existing MarR family proteins [175, 176], the two regions of PapX sensitive to 
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Figure 2-4. Motility index of 15 bp insertional mutants of papX. (A) Thirty in-frame 
15 bp insertions were made in papX in pPxWT. Constructs, pPxWT (WT papX) and 
pVector (empty vector) were electroporated into CFT073 papX. Motility was assessed 
in soft agar and compared relative to CFT073 papX electroporated with pPxWT. 
Vertical boxes indicate regions of loss of function. Top and bottom horizontal boxes 
represent motility of CFT073 papX electroporated with pVector or with pPxWT, 
respectively. Presence of positively charged residues is indicated along the bottom of the 
figure. (B) I-TASSER software was used to generate a predicted structural model based 
on the amino acid sequence of PapX. Arrows indicate putative DNA binding (Arg
127
) and 
dimerization (Lys
54
) regions of the protein. (C) Site-directed mutants of papX were made 
in pPxWT and transformed into a CFT073 papX background.  Soft-agar motility assays 
were performed on the resulting constructs, performed in triplicate using biological 
triplicates. Boxes indicate regions sensitive to mutation determined in (A) by linker-
insertional mutagenesis. Solid bars are not significantly different from vector control 
(dashed line). (D) Western blot showing pPxWT (WT PapX), pR127G (PapX Arg
127
Gly 
mutant) and pK54N (PapX Lys
54
Asn mutant) transformed into E. coli strain K12 either 
uninduced or induced with 300 M IPTG. Bands migrate with the same electrophoretic 
mobility for mutants and wiltype PapX by semi-native SDS-PAGE (12% acrylamide). 
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Table 2-2. Bacterial strains and plasmids used in this study. 
Plasmid or strain name Function 
pMCSG7 Recombinant PapX-His 6 
pMCSG7_R127G  PapX-His 6 including an Arg
127
Gly point mutant  
pMCSG7_K54N PapX-His 6 including an Lys
54
Asn point mutant 
pMCSG7_T21A PapX-His 6 including an Thr
21
Ala point mutant 
pRS551  Promoterless lacZ containing vector  
pRS551A  lacZ fused to the first 130 bases of flhD promoter  
pRS551B  lacZ fused to the first 215 bases of flhD promoter  
pRS551C  lacZ fused to the first 360 bases of flhD promoter  
pRS551D  lacZ fused to the first 501 bases of flhD promoter  
pRS551E  lacZ fused to the first 597 bases of flhD promoter  
pRS551F  lacZ fused to the first 718 bases of flhD promoter  
pRS551GX lacZ fused to the 262 bases between papX and papG 
pRS551BA lacZ fused to the 330 bases between papI and papB 
pLX3607 or pVector  Empty IPTG-inducible vector  
pDRM001 or pPxWT  Wildtype papX made in pLX3607 
pDRM002 or pR127G  papX_Arg
127
Gly constructed in pDRM001  
pDRM003 or pK54N  papX_Lys
54
Asn constructed in pDRM001  
pDRM004 or pR127K  papX_Arg
127
Lys constructed in pDRM001  
pDRM005 or pT21A  papX_Thr
21
Ala constructed in pDRM001  
pDRM006 or pR51A  papX_Arg
51
Ala constructed in pDRM001  
pDRM008 or pR55G  papX_Arg
55
Gly constructed in pDRM001  
pDRM009 or pH71A  papX_His
71
Ala constructed in pDRM001  
pDRM010 or pR101A  papX_Arg
101
Ala constructed in pDRM001  
pDRM011 or pR106A  papX_Arg
106
Ala constructed in pDRM001  
pDRM012 or pK113N  papX_Lys
113
Asn constructed in pDRM001  
pDRM013 or pK118A  papX_ Lys
118
Ala constructed in pDRM001  
pDRM014 or pR119A  papX_Arg
119
Ala constructed in pDRM001  
pDRM015 or pR123A  papX_Arg
123
Ala constructed in pDRM001  
pDRM016 or pR126A  papX_Arg
126
Ala constructed in pDRM001  
pDRM017 or pK129A  papX_ Lys
129
Ala constructed in pDRM001  
pDRM018 or pK130A  papX_ Lys
130
Ala constructed in pDRM001  
pKD3  red encoding chloramphenicol resistance cassette  
pKD4    red encoding kanamycin resistance cassette  
pCP20    red encoding recombinase to remove cassettes  
pKD46    red encoding recombinase to insert cassettes  
CFT073 Prototypical strain of pyelonephritogenic UPEC 
CFT073 papX Deletion of papX in strain CFT073 
CFT073 focX Deletion of focX in strain CFT073 
CFT073 papXfocX Deletion of papX and focX in strain CFT073 
CFT073 papXlacZ Deletion of papX and lacZ in strain CFT073 
CFT073 lacZ Deletion of lacZ in strain CFT073 
K12 MG1655 Fecal/commensal strain K12 MG1655 
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insertional mutagenesis (amino acid residues 51-74 and 103-133) were predicted to occur 
in dimerization and DNA-binding domains, respectively (Figure 2-4B arrows). 
To investigate the role of the two regions in PapX highlighted by insertional 
mutagenesis, site-directed mutants were constructed, in which positively-charged 
residues were substituted with non-positively charged residues in pPxWT (Table 2-2). 
Site-directed mutant constructs were transformed into CFT073 papX and motility assays 
were performed for the resulting transformants (Figure 2-4C).  We found that two 
mutations, Lys
54
Asn and Arg
127
Gly, abolished PapX activity, producing the same 
motility phenotype as vector control (solid bars).  We confirmed that each of these 
mutants produced PapX of the predicted apparent molecular weight as assessed by 
western blot (Figure 2-4D) by over-expressing each construct from an inducible vector in 
the K12 background, which lacks a native papX or papX homolog.  These results 
indicated that either of these single amino acid substitutions alone is capable of ablating 
PapX activity, suggesting that Lys
54
 and Arg
127
 are key residues necessary for PapX 
function. 
By homology modeling, Lys
54
 and Arg
127
 occur in the predicted dimerization 
domain and DNA binding domain of PapX, respectively. As discussed in the 
introduction, MarR family proteins often depend on an Arg in the wing of the winged-
helix domain in DNA-binding [175-179].  Our alignment suggested that this conserved 
Arg corresponds to Arg
127
 in PapX.  To further investigate the Arg
127
 mutant, we used 
site-directed mutagenesis to construct an Arg
127
Lys mutant containing a different 
positively charged residue.  Surprisingly, the Arg
127
Lys mutant also disrupted PapX 
function as assessed by motility assay (Figure 2-5A), indicating that Arg
127
 is a key  
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Figure 2-5. PapX Arg
127
Gly mediates motility and flagellar transcription. (A) 
CFT073 papX was complemented with pVector, pPxWT (WT papX) or pR127K (PapX 
Arg
127
Lys mutant), and motility was assayed for each construct using soft-agar motility 
assays. Motility of CFT073 papX electroporated with either pVector or pR127K was 
not significantly different from one another (NS, P > 0.05), and both were significantly 
more motile (*, P < 0.05)  than CFT073 papX electroporated with pPxWT. (B) pR127G 
(PapX Arg
127
Gly mutant), pPxWT (WT papX) and pVector (empty vector) were 
electroporated into CFT073 papX. RNA was isolated and analyzed using quantitative 
PCR, using gapA as the normalizer. Bars indicate fold-change in expression of flhD and 
flhC compared to CFT073 papX electroporated with vector control. Dashed lines 
indicate 1 and -1 fold (no differential change in expression). Compared to the presence of 
pVector, both flhD and flhC transcript levels were decreased in the presence of pPxWT, 
but levels were unchanged in the presence of pR127G.  
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residue in PapX that is characteristic of the MarR family’s DNA binding protein fold 
[175, 176] and that positive charge at position 127 alone is not sufficient for activity. 
To better understand the motility phenotype of the Arg
127
 mutant, we compared 
the transcriptional profile of our Arg
127
Gly mutant expressed from pR127G, wild-type 
PapX expressed from pPxWT, and vector control expressed from pVector in CFT073 
papX by quantitative real-time PCR (Figure 2-5B).  Expression of flhD and flhC in the 
presence of the pR127G mutant was not significantly different from vector control, while 
pPxWT significantly reduced transcription of flhD and flhC (P = 0.0091 and P = 0.0469, 
respectively) (Figure 2-5B).  Taken together, these results suggest that Arg
127
 is a key 
residue required for full PapX function, and plays a residue-specific role in the repression 
of motility by regulating expression of flhD and flhC. 
 
PapX binds to a specific DNA motif within the flhDC promoter 
Transcriptional data assessed by microarray, quantitative real-time PCR, and 
homology modeling suggested that PapX is a DNA-binding protein that acts directly on 
the flhDC promoter ([169], Figure 2-4B, Figure 2-5B).  As previously assessed by 
electrophoretic mobility shift assay (EMSA), PapX interacts with the 500 bases upstream 
of the flhD translational start site [169].  However, we had no data regarding sequence 
specificity of the target.  To validate these results and to hone in on the region of the 
flhDC promoter recognized by PapX, we constructed nested deletions of the flhDC 
promoter and fused them to a promoterless lacZ in pRS551.  Fusion constructs were 
transformed into CFT073 lacZpapX and CFT073 lacZ.  -galactosidase activity was 
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Figure 2-6. PapX repression of flhDC-lacZ promoter fusions. Nested deletions of the 
flhDC promoter were fused to promoterless lacZ in pRS551. Deletions contained 
progressively less of the 5’ end of the promoter. pRS551-flhDC promoter constructs were 
transformed into CFT073 WT (black bars) or CFT073 papX (white bars). No significant 
difference (NS, P > 0.05) was observed in -galactosidase activity as assessed by Miller 
assay between CFT073 WT and CFT073 papX using one-tailed t-test when only the 
first 360 bases of the flhDC promoter was included. Significant differences (*, P < 0.025) 
were observed when 501 bases or more of the flhDC promoter was included in the fusion 
construct.  
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measured using a modified Miller assay as a surrogate for promoter activity [195] 
(Figure 2-6).  A significant PapX-dependent difference in -galactosidase activity was 
observed in all fragments containing at least 501 bases of the flhDC promoter (P < 
0.025), but not in the fragment containing < 360 bases of the flhDC promoter (P > 0.13).  
Thus it is likely that PapX exerts its effect between -360 and -501 bases upstream of the 
flhDC start site.  Additionally, DNase protection and EMSA assays on the first 360 bases 
of the flhDC promoter failed to demonstrate sequence-specific effects (Supplementary 
Figure 2-3).  This is consistent with previous findings in EHEC, a relative of UPEC, in 
which the flhDC promoter has a drastically reduced ability to drive gene expression when 
fewer than 300 bases of the 3’ end of the promoter are present [151], as is the case with 
our fusions.  The promoter fusion data suggest positive factors interact upstream of 300 
bases that could be antagonized by a suppressor of flhDC transcription such as PapX. 
 
PapX binds to a short motif in the CFT073 chromosome 
To determine the exact binding site of PapX, we used SELEX methodology, an 
unbiased whole-genome approach [185], in conjunction with high-throughput sequencing 
technology.  This combined two robust methods for identifying subtle, but specific, 
binding motifs [187].  To identify such a motif, wild-type CFT073 genomic DNA was 
sheared to generate 80-100 bp fragments.  The resulting pool represented every possible 
80-100 bp fragment from the CFT073 genome (confirmed after construction by high-
throughput sequencing), or roughly 5x10
6
 unique members. Adaptors of approximately 
50-bp in length were paired-end ligated onto each fragment to complete library synthesis. 
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Table 2-3. Recombinant PapX purity by LC-MS/MS 
Protein  Ontology emPAI*  Coverage 
PapX Transcriptional regulator 28.21 60% 
L-glutamine:D-fructose-6-phosphate 
aminotransferase  
Metabolism .69 44% 
cAMP receptor protein Transcriptional regulator 2.27 53% 
FKBP-type peptidyl-prolyl cis-trans 
isomerase 
Protein folding .55 17% 
Aconitate hydrase B Metabolism .03 1% 
30S Ribosomal subunit S3 Translation .13 5% 
*Exponentially Modified Protein Abundance Index (emPAI) is an estimate of the prevalence of a species in a 
sample analyzed by LC-MS/MS. 
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Recombinant PapX-His6 was purified and analyzed by mass spectroscopy to 
confirm that it was the predominant species after purification (Table 2-3).  PapX-His6  
was then bound to Ni-NTA resin and a sample (200 l) of resin-bound PapX-His6 was 
incubated with library DNA (150 ng, 30 min, 37
o
C). Unbound DNA was removed with 
three washes in 20 mM imidazole column buffer; bound PapX-DNA complexes were 
eluted using 500 mM imidazole elution buffer.  DNA, isolated from the eluted PapX-
DNA complexes by phenol:chloroform-extraction, was PCR-amplified using primers 
specific for the paired-end adapters to ensure that only the library, and not contaminating 
DNA, was amplified.  The enriched library DNA was quantified with real-time PCR 
using primers specific to the adapters (but internal to the amplification primers) and then 
applied to a new Ni-NTA column containing bound PapX-His6. The entire process of 
binding the library to Ni-NTA-bound PapX-His6, amplifying bound members and re-
applying the enriched library to Ni-NTA-bound PapX-His6 was repeated for four cycles.  
The amounts of PapX-His6 and DNA used were empirically determined to be the least 
quantities that still allowed for low-cycle (i.e. unbiased) amplification [196] of each 
cycle’s DNA output to regenerate sufficient template for the next cycle of SELEX.  
The initial CFT073 sheared genome library, as well as the second, third and 
fourth libraries enriched by serial rounds of SELEX, were sequenced using a high-
throughput Illumina sequencing.  On average, 24  2.8 x 106 80-bp reads were obtained 
for each SELEX round, representing 400-fold coverage of the CFT073 genome.  
Sequences for each round were aligned to the CFT073 genome using a local BLAST 
(Figure 2-7A), showing a clear pattern of site-specific enrichment.  A dot-plot of the 
frequencies of hits at each position in the chromosome is shown for a single 
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Figure 2-7. Analysis of SELEX Illumina sequencing results. (A) The fourth 
enrichment of SELEX was sequenced and results were aligned to the genomic sequence 
of strain CFT073 using a local BLAST.  Frequencies of a sequence read at every 
chromosomal position were plotted using a dot-plot.  (B) Dot-plot of frequencies across 
SELEX rounds zero, two, three and four in the chromosomal vicinity of a prototypical 
low-frequency best-grade peak. (C) Representative example of chromosomal peak 
positions and their frequencies plotted against SELEX rounds zero, two, three and four.  
Grades of peaks are based on their pattern of frequencies across rounds and appears to the 
right (defined in the footnote of Table 2).  The MEME suite of sequence analysis tools 
were employed to determine if motifs were present in the list of 366 Best-grade peaks, 
generating two significant motifs.  (D) Position weight matrix present in 362 of the 366 
Best-grade peaks, E-value 4.5 x 10
-142
.  (E) Position weight matrix present in 269 of the 
366 Best-grade peaks, E-value 4.7 x 10
-140
.  
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representative peak across all sequenced rounds of SELEX (Figure 2-7B).  The width of 
peaks (160-200 bp) corresponds to roughly twice the size of an average member of the 
sheared genomic library, suggesting that PapX-His6 interacts with the CFT073 genome in 
a strongly sequence-specific manner.  Peak positions generated from the library of the 
final round of SELEX were overlaid onto each sequenced round of enrichment, and the 
frequency of occurrence at that chromosomal position was plotted against the round of 
enrichment (Figure 2-7C).  Peaks were graded based on their rate of enrichment across 
rounds (Table 2-4), with heavy weight given to positions that enriched under the most 
stringent environment (that is, the final rounds of enrichment), and discarded if they were 
too heavily represented in the control library at greater than two standard deviations 
above the mean positional frequency across the entire genome of the unselected initial 
library.  Sufficient selective enrichment occurred as indicated by the background 
representation of library members dropping to zero between peaks (Figure 2-7B).  These 
data were sufficiently rich to generate bell-shaped curves of predicted width (160-200 bp) 
and appropriate distribution from dot-plots, indicating that the protocol was successful at 
amplifying only regions that contained short, PapX-specific binding sequences.  Of the 
sequences generated from the fourth round of SELEX, frequencies at 94% of the 
chromosome were below the mean of the unselected library, and the frequency at 64% of 
chromosomal positions was 0.  This demonstrates that the majority of the chromosome 
was successfully counter-selected and did not interact with PapX as assessed by SELEX. 
Of 4,407 total peaks in the final round of enrichment, 366 satisfied the “best” 
criteria for peaks (Table 2-4).  Sequence flanking each best peak by 30 bases both up and 
downstream in the chromosome was analyzed using the online MEME suite of tools  
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Table 2-4. Positional-weight matrix motif derivatives prevalence in graded peaks and 
randomly selected sequences 
Motif All 
peaks
1
 
Best
2
 Good
3
 Moderate
4
 Poor
5
 Worst
6
 Control
7
 
Derivatives of 
GWWAWWWTWWC 
% % % % % % % 
 
AAAAT 50 62 49 41 49 46 18 
 
AAATT 34 48 34 23 34 23 11 
 
AAATTT 7 10 6 3 7 7 2 
 
AATTTC 12 22 12 5 11 7 3 
 
ATTTC 35 52 39 32 32 23 12 
 
TTATT 47 69 48 38 45 30 12 
 1 4407 peaks 
2 “Best” quality peaks are the 366 peaks that increased in frequency each round of SELEX 
3 “Good” quality peaks are the 932 peaks that increased in frequency in the final round of SELEX, and had a 
fourth round frequency greater than 2,800 
4 “Moderate” quality peaks are the 269 peaks that increased in frequency in the final round of SELEX, and had 
a fourth round frequency less than 2,800 
5 “Poor” quality peaks are the 2827 peaks that increased in frequency only in the first round of SELEX 
6 “Worst” quality peaks are the 13 peaks that decreased in frequency in the first round of SELEX 
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[192].  362 of the 366 (99%) best peaks contained a single core motif represented by 
positional weight matrix (Figure 2-7D), with an E-value of 4.1x10
-142
.  [E-value is an 
estimate of the expected number of a particular motif one would find in a similar, random 
set of sequences; thus, an E-value of 4.1x10
-142
 indicates a 4.1x10
-142
 probability the 
motif arose by chance.]  A second, modified version of this motif was found present in 
269 of the 366 (73%) best peak sequences and represented by positional-weight matrix  
with an E-value of 4.7x10
-140 
(Figure 2-7E).  Because motifs were calculated presuming 
positional independence, palindromes were more difficult to identify using the bits 
scoring system.  Within the 269 sequences, the second motif appeared as a palindrome, 
described using the International Union of Pure and Applied Chemistry (IUPAC) 
nomenclature as TT(7n)GWWAWWWTWWC(7n)AA (where W is A or T).  Database 
analysis using Microsoft Access verified that the palindromic form of the second, 
modified core motif appeared significantly more often than if by chance within the 269 
sequences in which the second motif was present (Table 2-4).  Altogether these 
represented the motifs with the lowest E-values within the set; the next lowest value 
motif was represented by fewer than 4 members with E-values greater than 10
-5
. 
To verify that these motifs were not emerging at random, two methods of 
validation were employed.  The input sequences were shuffled randomly and analyzed 
for motifs, which produced no motifs with E-values lower than 1,000 (that is, motifs 
generated from the shuffled set were very likely to have arisen by chance).  Additionally, 
six groups of 366 random peaks were generated using Matlab and analyzed in the same 
manner as the best peaks.  The rates of the predicted motif (Figure 2-7D) and several 
derivatives were significantly less common in the random peaks using Microsoft Access 
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(Table 2-4) and MEME could detect no significantly represented motifs from the random 
peak sets.  Together, these data suggested that PapX binds to the CFT073 chromosome in 
a sequence-dependent manner at a motif 11-29 bases long. 
 
PapX interacts with a short sequence within the flhDC promoter of CFT073 
Two best-quality peaks appear within the flhDC promoter (Figure 2-8A).  The 
larger of the two peaks, centered 410 bp upstream of the flhDC translational start site, 
centers around a perfect match to both predicted motifs, matching 11 of 11 and 29 of 29 
bases (Figure 2-8B).  The second, smaller peak at -624 bases upstream of the flhDC 
translational start site is a degenerate version of the motif, matching only 9 of 11 and 25 
of 29 bases.  To validate our findings, we used EMSA to shift the 154-bp fragment, -501 
to -346 bp upstream of the flhD translational start site, containing the best version of the 
predicted motif (Figure 2-8C).  The motility of the fragment through a 5% acrylamide 
gel was retarded in the presence recombinant PapX-His6.  This shift was dose-dependent 
with increasing concentrations of PapX.  In a competition assay, we competed the DNA-
binding reaction with unlabeled short sequences.  A 29-bp sequence (Figure 2-8B, bold, 
underlined) found within the 154 bp target fragment (representing a 29 of 29 nucleotide 
match with the second, modified core motif (TT(7n)GWWAWWWTWWC(7n)AA)) was 
added in 50-fold excess by mass (250-fold by molarity) to the DNA binding reaction 
between PapX and the 154 bp fragment, and was able to inhibit the shift.  A second 29 bp 
fragment derived from gapA was unable to reverse the shift under the same conditions 
(Figure 2-8C).  The 29 bp fragment found in the flhDC promoter appears only 
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Figure 2-8. PapX binds to the flhDC promoter. (A) Dot-plot of chromosomal 
frequencies by SELEX revealed two significant peaks within the flhDC promoter (arrows 
1 and 2). The peak under arrow 1 includes the predicted PapX binding site. (B) 
Schematic of the flhDC promoter, indicating the region -346 to -501 bases upstream of 
the flhD translational start used in subsequent gel-shifts. A perfectly identical (29/29) 
predicted PapX binding site is indicated in bold underline and is centered 410 bp 
upstream of the flhD translational start site. (C) Increasing amounts of PapX protein were 
added to 3.2 ng of DIG-UTP-end-labeled 154 base pair fragments derived from the flhDC 
promoter, the sequence shown in (B). Unlabeled competitor DNA at 50-fold excess by 
mass was added to the protein-DNA binding reaction for each of the last two lanes. “flhD 
29 bp seq” is the sequence indicated in bold underline in (B). “gapA 29 bp seq” is the 
sequence ACTCCACTCACGGCCGTTTCGACGGTACCG from gapA. (D) The 
competition assay performed in (C) was repeated using only the 0.50 g amount of 
PapX-His6 protein.  Additional sequences derived from the 29 bp competitor 
(TTACGGTGAGTTATTTTAAC, indicated by “flhD 21 bp seq” in the figure and 
GTTATTTTAAC, indicated by “flhD 11 bp seq” in the figure), determined by sequence 
analysis in (Fig. 2-7D) and (Fig. 2-7E) were also used in 50-fold excess by mass.  (E) 
Gel shifts were repeated with the same 154 bp fragment as in (C) and with 0.50 g 
amounts of wildtype PapX-His6 protein and PapX-His6 containing the Arg
127
Gly 
mutation.  
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once in the E. coli strain CFT073 genome, and no similar sequences appear in the 
TRANSFAC database by TfBlast. 
We also tested the ability of the motifs predicted by SELEX (Figure 2-7D, 2-7E) 
to bind PapX using the same competition assay approach.  Oligos matching the 11 bp 
sequence and 21 bp sequence were assayed for their ability to compete with DNA 
binding to the 154 bp flhD promoter fragment.  All competing fragments were added in 
50-fold excess by mass.  Results indicated that only the 29 bp fragment was able to bind 
PapX, demonstrated by its unique ability among competitor DNA fragments to reverse 
the shift observed with wildtype recombinant purified PapX and the 154 bp flhD 
promoter fragment (Figure 2-8D). 
As mentioned earlier, structural modeling predictions based on I-TASSER and 
alignments suggested that Arg
127
 in PapX could represent a key residue required for DNA 
binding [175-179].  To test this hypothesis, recombinant purified PapX-His6 containing 
the Arg
127
Gly point mutation was used in an EMSA assay against the 154 bp fragment of 
the flhD promoter (Figure 2-8E).  Wildtype recombinant PapX-His6 was able to shift the 
fragment, indicating binding, whereas the binding of the Arg
127
Gly mutant was ablated 
(Figure 2-8E). 
Taken together, these results suggest that PapX binds to the flhDC promoter in a 
sequence-specific manner at a novel, unique motif predicted by SELEX, at a position 
consistent with the findings of our flhDC promoter-fusion experiment. 
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Discussion 
Previously, we have shown that PapX regulates motility via transcriptional 
regulation of flhD and flhC in UPEC [169].  The current study expands upon this finding, 
defining the mechanism by which PapX, a 43 kDa non structural dimeric protein encoded 
by an operon that encodes P fimbria, mediates its effect.  Our structural and functional 
results indicate that PapX is a dimeric, helix-turn-helix DNA-binding protein of the 17 
kDa family, a MarR homolog that relies on Lys
54
 and Arg
127
 for full activity. Our novel 
use of SELEX in conjunction with high-throughput sequencing in bacteria indicates that 
PapX exerts its effect by binding to a unique, specific, previously unknown sequence, 
TTACGGTGAGTTATTTTAACTGTGCGCAA, within the flhDC promoter, centered at 
a position 410 bp upstream of the flhD translational start site.  Because PapX homologs 
are so closely related (>93% amino acid sequence identity), these findings have 
implications across a broad range of ExPEC strains and their likely regulation of motility 
and adherence. 
 
Evaluating the interaction of PapX and the flhDC promoter 
MarR family proteins tend to bind motifs between 21 and 45 bases long [180].  In 
addition, we demonstrated that neither the 21 bp motif (Figure 2-7E) nor the 11 bp motif 
(Figure 2-7D) are alone sufficient to bind PapX (Figure 2-8D).  The 29 bp palindromic 
form of the 21 bp motif, however was sufficient to bind PapX, whereas a 29 bp sequence 
that did not contain either the 21 bp or 11 bp motifs generated from gapA was unable to 
bind PapX (Figure 2-8C).  These data indicate that both the specific sequence content, as 
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well as the length of the sequence, are together necessary to mediate PapX binding to 
DNA.  This may explain why the palindromic form of the 21 bp motif did not appear in 
the Best-grade peaks; the software used to identify motifs, MEME [192], analyzes 
sequences for conserved nucleotides at given positions, but cannot predict important 
regions that are necessary for topological reasons or that contain degenerate sequence.  
Both motifs (Figure 2-7D, 2-7E) appear to be necessary and specific sequences, as 
indicated experimentally (Figure 2-8C, 2-8D).  This is supported as well in silico by their 
comparably low E-values, which were by far lower than any other motif identified.  This 
suggests that SELEX with high-throughput sequencing was successful at identifying 
necessary binding elements for PapX. 
Interestingly, a degenerate version of the 11 bp motif exists at the 5’ end of the 
360 bp fragment used in the lacZ fusions (Figure 2-6).  This may have produced a small 
degree of PapX interaction with the fragment, and may explain the elevated variance seen 
between replicate assays with the 360 bp fragment.  The variance appeared to be 
biological in origin, persisting across three repeats of the experiment, each using 
biological triplicates and technical duplicates.  It is also possible that PapX acts by 
antagonizing an activator, so a PapX binding site may be present in the 360 bp fragment 
but reduced upstream activator binding may explain the difference in -galactosidase 
activity. 
Over half of the 366 best peaks fall within predicted promoter regions for genes.  
As mentioned, over-expression and deletion of papX has a transcriptionally specific 
effect [169], with transcriptional regulation confined to a small list of genes or gene-
classes.  There are several possible explanations for this mismatch phenomenon.  First, 
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SELEX is a molecular technique that helps to make inferences about binding energy 
between a ligand and a nucleic acid sequence.  When aptameric libraries are used, limited 
inference about biological relevance of the strength of in silico ligand-protein interactions 
can be drawn.  SELEX is best used to identify target motifs, but follow-up, such as by 
EMSA or competition assay, is necessary to demonstrate biological significance. 
We have confirmed a direct interaction of PapX with a specific sequence within 
the flhDC promoter, and demonstrated a transcriptional effect on the downstream genes.  
By investigating a binding site known to produce an effect, we may discover additional 
clues to the mechanism whereby PapX regulates gene expression.  When theoretical sites 
are determined using aptameric libraries, there must be follow-up to confirm biological 
relevance, as the fact of DNA-protein interaction by SELEX is not sufficient to guarantee 
physiologically-relevant action.  Our studies have successfully demonstrated the utility of 
SELEX to identify a short, specific sequence within which a protein acts to modulate 
transcriptional regulation. 
 
Pathogen specificity of PapX-flhDC promoter interaction 
Our multiplex results (Figure 2-2) and motility assays (Figure 2-3) indicated that 
the effect of PapX is pathogen-specific.  However, the binding site identified by SELEX 
(Figure 2-8B, bold, underlined) appears as a 29/29 nucleotide match in the flhDC 
promoter of strain K12.  In this work and previously, control of motility in UPEC by 
PapX is mediated by flhD and flhC transcriptional repression.  Taken together, this 
suggests that there are additional factors present in strain CFT073 and absent in strain 
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K12 that affect the activity of PapX on flhD and flhC transcription, and that the mere 
presence of a nucleotide sequence with likely PapX affinity is insufficient to regulate 
downstream transcription in the commensal strain.  For example, PapX may be regulated 
by other factors (such as small molecules, as with salicylate derivatives and MarR [176]) 
that locally affect PapX activity at the site of regulation.  This may help to explain the 
discrepancy between the transcriptional effect of PapX described previously [169], which 
is limited to 42 differentially regulated genes (38 of which are downstream of flhD and 
flhC), and the list of hundreds of peaks by PapX with SELEX.  It is possible that PapX 
binds most or all of the peak regions identified, but that other factors are necessary to 
produce a differential transcriptional effect. Models of such an interaction include PapX 
binding resulting in displacement of activators, PapX acting as a scaffold for repressors, 
or PapX undergoing allosteric and conformational changes that would modify DNA 
topology and modify the binding properties of the flhD promoter for i.e. RNA 
polymerase. Additionally, the presence of a cofactor may reduce the promiscuity of 
afSELEX-seq selection for fragments.  The 29 bp fragment found in the flhDC promoter 
appears only once in the E. coli CFT073 and E. coli K12 genomes, offering further 
evidence of the specificity of transcriptional effect by PapX. 
 
Functional characterization of PapX 
Our data suggest that Arg
127
 in PapX is crucial for DNA binding (Figure 2-8E).  
Taken together with the loss of wildtype PapX phenotype of the Arg
127
Gly mutant seen 
by motility assay (Figure 2-3, Figure 2-4) and loss of transcriptional repression (Figure 
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2-5), suggesting that it is essential for PapX to bind DNA to exert its motility-repressing 
phenotype. 
In addition, within the PapX homologs, Ala to Thr substitutions are found 
commonly (Figure 2-1), occurring at residue positions 52, 82, 114 and 160.  Ala-Thr 
substitutions also affect protein activity in other proteins [197].  Our Ala
21
Thr mutation 
had full PapX activity by motility assay suggesting that at least at some positions this 
substitution is inconsequential for PapX activity.  It would stand to reason that 
substitutions that have a small or no impact on protein function will emerge by chance 
and not remain conserved, offering a potential explanation of why the Ala-Thr 
substitutions are common among the homologs. 
The combination of SELEX and Illumina high-throughput sequencing provided a 
high resolution map of putative PapX binding sites.  A single unique sequence within the 
genome of E. coli CFT073, a prototype of UPEC strains, was identified within the flhDC 
promoter, which controls flagellar gene expression.  Direct binding of the target sequence 
by PapX was demonstrated.  Repression of motility was observed in the pathogenic strain 
but not a non-pathogenic strain, suggesting the presence of additional factors required for 
this regulation.  Such accessory factors will be the target of future studies, which will also 
aim to address the discrepancy between the specific list of papX differentially regulated 
genes seen previously [169] and the more extensive number of peaks determined by 
SELEX.
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CHAPTER 3 
INVESTIGATING THE REGULATION OF PAPX 
 
Introduction 
To understand the mechanism of reciprocal control of motility by adherence, in Chapter 2 
we focused on the mechanism of action of PapX and its role in suppressing motility. 
Though we have begun to understand the mechanism of action of PapX, what remains to 
be understood is how PapX itself is regulated. Underscored in the model of reciprocal 
control is that motility-suppressing mechanisms should be up-regulated in the context of 
adherence. Thus, we sought to determine the relationship between PapX and adherence. 
As discussed in Chapter 2, uropathogens encoding papX also encode the pap operon up 
to 80% of the time. This suggests that there is an association between PapX and 
adherence. To further explore the relationship, we examined the levels of expression of 
papX mRNA and compared them to the levels of transcription of members of the pap 
operon. If papX expression is tied to that of the pap operon, we would expect analysis of 
the transcription of each under identical circumstances to be illuminating about the 
mechanism of papX regulation. We also created fusions of the region upstream of papX 
to a promoterless lacZ and assayed for -galactosidase activity to determine whether or 
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not papX may have its own promoter and own set of transcriptional controls. Results 
from transcriptional profiling and fusions lead us to consider other mechanism of control 
of PapX. 
As discussed in Chapter 2, an Arg
127
Gly mutant of PapX fails to inhibit motility 
of E. coli CFT073, and it is unable to bind the flhD promoter as judged by EMSA. Thus a 
simple model of PapX inactivation is that Arg
127
 is a crucial residue for establishing 
contact between PapX and DNA. Disruption of this contact would inhibit PapX 
repression of flhD. We also noted that a Lys
54
Asn mutant of PapX is unable to repress 
motility in E. coli CFT073. We sought to determine the contribution of Lys
54
, to shed 
light on the mechanism of action of wild type PapX. We performed DNA binding assays 
using the Lys
54
Asn mutant and found it bound flhD promoter DNA. This led us to 
consider an additional feature of PapX apart from merely binding of flhD DNA, and led 
us to postulate that post-binding events are important in the regulation of PapX activity. 
To attempt to determine if PapX interacts with cofactors that might explain the Lys
54
Asn 
inactivation phenotype, we performed co-precipitation experiments, in which 
immobilized, purified PapX was used to bind putative cofactors present in pooled 
wildtype E. coli strain CFT073 lysates. We predicted that by examining the enriched 
products of a co-precipitation, we would discover factors interacting with PapX to help 
explain how PapX’s post-binding activity is regulated. 
 
Results 
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Investigating papX transcriptional regulation 
We wanted to investigate how papX and its effects on the cell were regulated. 
Previous work has shown that papX mRNA can be amplified from a transcript of the pap 
operon [169]. That result suggested the simple model that regulation of papX may 
proceed via transcriptional control and that papX and pap expression should be 
coincident. This model is appealing because it provides a direct explanation of how an 
adherence factor might suppress motility. Microarray studies have compared CFT073 
collected from the urine of infected mice (in vivo condition) to CFT073 cultured in LB, 
either cultured statically or with aeration (in vitro conditions) [38]. In that work, most 
genes within the pap operon varied significantly between in vivo and in vitro conditions, 
but papX transcript levels did not change significantly (Figure 3-1A), suggesting that 
regulation of papX expression is influenced by other factors than merely the transcript 
levels of the pap operon. Additionally, the comparison between groups indicated that the 
pap operon is repressed in vivo compared to in vitro conditions. Later work scrutinizing 
the expression of mRNAs from human UTI isolates indicated that papX is generally up-
regulated in vivo [106]. Consistent with fliC in vivo, this further supports the notion that 
papX may be transcriptionally regulated at least in part independently of the pap operon, 
or perhaps that the phenotypic effects of papX on the cell are not regulated at the level of 
transcription. 
Past work by our lab had shown that suppression of motility in E. coli strains 
constitutively expressing Type 1 fimbriae (L-ON) is dependent upon papX, because 
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Figure 3-1. papX transcription is not regulated by the pap operon. (A) Transcript 
levels of the pap operon in E. coli CFT073 derived from mouse urinary tracts (left) or 
from culture in LB (right) as determined by microarray. papX transcript levels do not 
vary significantly between the two conditions. papAHDJKEF all vary. Data extracted 
from [38]. (B) papA and papX transcript levels as determined by qPCR in E. coli CFT073 
L-ON compared to L-OFF. papA transcript levels are 3.5 fold lower in E. coli CFT073 L-
ON as compared to L-OFF (p < 0.05). papX transcript levels did not vary significantly 
from a fold change of 1 between L-ON as compared to L-OFF.  
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deletion of papX in L-ON strains of E. coli CFT073 partially rescues the reduced-motility 
phenotype [169, 171]. Prior data also indicate that the Type 1 fimbria L-ON and L-OFF 
strains affect pap operon expression [113]. When incubated statically in liquid broth, 
known to induce Type 1 fimbrial expression [68] and suppress P fimbrial expression 
[107], L-ON strains repressed pap operon expression, especially pap_2, when compared 
to L-OFF strains of E. coli CFT073. 
We decided to test whether papX and pap operon expression would vary under 
conditions of L-ON compared to L-OFF strains of E. coli CFT073 under conditions of 
growth in aerated liquid culture. Using quantitative reverse-transcriptase PCR we directly 
compared the levels of expression of papA and papX mRNAs between the L-OFF and L-
ON strains. In our hands, papA expression was increased 3.5-fold in the L-ON strain 
compared to the L-OFF strain as judged by quantitative PCR (Figure 3-1B). Under the 
same conditions, papX expression was not significantly affected, as indicated by 
quantitative PCR (Figure 3-1B). The difference in trend of pap expression and type 1 
fimbrial expression is likely due to the difference in culturing conditions. We cultured the 
strains under aeration while previous work had studied the transcriptional effect under 
static growth conditions. This confirmed the trend that the phase-state of Type 1 fimbriae 
influences pap expression, and highlights the interesting feature that culture conditions 
influence fimbrial expression. In all cases, variation in expression of the pap operon 
appears to occur with no significant impact on the expression of papX. These data 
support the model that papX expression is regulated independently of pap operon 
expression. 
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To test this model, we cloned the DNA sequence between papG and papX within 
the pap operon in front of a promoterless lacZ in plasmid pRS551GX. The same technique 
was applied to the promoter of the pap operon to generate pRS551BA. Both constructs 
pRS551GX and pRS551BA drove lacZ expression compared to empty vector, suggesting 
that each of these regions contains at least minimal promoter elements. pRS551BA had 
roughly two-fold increased strength according to Miller assay as compared to pRS551GX 
(Figure 3-2A). In the L-ON background, the pRS551BA demonstrated a 2-fold increase in 
expression of lacZ compared to the L-OFF strain (Figure 3-2B, 3-2D). Both vector and 
pRS551GX showed no significant difference in lacZ expression between either L-ON or 
L-OFF backgrounds (Figure 3-2C, 3-2D). Together, these findings suggest that papX has 
its own promoter, and that expression of papX is neither dependent on Type 1 nor P 
fimbrial expression. 
 
Other regulators of PapX 
In Chapter 2, we demonstrated that PapX binds to the flhD promoter, and that it is 
likely that this binding is necessary for activity. We found that a Lys
54
Asn mutant of 
PapX does not repress motility in E. coli strain CFT073 by motility assay (Figure 2-4C). 
However, this mutant PapX does bind the flhD promoter by EMSA (Figure 3-3A). 
Binding without repression of motility suggests there are additional processes 
downstream of binding relevant to the motility-repressing effect of PapX. We were 
curious whether there were cofactors involved in full PapX activity. Several parallel  
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Figure 3-2. Type 1 phase state does not influence papX expression. (A) -
galactosidase activity was measured and calculated in Miller Units as a surrogate for 
promoter strength in the promoterless pRS551. pRS551GX and pRS551BA each drive lacZ 
expression, indicating that the fusions contain promoter elements. Vector did not express 
lacZ significantly over background. (B) pRS551BA drives statistically significantly (p < 
0.05) increased lacZ expression in L-ON strains than in L-OFF strains of E. coli CFT073. 
Vector control does not vary significantly from background in either background. (C) 
pRS551GX drives equivalent lacZ expression in L-ON strains than in L-OFF strains of E. 
coli CFT073. Vector control does not vary significantly from background in either 
background. (D) Fold change of -galactosidase activity attributable to pRS551BA and 
pRS551GX in L-ON relative to L-OFF backgrounds of E. coli strain CFT073. pRS551BA 
demonstrated significantly repressed -galactosidase in L-OFF compared to L-ON strains 
of E. coli CFT073. pRS551GX and vector did not demonstrate significantly repressed -
galactosidase in L-OFF compared to L-ON strains of E. coli CFT073.  
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Figure 3-3. PapX Lys
54
Asn binds flhD promoter but doesn’t repress motility. (A). 
0.50-g of recombinant PapX-His6 protein shifts 3.2 ng of DIG-UTP-end-labeled 154 bp 
fragment of the flhD promoter. An equal amount of the Lys
54
Asn mutant form of PapX is 
also able to shift the fragment under identical conditions. (B) WT papX encoded on 
pPxWT significantly (p < 0.05) represses motility of the UPEC strains F11 and 536 as 
compared to vector control. Lys
54
Asn encoded on pK54N does not significantly influence 
motility as compared to vector control.  
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approaches were employed to aid in discovering such a factor. First, we reasoned that 
strains of E. coli that display repressed motility in the presence of papX should have the 
factor present. As demonstrated in Chapter 2 (Figure 2-3), E. coli CFT073 displays 
repressed motility in the presence of papX, but E. coli K12 does not, suggesting that, if 
there is a factor, it is present in the former but not the latter. This experiment was 
repeated using other uropathogenic E. coli strains F11 and 536, both of which displayed 
repressed motility in the presence of papX (Figure 3-3B). 
To further refine the list of candidate proteins that may act in concert, we 
performed a co-purification. We reasoned that if a cofactor or cofactors exist, they should 
be associated with PapX. Nickel-NTA resin, either without modification (mock group) or 
loaded with recombinant, purified, His-tagged PapX (PapX group), was incubated with 
wild type E. coli strain CFT073 lysate. His-tagged PapX has been shown to be 
phenotypically active by motility assay (data not shown). Eluate was subjected to tandem 
LC-MS/MS mass spectroscopy, and the resulting species of each group were compared to 
highlight factors from the lysate of E. coli CFT073’s lysate present or enriched in the 
presence of PapX-His6 but not by Nickel-NTA resin alone. Proteins were identified by 
searching an E. coli CFT073 database. We searched only for proteins with at least 5 
spectra using Assigned Spectra in Scaffold (Proteome Software Inc. 2005-2010) with a 
minimum peptide value of 95% and protein value 99.9%. 21 proteins had more spectra in 
the PapX group as compared to the mock group, and only 6 proteins had no spectra in the 
mock and at least 5 in the PapX group, which we took to be the enriched proteins. We 
scrutinized the enriched proteins for members that were different between E. coli K12 
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Table 3-1 Tandem LC-MS/MS spectroscopy results 
Identified Protein 
Molecular 
Weight # spectra
1
 in mock # spectra
1
 in PapX 
PapX 19 kDa 2 161 
PapX 19 kDa 0 14 
OmpA 37 kDa 0 5 
1
# spectra refers to the total number of spectra in the LC-MS/MS analysis that matched 
an identified protein. This is an estimate for the presence of a given protein species. 
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and E. coli CFT073, F11 and 536. Three proteins were not 100% identical between K12 
and the pathogenic strains (Table 3-1). The first two were identified as PapX and are 
likely two products of the same species, which was enriched 88-fold in the PapX group as 
compared to mock. The other two was the outer membrane protein OmpA, which was 
absent in the mock as determined by LC-MS/MS. 
In E. coli strains CFT073, 536 and F11, OmpA is 96%, 98% and 36% identical to 
that of K12. The OmpA of E. coli CFT073 has an additional 5 amino acid domain 
between positions 160-165, whereas the OmpA of E. coli strain 536 has only sporadic 
substitutions and the OmpA of E. coli strain F11 almost wholly distinct. The deviations 
of OmpA in the uropathogenic strains from OmpA of the commensal strain were not 
conserved.  
 
Discussion 
 
PapX is not regulated in the same manner as the pap operon 
papX resides at the 3’ end of the pap operon, so the simplest model of regulation 
of PapX activity put forward was that papX expression would increase when pap 
expression increased, increasing PapX activity and reducing motility when adherence 
was up-regulated. However, using qPCR, we found that papX transcript levels were 
unaffected when expression of the pap operon varied significantly. This result supported 
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prior microarray findings (Figure 3-1B). Even though expression state of Type 1 
fimbriae (L-ON vs L-OFF) has been shown to mediate motility in a partially papX-
dependent manner [169], we found that papX expression was no different in E. coli strain 
CFT073 when Type 1 fimbirae were L-ON as compared to L-OFF by qPCR (Figure 3-
1B). Our results suggested that papX has its own promoter in addition to being expressed 
on a transcript that includes the rest of the pap operon, and indeed, the region between the 
end of papG and the start of papX was able to drive lacZ expression in the pRS551GX 
construct (Figure 3-2A-D). In Type 1 fimbrial L-ON and L-OFF E. coli CFT073 
backgrounds, these fusions also showed no difference in lacZ expression, indicating that 
the putative promoter before papX does not vary in strength of expression in a Type 1 
fimbrial-dependent manner. We concluded that a model was likely in which papX has its 
own promoter, and that PapX activity is not regulated at the level of transcription. The 
papX homolog, prsX, shares an identical putative promoter region, whereas the other 
homologs of papX in UPEC strains, namely focX, sfaX, fotX, and prfX, contain unique 
putative promoter regions preceding the genes. The shared promoter elements indicate 
that our findings pertinent to papX transcriptional regulation are applicable to several 
members of the 17 kDa-protein family in UPEC. Future studies could be performed to 
determine whether or not focX, sfaX, fotX, or prfX are regulated at the transcriptional 
level. 
This left us with the question of how PapX activity may be regulated. Previous 
work has demonstrated that MarR-type transcription factors can be regulated post-
translationally. Our afSELEX-seq data predicts that PapX can bind at numerous regions 
within the CFT073 genome in vitro, as many non-identical fragments were enriched 
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during afSELEX-seq (Figure 2-7A). However, as mentioned, over-expression and 
deletion of papX has a transcriptionally specific effect [169]. In addition, the E. coli strain 
K12 used in Chapter 2 (Figure 2-3) has an identical flhD promoter region to that of E. 
coli CFT073, yet papX exerts no phenotypic effect on the motility of E. coli strain K12. If 
the predictions from afSELEX-seq are accurate and PapX is able to bind promiscuously, 
but only regulates the expression of a much smaller number of genes, then another factor 
or condition must be invoked to explain the discrepancy. One possible explanation is that 
a local (i.e., non-diffusible) factor interacts with papX at certain promoters, acting as a 
cofactor in transcriptional regulation. 
 
Other factors may interact with PapX 
In Chapter 2 we demonstrated that Arg
127
Gly and Lys
54
Asn mutations of PapX 
are incapable of repressing swimming motility at 30
o
C (Figure 2-3). Arg
127
Gly does not 
bind DNA by EMSA (Figure 2-8), and so presumably is incapable of targeting the flhD 
operon for repression. However, Lys
54
Asn is able to shift the same fragment of the flhD 
promoter as wildtype PapX (Figure 3-3A), indicating that it can bind the flhD promoter 
under certain conditions. This result suggests that there are downstream events that 
follow PapX binding that also influence motility, and that binding alone is insufficient to 
repress motility. The Lys
54
 is found within the putative dimerization domain of PapX, but 
we have shown that the Lys
54
Asn mutant still dimerizes. pK54N does not increase 
motility in WT E. coli CFT073, indicating that the mutation does not display a dominant 
negative phenotype. This domain could also potentially serve as a binding domain for 
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other similar proteins, so the mutation may disrupt the interaction of PapX with a 
cofactor. MarR family proteins may be allosterically regulated by small molecules and 
proteinaceous cofactors instead of, or in addition to, being regulated by transcriptional 
mechanisms controlling expression [176-178, 180]. 
To narrow the list of candidate factors, we expanded the number of strains that 
did or did not experience repressed motility in the presence of papX. Motility assays 
performed on uropathogenic E. coli strains F11 and 536 in the presence or absence of 
pPxWT (encoding wildtype PapX), pVector, and pK54N indicated that motility of these 
strains was repressed in the presence of papX (Figure 3-3B). This result helps us to 
narrow the candidate list of factors that may influence PapX activity. If a single unique 
factor explains the difference in response, then only factors common to E. coli strains 
CFT073, F11 and 536, but not present in E. coli strain K12, should be responsible for the 
difference in response to papX. A simple model to explain the difference in response to 
PapX between pathogenic and non-pathogenic strains is that one or more proteins could 
be cofactors for PapX. 
To discover factors that interact directly with PapX, we performed a co-
precipitation experiment. PapX was 88-fold enriched in the PapX group compared to the 
mock, confirming that there was a sharp difference in the conditions. PapX levels were 
the most different between mock and the PapX group, suggesting that the differences 
between groups can be most directly attributed to PapX itself. 21 Proteins were enriched 
in the PapX group compared to the mock group, indicating that we had concentrated 
factors that are associated with the presence of PapX. Of those proteins, only one, OmpA, 
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was enriched that was common to E. coli strains CFT073, F11 and 536, but was not 
identical in E. coli strain K12. OmpA has been tenuously linked to motility and flagellar 
rotation, so it is possible that it serves as a cofactor or is acted upon by PapX to produce a 
phenotype [198]. 
OmpA is also involved in acid stress response [199], which is also known to 
affect motility, so it is plausible that OmpA could be an environmental sensor coupled to 
PapX. Acid stress may be related to motility because it affects proton motive force and 
proton transport across the membrane, which is necessary for flagellar rotation [147]. 
OmpA is an appealing candidate because it has been shown that ompA is one of the most 
highly up-regulated genes during UTI [38]. Unfortunately, non-identical regions of 
OmpA of uropathogenic strains and OmpA of the commensal strain are not completely 
conserved. If changes were uniquely linked to PapX, we would expect some of the 
changes to remain consistent between strains. However, given that single amino acid 
substitutions in PapX are sufficient to abolish activity, it is possible that the differences in 
OmpA sequence are meaningfully linked to activity. It is possible that any disruption of 
OmpA is sufficient to change its interaction with PapX. It is also possible that 
uropathogenic strains express OmpA at different times or to different levels than 
commensal strains of E. coli. Future work could consider examining the effects of 
pPxWT on strains lacking OmpA and assaying for an impact on motility. OmpA from a 
uropathogenic strain could also be transformed into a commensal strain of E. coli, and 
motility could then be assayed. 
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OmpA is an outer membrane that acts as a large porin, capable of transmitting 
many compounds. If PapX affects OmpA activity, one might hypothesize that 
compounds transmitted into the periplasm and intracellular space by OmpA (such as ions 
or small molecules) could influence PapX binding behavior, impacting downstream PapX 
activity negatively or positively. However, OmpA is located at the outer membrane, 
whereas PapX is cystosolic. Cytosolic proteins are typically separated from direct 
interaction with outer membrane proteins by the cell membrane, and this physical 
separation of compartments raises a question over how these proteins might interact. Our 
co-purification study should assay for direct interactions, so either recombinant PapX-
His6 interacts with the outer membrane, or it could be interacting with OmpA as it is 
being synthesized in the cytosol. I have already presented evidence that PapX is a direct 
DNA binding protein and that DNA binding is important to activity, so the most 
parsimonious model is that PapX interacts with OmpA in the cytosol. Only small 
quantities of incomplete OmpA peptide should be present in the cytosol relative to the 
outer membrane, perhaps explaining why so few spectra of OmpA were seeing in the co-
purification. One hypothesis is that PapX may affect OmpA folding or trafficking to the 
membrane, which in turn affects E. coli cell membrane permeability to outside 
compounds, which themselves interact with PapX to modulate activity. 
Further experimental investigation of this model is required. Studies investigating 
the affinity of PapX for OmpA could be performed using a yeast two-hybrid screen. Our 
co-purification is performed in vitro, and thus falls prey to the pitfall of potentially not 
representing the biologically relevant and physiological conditions of a bacterial cell. 
Alternatively or in parallel to the in vitro co-purification, antibodies to PapX could be 
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synthesized and an in vivo co-precipitation could be done to attempt to discover proteins 
interacting with PapX under native conditions. Preliminary results suggest that PapX is 
not present in large quantities within the cell, so this approach could have the advantage 
of not misrepresenting stoichiometry of native interactions. However, in turn, the quantity 
of starting material to be co-precipitated would have to be large so that sufficient sample 
could be analyzed by LC-MS/MS or other protein identification and quantitation 
methods. 
It is possible that no single factor can explain the difference in responsiveness 
between commensal and uropathogenic strains of E. coli in response to PapX. If a group 
of factors act in tandem, or if a scaffold that associates factors together is causative, for 
example, then the results of a co-precipitation will be more difficult to interpret. Proteins 
and factors may be identical between uropathogenic strains and commensal strains, but 
the ratios, combinations, or other conditions (such as pH or ion concentration) in the 
cytosol may be the explanatory factor. These would not have appeared as single enriched 
species in a co-precipitation. In addition, though we made efforts to generate 
stoichiometrically physiologic ratios of PapX to other E. coli strain CFT073 cystosolic 
proteins, expression is often difficult to balance precisely. PapX in excess of native levels 
may bind promiscuously or saturate binding too quickly on a physiologically relevant 
target. We know from past experience that PapX is prone to precipitating out of solution 
at inconvenient concentrations and times, which suggests it may bind non-specifically 
under the proper conditions. 
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CHAPTER 4 
A NOVEL APPROACH FOR TRANSCRIPTION FACTOR ANALYSIS USING 
SELEX WITH HIGH-THROUGHPUT SEQUENCING (TFAST) 
 
Introduction 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX) is a 
technique for determining nucleotide binding sites of transcription factors ([183, 184] and 
reviewed in [185]). SELEX is an iterative method where the products of one cycle are 
used to generate the input for the next (Figure 4-1A), enriching strongly binding 
sequences in the output. In the past, only the terminal cycle was analyzed, and typically 
50 or fewer members of the cloned output library were sequenced, which typically meant 
that SELEX had to be performed so that the vast majority of the final library consisted of 
a single or very few species  [183, 184]. However, doing so runs the risk of eliminating 
physiologically relevant, but less strongly binding, DNA targets. High-throughput 
sequencing has made SELEX-seq possible, in which intermediate cycles are analyzed and 
millions of members of each cycle are sequenced. Using SELEX-seq, it is possible to 
identify the cycle at which all non-binding species have been selected against (when the 
background frequency drops below that of the initial library), and to halt iterative cycles 
before potentially biologically important species have been eliminated from the pool. In 
this way, SELEX-seq permits the accumulation of many more potential target species
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Figure 4-1. Schematic of the TFAST workflow. TFAST analyzes data produced using 
SELEX and high-throughput sequencing. (A) An overview of SELEX. Members of an 
input DNA fragment library compete to bind a protein of interest. Out-competed 
fragments are washed away and removed. Fragments that bind competitively are 
recovered and separated from the protein (e.g., by phenol-chloroform extraction). 
Recovered fragments are amplified using low-cycle PCR, and the resultant library 
becomes the input for the next cycle. n cycles are repeated to enrich for strongly binding 
fragments. (B) DNA inputs for each cycle are subjected to high-throughput sequencing. 
Sequence reads are aligned to the relevant target genome, producing (C) frequency-
position plots for each input sequenced. Shown is a magnified example of a region of the 
chromosome that behaves as a true binding site, enriching in frequency with each cycle. 
“Cycle 1” refers to the initial DNA library. (D) TFAST identifies and evaluates peaks and 
compares peak characteristics across all sequenced inputs. TFAST assigns quality scores 
to peaks and predicts binding site features. TFAST also generates quality scores on 
randomly selected regions of the chromosome to act as background controls, to improve 
downstream motif analysis.  
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than SELEX as it has been classically performed. In addition, SELEX-seq represents an 
improvement over SELEX in the detection and analysis of binding sites because behavior 
of the library can be scrutinized in million-fold greater detail. 
The elevated level of detail in SELEX-seq compared to SELEX is similar to the 
increase in detail between terminal (discrete) transcriptional profiling, such as PCR, and 
real-time (continuous) methods, such as qPCR. Determining DNA binding sites has 
traditionally been a labor-intensive and intricate process. The improved resolution of 
SELEX-seq over SELEX represents an increase in dynamic range and a concurrent 
reduction in type II error, which improves confidence in the results of SELEX-seq 
analysis and makes SELEX-seq less subject to in vitro biases because library behavior 
can be tracked across cycles, so loss of binding candidates can be tracked to specific 
environments. The resulting increased level of detail allows the results of SELEX-seq to 
be used for inferences about binding site affinity and length, where SELEX can only 
approximate species with discrete high or low affinity, and cannot speak to site length or 
genomic context. 
SELEX-seq can detect the presence of library members and quantify their 
representation, making it possible to estimate binding affinities of many sequences and to 
compare sequences to one another to generate motifs [186-189]. This advance also 
obviates the need to run the protocol until only a single sequence predominates in the 
terminal cycle. In fact, successful SELEX-seq experiments depend on multiple species 
being detectable in the terminal sequenced cycle to accurately infer binding 
characteristics [186]. 
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Usually, the library of DNA to be enriched consists of random-sequence 10-20 bp 
oligonucleotides, called aptamers. This type of library is especially useful when a specific 
subset of aptamers is itself the desired end-product. Inter-cycle computational 
comparators (see [186, 187, 200] for examples) utilize the iterative nature of SELEX-seq 
to calculate binding affinity and activity of individual aptamers or aptamer sets, which is 
useful in designing therapeutic aptamers [201-203]. However, use of aptameric SELEX-
seq for discovery of genomic binding sites may be problematic. Aptameric libraries are 
by definition random, so a given sequence may not be found within a target genome and 
thus discovered sequences may lack physiological relevance. Aptamers also lack 
genomic context, so that binding behavior may obscure in vivo findings by too strongly 
reflecting in vitro conditions [204]. 
To address these potential pitfalls of SELEX-seq, we designed an aptamer-free 
SELEX-seq protocol (afSELEX-seq) that uses sheared genomic dsDNA as the input 
library, with which we successfully identified a novel and single-copy transcription factor 
binding site [188]. Our approach incorporates the advantage of multiple-round 
enrichment with a physiologically relevant target library. In afSELEX-seq, the results of 
every sequenced cycle are aligned to a target genome (though not every cycle needs to be 
sequenced), and alignments are compared between rounds to predict binding sites. To 
process our results, it was necessary to develop software capable of both analyzing 
chromosomal alignments and acting as an inter-cycle comparator. Transcription Factor 
Analysis using SELEX with High-Throughput sequencing (TFAST) was written in Java, 
and once sequences have been aligned to the genome of the target organism (for example, 
with BLASTn [205] or BOWTIE [206]), TFAST completes analysis in minutes on a 
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personal computer. TFAST was designed to be useful to a broad range of biologists, so it 
employs an uncomplicated graphical interface to streamline its use. It is easy to install, 
requiring no special expertise in bioinformatics. 
 
Materials and methods 
 
Peak identification 
afSELEX-seq is performed using sheared genomic fragments, and the products of 
each of multiple cycles are subjected to high-throughput sequencing. Sequence data are 
aligned to the target chromosome using either BLASTn or any alignment method capable 
of producing output in SAM format (Figure 4-1B). TFAST processes the same number 
of aligned reads from each cycle, thus reducing the impact of variability in sample read 
quality and completeness, to generate single column tables representing frequencies of 
aligned tags at every position within the target genome. TFAST then uses a modified 
sliding window algorithm (see [207] for a review of sliding window algorithms) to 
identify peaks in the final round of afSELEX-seq (Figure  4-1C). The sliding window 
width is set to twice the estimated fragment length of an average library member and 
proceeds along the chromosome in single-nucleotide increments to identify strict 
maxima. To be considered peaks, maxima must be greater than two standard deviations 
above the mean frequency of the control (unselected) cycle within a range around the 
peak (distance set by user). Minimum spacing to identify individual peaks is set at a 
single fragment length, with the exceptions that deep valleys (<50% adjacent peak value) 
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between peaks or adjacent peaks within 75% frequency of one another are both delimited 
as separate. 
 
Peak scoring 
Frequencies at each peak position are compared across all cycles of afSELEX-
seq, allowing the program to score peaks based on rate of enrichment as a proxy for 
binding affinity consistent with existing models of enrichment during SELEX (Figure 4-
1C and D) [185, 186, 189, 208, 209]. Sequences are given a cumulative score for each 
round in which they are able to enrich, so that sequences that remain strongly competitive 
for binding throughout afSELEX-seq achieve the highest scores. To reflect the increasing 
stringency of competition for binding in later rounds, the user should set scores for 
enrichment between cycles to be directly proportional to the bulk affinity of the library 
within each cycle. This causes TFAST to weigh later-round (i.e., more stringent) 
enrichment more heavily than early-round enrichment, improving the discrimination of 
strongly-binding sequences. 
TFAST then generates information on the relative representation of each peak, 
annotated as a raw final frequency and fraction of the area under a given peak in 
comparison to the total area under all other peaks in that cycle. TFAST also prints the 
genomic sequence under each peak (range determined by user) and outputs all data in 
tab-delimited format for downstream analysis. This format is designed to dovetail 
smoothly with methods for the discovery of DNA binding-site motifs. TFAST also 
automatically produces and analyzes sets of random sequence positions denoted “spoof” 
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peaks, which can be used to improve motif discovery through counter-selection and 
background modeling. TFAST does not generate negative peaks, which are sometimes 
used to refine motif discovery, because counter-selection in afSELEX-seq produces a 
background of zero frequency between peaks. This means that negative peaks are 
artifacts of variation in control cycle sequencing and not indicative of especially poor 
regions of protein:DNA interaction. 
 
Binding site sequence length prediction 
TFAST is designed to estimate the length of a putative region of protein:DNA 
interaction. Members of a dsDNA library should only have specific affinity for the 
protein of interest if they include the binding sequence. The full width of any peak over a 
single binding site will be twice the length of an average library member less the length 
of the binding site. TFAST calculates the full width of a peak as the range along the 
chromosome that includes 99% of the area under the peak, and then uses the width to 
calculate a predicted length for any binding site. Predicted length is included with the 
output of peak features. 
 
Results and discussion 
 
TFAST accurately discriminates peaks in afSELEX-seq data 
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To validate our peak calling method, we compared peak detection between 
TFAST and MACS [191] in an afSELEX-seq dataset generated in prior work [188]. We 
chose MACS because it is an established and well-vetted peak finding program designed 
for use with aligned high-throughput sequence data. TFAST called 96% of regions 
identified by MACS as peaks, and subdivided large peaks into multiple smaller ones 
(Figure 4-2A). In detection of enriched regions, TFAST and MACS had a simple 
agreement of 0.98 and a  value of 0.89, values generally considered to indicate near 
perfect agreement. [Footnote: The simple agreement of 0.98 and the of 0.89 between 
MACS and TFAST were calculated under the simplifying assumption that the 5,231,428 
bp genome of E. coli strain CFT073 is divided into 26,157 candidate peak regions of 200 
bp. Analysis assuming 13,079 candidate peak regions of 400 bp yields a simple 
agreement of 0.96 and a  value of 0.88.] 
 
TFAST peak grading correlates with informational density of discovered 
motifs 
When TFAST was used to process our dataset, 2,628 total peaks were identified, 
of which 457 achieved the highest weight (“Best” peaks), or 17.4% of the total peaks 
called. When peaks are called without using the last or last two enrichment cycles, 4,255 
and 7,274 peaks are identified, respectively, with a concurrent loss in specificity in 
identifying the “Best” peaks (31% and 100%, respectively) (Table 4-1). This 
demonstrates TFAST’s unique advantage of using iterative cycles over simply the final 
set of peaks. Additionally, we instructed MEME [192] to discover 15 bp positional 
weight matrices (motifs) from peaks picked by TFAST or MACS  (Figure 4-2B-K).  
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Figure 4-2. TFAST identifies peaks with discoverable motifs from afSELEX-seq 
data. TFAST and MACS were used to pick and evaluate peaks from our data set. (A) 
TFAST picked a total of 2,628 peaks, of which 2,197 covered 96% of the peaks identified 
by MACS in the final cycle of afSELEX-seq. Positional weight matrices generated in 
MEME instructed to search for a 15 bp motif using 200 sequences from (B) the 457 
“Best” weight (most enriched) peaks, (C) the 888 next-best weight (second most 
enriched) peaks, (D) the 1,283 worst weight (least enriched) peaks, (E) all peaks called 
by TFAST pooled together and (F) 200 peaks called by MACS with the lowest false 
discovery rate (FDR). Sets of peaks from (B-F) were subjected again to analysis by 
MEME under the similar conditions but with the inclusion of a zero-order background 
Markov model to generate (G-K). E-value (the chance that a motif arose from a dataset 
by chance) and bit score (the total information content of a positional weight matrix) are 
shown below each logo.  
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Peaks with the best, second best and worst weight scores identified by TFAST had e-
values (an estimate for likelihood of a motif arising by chance) of 1.2 x 10
-73
, 2.9 x 10
-46
 
and 4.5 x 10
12
, respectively, and informational content of 12.5, 11.9 and 11.0 bits, 
respectively (Figure 4-2B-E). This indicates that TFAST was successful at stratifying 
classes of peaks over consistent sequences in the genome, and that positional weight 
matrix reliability was greatest in the “Best” peaks. 
All peaks discovered by TFAST pooled together generated a positional weight 
matrix with an e-value of 2.5 x 10
-107
, an intermediate value that was less significant than 
“Best” peaks selected by TFAST (Figure 4-2E). Furthermore, pooled peaks picked by 
MACS produced a logo with an e-value of 0.54, which was not significant. Using the 200 
MACS peaks with the lowest false discovery rate (FDR), MEME was able to generate a 
positional weight matrix with an e-value of 1.8 x 10
-3
 and informational content of 9.8 
bits (Figure 4-2F). No other subset of MACS peaks (i.e., peaks with lowest p-value, 
greatest fold enrichment, etc) generated a logo with an e-value less than 1. This is a 
substantially larger e-value than that generated from the peaks discovered in TFAST, 
likely because the average width of peaks picked by MACS was 503 ± a standard error of 
9.71, whereas all peaks picked by TFAST were under 200 bp wide. These findings 
support the method employed by TFAST of picking many narrow peaks based on 
absolute local maxima, coupled with fragment length, rather than statistical modeling of 
aligned sequences. 
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Table 4-1. Incorporation of increased SELEX cycle number improves peak 
discrimination 
Number of cycles 
used
a
 
Total peaks 
called
b
 
Number of “Best” 
peaks
c
 
Percent “Best” peaks of 
total 
3 2,628 457 17.4 
2 4,255 1,350 31.7 
1 7,274 7,274 100 
a. “Number of cycles used” does not include control 
b. “Total peaks called” refers to peaks called using TFAST’s algorithm 
c. “Best” peaks are peaks with the highest weight scores for that set, as calculated by TFAST. 
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Background models derived from TFAST improve motif discovery 
To validate the use of spoof peaks (described in methods) to improve motif 
discovery, we generated a zero-order Markov model from the spoof output of TFAST. 
When we incorporated the model into our motif discovery using MEME, the information 
content of the motifs rose by an average of 0.78 bits or 6.3%, and e-value fell by an 
average of 8.2 x 10
-133 
for peaks picked by TFAST (Figure 4-2G-J). Additionally, the 
Markov-corrected 15 bp motif from the “Best” weight sequences picked by TFAST most 
accurately predicted the 15 bp core of the previously validated binding site 
GTTATTTTAAC [188]. Use of the Markov model also strengthened the motif generated 
from MACS, improving information content from 9.8 to 10.0 bits or 2.0% and the e-
value from 1.8 x 10
-3
 to 2.3 x 10
-87 
(Figure 4-2F, 4-2K). Overall, this supports the notion 
that using an accurate background model generated from TFAST can improve the ability 
to discover significant motifs in downstream peak analysis, and improves total motif 
informational content. 
 
TFAST can accurately predict binding site sequence length 
In our data set, TFAST predicted a binding site width for the “Best” peaks of 
20.88 bp ± a standard deviation of 10.33 bp, consistent with the motifs discovered. 
Additionally, TFAST predicted the binding site for the peak in the flhD promoter of 
CFT073 for PapX to be 28 bp. Experimentally, PapX binds a 29 bp fragment of the flhD 
promoter, but not a truncated 21 bp fragment [188]. The consistency between the 
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prediction made by TFAST and the experimentally verified binding site indicates that 
TFAST is capable of predicting binding site length from afSELEX-seq data. 
 
Advantages of afSELEX-seq over SELEX and SELEX-seq 
afSELEX-seq has several advantages over SELEX and SELEX-seq.  Instead of 
using an aptameric library [185], our library was constructed directly from sheared 
CFT073 genomic DNA, generating paired-end ligated 80-100 bp fragments.  A typical 
SELEX-seq aptameric library contains 10
13
-10
15
 members of 10-20 nucleotides in length 
[210], whereas our library contained only 5 x 10
6 
unique members (and 10
6
 of each 
unique member per cycle of SELEX), each 80-100 bp in length, resulting in a high-
stringency selection throughout.  Because we had substantial evidence that the putative 
transcription factor under investigation, PapX, exerted its effect on genes within the 
CFT073 genome [169] (Figure 2-3), the best binding site was, of course, likely to be 
present in this library.  Additionally, because aptameric libraries are usually generated at 
random and aptamers may be shorter than a complete binding site, a problem that SELEX 
and SELEX-seq encounter is questionable physiologic relevance of a determined motif 
[209].  Therefore, a maximally bound motif may not actually be present in any organism.  
afSELEX-seq circumvents this weakness.  In addition, some physiologically relevant 
consensus sequences rarely appear as perfect matches; for example, the Shine-Dalgarno 
sequence, a ubiquitous ribosomal binding site found in E. coli, frequently appears as an 
imperfect, 4/6 or 5/6 match, yet still remains functional.  In fact, varying the degree to 
which a given Shine-Dalgarno site matches the consensus is a means of regulating 
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translation [211].  Indeed, any positive hits from our library should be, by definition, 
present in the CFT073 genome and are thus more likely to be physiologically relevant. 
Additionally, because afSELEX-seq uses longer probes than SELEX-seq (80-100 
bp and 10-20 bp, respectively), information about neighboring binding sites is retained in 
afSELEX-seq that might have been lost in SELEX-seq. For example, if the transcription 
factor under investigation frequently binds in the proximity of other associated 
chromosomal target regions of other factors, those sites may be revealed and provide 
insight into novel interactions between that transcription factor and other species.  It is 
more difficult to precisely contextualize aptamers in an organism’s genome because their 
short length reduces the strength of an alignment. 
To identify target sequences using SELEX and high-throughput sequencing, a 
sufficient coverage of the target genome must be used in the initial library.  For each 
cycle of SELEX, roughly 3 x 10
12
 80-bp fragments (or 2.4 x 10
14
 nucleotides) were 
exposed to immobilized protein.  The quantity of fragments selected suggest that this 
technique could be adapted to eukaryotic genomes and still preserve hundred-thousand 
ranges of representation at each nucleotide position in the probed sample.  The 2.5 x 10
7
 
reads per lane generated in high-throughput sequencing limits the use of the control 
library in establishing quality scores for peak enrichment.  However, the peak scoring 
algorithm applies between enriched rounds as well as between the control library and the 
first enrichment, and so a few rounds of SELEX should be sufficient to generate initial 
peaks from which to base subsequent scoring in a eukaryotic schema. 
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Conclusions 
Here we present TFAST, an easy-to-use tool for rapidly and accurately analyzing 
data generated by afSELEX-seq to discover and characterize transcription factor binding 
sites. Currently, no other software is designed to analyze afSELEX-seq. The peak finding 
component of TFAST compares favorably to that of MACS. For use with afSELEX-seq, 
TFAST outperforms MACS in generating significant motifs. The scheme TFAST 
employs for grading and analyzing peaks uniquely leverages the cyclical nature of 
SELEX and direct protein:genomic dsDNA interactions to accurately and sensitively 
predict binding site sequence and length, as demonstrated by the consistent concurrence 
between predictions generated by TFAST and our experimental findings [188]. 
afSELEX-seq offers an alternative to current methods of discovering DNA 
binding sites, and requires no antibody generation (unlike ChIP-seq (reviewed in [181] 
and references therein)) or complex biological screens (unlike bacterial 1-hybrid systems 
[190]). Large libraries of purified, tagged bacterial proteins of unknown function 
currently exist at institutions participating in the Protein Structure Initiative [212]. This is 
sufficient material to run afSELEX-seq, and with only minor modifications the binding 
sites of hundreds if not thousands of transcription factors could be quickly elucidated. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary of results 
The studies presented here address the role of PapX in repressing motility as a 
component of reciprocal control of motility and adherence. Specifically, we investigated 
the mechanism by which PapX exerts its effects, and made progress in identifying 
mechanisms by which PapX may be regulated. The major findings of this work are 
described briefly: 
*PapX and its numerous homologs are commonly present in ExPEC and UPEC 
strains. 
*Uropathogenic strains of E. coli encode papX, but not the close homolog focX, 
more commonly than commensal strains of E. coli, suggesting a role in urovirulence for 
papX. 
*The effects of PapX are pathogen-specific, indicated by its suppression of 
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motility in uropathogenic strains of E. coli but not commensal strains of E. coli. 
*PapX is dependent on Arg
127 
and Lys
54
 for its activity. 
*PapX binds to a specific sequence of DNA found uniquely within the flhD 
promoter of the CFT073 genome. 
*Binding of PapX to the flhD promoter appears to be necessary, but not sufficient, 
for its activity, as indicated by the fact that an Arg
127
Gly mutant of PapX is unable to 
bind DNA and unable to repress motility of E. coli CFT073, and that a Lys
54
Asn mutant 
binds to the flhD promoter, but does not repress motility. 
*PapX activity is not regulated at the level of transcription of the rest of the pap 
operon. 
*PapX likely interacts with environmental and metabolic triggers or factors. 
 
Conclusions and perspectives 
In this work, we elucidated the mechanism whereby an adherence-associated 
factor, PapX, negatively regulates motility. To answer the fundamental questions of how 
PapX is able to accomplish this feat, we deployed novel computational approaches and 
engineered software designed to be useful for any bench-top scientist investigating 
related fields of study. The findings here expand and enrich our understanding of 
reciprocal control of motility by adherence, and add valuable new tools that can help 
illuminate the unresolved questions about protein:DNA interactions at a molecular level 
of detail. We employed a combination of bench and computational techniques to answer 
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questions of potentially broad significance within the world of microbiology, adherence, 
and motility. 
UPEC strains can encode up to 15 epidemiologically and genetically distinct 
clusters of fimbriae, some of which are important components of UTI pathogenesis [61]. 
Our work has supported observations that the clusters encoding fimbriae exhibit cross 
talk with other systems within the bacterium. Other work has indicated this as well, such 
as the observation that PapB, a regulatory protein involved in the expression of the pap 
operon, suppresses Type 1 fimbria from remaining in the L-ON state [111, 213]. FocB, of 
the sfa operon in meningitis-causing E. coli, also shares this property, and the binding site 
of FocB was recently demonstrated crystallographically [214]. Interactions between 
various systems, both within adherence-encoding systems and without, suggest that the 
interplay between fimbriae, adherence, and numerous regulatory networks within the cell 
are extensive and merit further scrutiny. 
The conditions under which the numerous other fimbriae of UPEC strains are 
expressed remains an active field of inquiry. Why UPEC encodes so many fimbriae is an 
interesting question to which there is currently no definitive answer. However, prior data 
has linked the presence of fimbriae on bacteria in the context of an appropriate substrate 
to clinically significant phenotypes, such the reduced urovirulence of UPEC strains in 
mice under the influence of pilicides [215], or the complementable defects in 
urovirulence when specific fimbriae are knocked out [51-54]. In addition, the receptors 
for fimbriae have been identified in the environments in which those fimbriae are thought 
to influence urovirulence, such as uroplakin Ia or P blood group antigen [73, 126-128]. 
Results of this type suggest that the other, as-yet uncharacterized fimbriae of UPEC 
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strains must also have substrate specificity, and thus imply the existence of 
environmental niches in which their presence or absence meaningfully contributes to 
UPEC survival or phenotype. 
There is good reason to believe that UPEC require many kinds of adherence 
organelles, and that UPEC must regulate them carefully. Even within the urinary tract, 
UPEC faces different environmental niches. Studies have indicated that even the variable 
oxygen content can affect pap expression [38], and within perturbed urinary tracts there 
are obvious changes in urine characteristics, such as glucose levels in diabetes or protein 
levels in kidney failure. Osmolarity of urine, too, appears to be relevant to UPEC 
pathogenesis as OmpA, an outer-membrane osmolarity regulator, has been shown to be 
important for uropathogenesis [216]. Osmolarity of urine does not even remain consistent 
over the course of hours, and so we expect the genes involved in environmental 
responsiveness within the urinary tract and beyond to be precisely and coordinately 
regulated, to be expressed when needed and to incur minimal costs to avoid the 
disadvantage of expressing proteins that will not assist in (or may even hinder) survival. 
As UPEC does not disseminate from one urinary tract to the next, there are obligate 
intermediate niches through which it must pass, and for which UPEC must be able to 
adapt in short order. 
One area in which some inference can be made about the role of uncharacterized 
fimbriae is that of fimbrial operon expression. Currently, we lack knowledge of the 
conditions that induce many fimbriae to express. Data do suggest that not all fimbriae are 
expressed simultaneously, and, as mentioned, some fimbria appear to antagonize others, 
such as P fimbria and Type 1 fimbria [112]. The triggers that regulate the expression of 
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fimbrial systems remain largely unknown, however, and exploring these regulatory 
pathways may help to further our understanding of a vast, unknown aspect of UPEC 
environmental and pathogenic existence. The persistent existence of many kinds of 
fimbriae in UPEC, especially as compared to commensal strains [194], suggests that 
these fimbriae contribute to urovirulence. UPEC strains do not only encode more 
fimbriae than commensal strains, but each individual UPEC strain tends to carry a vast 
array of fimbriae.  
As it appears that only a few fimbriae are expressed highly in vivo [106] and thus 
putatively related to urovirulence within the urinary tract, suggesting that there are extra-
urinary-tract roles for these fimbriae, and that those roles are conserved among 
uropathogens. We do know that other ExPEC strains rely on different adherence profiles 
to attain full virulence, such as meningitis strains of E. coli seemingly depending on sfa-
encoded fimbriae in certain aspects of their virulence cycle [217]. Even in the case of the 
distinct meningitis-causing E. coli strains of ExPEC, an apparently similar regulatory 
mechanism is conserved among UPEC strains, in the form of the SfaX protein which 
shares many characteristics of PapX [213]. It would be logical that the mechanisms of 
crosstalk and fimbrial regulation were conserved across ExPEC strains, and the furthering 
of our knowledge of the mechanism of a UPEC strain in regards to this specific pathway 
should improve our understanding of the influence of adherence on other characteristics 
and pathways across a broad range of ExPEC. 
Given the numerous uncharacterized adherence systems, and the likelihood that 
they are influenced by environment and play roles in the UPEC cycle of dissemination 
and pathogenesis, we believe that our tools for rapid characterization of protein:DNA 
98 
 
interaction are exciting and highly useful, rife with potential. The utility of our approach 
is that it is broadly adaptable to any organism and permits the rapid discovery of 
meaningful interactions. In recent years, computation and molecular techniques in 
biology have grown in complexity and nuance. The sheer volume of data generated in 
any given molecular biology experiment has expanded exponentially. The increase in 
data volume attends a need for useful tools for analysis, and questions of DNA:protein 
interaction are ideally suited to be addressed using these techniques. Characterizing new 
fimbrial systems is exciting because it may lead to a rapid increase in knowledge of 
UPEC physiology and biology. Better understanding of UPEC biology will hopefully 
lead to targeted therapies and may help to structure approaches for disrupting UPEC 
virulence. If a detailed enough model of UPEC fimbrial interactions can be generated, it 
is possible that novel treatment methods could be designed, and that perhaps subtle 
variations in environment could reduce UTI substantially. SELEX-seq itself has been 
used to design therapeutic aptamers [201-203] and so it is even possible that by 
understanding the molecular mechanisms of fimbrial interactions, we may advance the 
design of therapeutic aptamers against UPEC. 
 
Future directions 
Two related questions focused on PapX beg further investigation. Subsequent to 
binding, how does PapX effect suppression of motility, and how is PapX activity 
regulated? Preliminary data indicate that the answers to these questions may be 
complementary. 
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afSELEX-seq indicated that PapX may bind to several degenerate sites in vitro. 
However, there is a transcriptionally specific effect of papX knockout and overexpression 
as illuminated by microarray, though the microarray was performed only under a single 
set of conditions. Additionally, papX is able to influence the swarming and swimming 
motility of P. mirabilis HI4320, but this strain contains in its flhD promoter a degenerate 
version of the binding site found within the E. coli strain CFT073 flhD promoter. If the 
microarray results are correct in revealing a transcriptionally specific effect of PapX, then 
further explanation is required to resolve this puzzle. Some answers may be found in the 
results of our co-precipitation, which indicate OmpA may be a candidate to explain the 
uropathogen-specific nature of the repression of motiliy by PapX. To further examine and 
investigate the downstream effects of PapX binding, this candidate gene should be 
knocked out in E. coli strain CFT073 and the effect of PapX on the motility of the 
resulting contruct should be examined to determine whether or OmpA plays a role in the 
repression of motility by PapX. In parallel to determine whether or not OmpA can make 
K12 responsive to the repression of motility by PapX, the OmpA encoded by E. coli 
CFT073 should be inserted into the chromosome of E. coli strain K12 and to determine 
whether or not either or both of these genes can make K12 responsive to the repression of 
motility by PapX. 
Concurrently, a genetic approach could be taken to seek out factors encoded by 
the E. coli strain CFT073 chromosome that might cause it to be sensitive to PapX. 
Currently, there exist reagents to insert fliC-lux reporter fusions into the chromosomes of 
E. coli. These reagents were necessary to perform the biophotonic imaging studies to 
examine the expression of fliC as a surrogate for flagella and motility in E. coli strain 
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CFT073 [59]. These same reagents could be used to generate fliC-lux reporter fusions in 
the chromosome of E. coli strain K12 (K12fliC-lux). That construct could then have papX 
inserted into its chromosome (K12flic-lux-papX). One could then transform K12flic-lux-papX  
with a cosmid library of E. coli strain CFT073’s chromosome and screen for colonies that 
demonstrate reduced luminescence as a marker for reduced fliC expression. The 
technique could be repeated with smaller fragments or only genes identified on the 
sequenced cosmid clones. Candidates would be discarded if they suppressed 
luminescence in K12fliC-lux because the motility-suppressing effects of those genes would 
presumably be independent of the presence of PapX. Colonies in which PapX was 
specifically attributable as the factor suppressing the expression of fliC could identify a 
cofactor or cofactors crucial for full PapX activity and may identify the salient difference 
between E. coli strains K12 and CFT073 when it comes to PapX activity. 
PapX affects both swimming and swarming motility in P. mirabilis HI4320 [218]. 
Prior data and the work presented herein scrutinized the effect of papX on swimming 
motility in E. coli strain CFT073, but recent preliminary data indicate that PapX also 
influences swarming motility in E. coli strain CFT073 (Figure 5-1). Interestingly, it 
appears that the homlog focX also influences swarming motility. Though this is 
unsurprising because the sequences of focX and papX are nearly identical, we had not 
pursued investigation of focX for several reasons. First, it was not identified in a screen 
for genes that de-repressed motility in Type 1 fimbrial L-ON strains [60]. Second, focX 
mutants of E. coli strain CFT073 have only a slight effect on the motility of the resulting 
contructs. Third, single knockouts of papX have a phenotypic and readily discernible 
genetic effect on E. coli strain CFT073, so we believed that the two proteins, PapX and  
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Figure 5-1. papX and focX affect swarming motility in E. coli in a temperature-
dependent manner. Single papX, focX, and double papX focX mutants of E. coli 
CFT073 were assessed for swarming motility at 23
o
C, 30
o
C and 37
o
C. Preliminary results 
suggest that papX and focX are each able to repress swarming motility at 37
o
C, as 
indicated by the increase in swarming motility when both are deleted. papX and focX had 
no discernible effect on motility at 23
o
C and 30
o
C. papX encoded on pPxWT was able to 
repress motility of the double papX focX knockout strain of E. coli CFT073.  
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FocX, were not perfectly or even highly redundant. Finally, our molecular 
epidemiological data from Chapter 2 (Figure 2-2C, E) indicates that the coding status of 
focX does not appear to track with pathogenicity of E. coli strains. The focX homolog, 
sfaXII, does appear to be important for the pathogenesis of another ExPEC strain, 
however [213], and our preliminary data indicate that focX is important to the swarming 
behavior of E. coli strain CFT073. The effect of focX and papX together on swarming is 
temperature-dependent, a feature that has never been described for either protein. This 
exciting result may also help to shed light on the questions of how papX is regulated and 
what factors are involved in its activation and suppression of motility. Temperature 
dependence may relate to the question of why uropathogenic strains, but not commensal 
strains, of E. coli demonstrate repressed motility in response to PapX. An intermediary 
temperature-dependent process may be invoked, or potentially PapX is itself altered by 
temperature For example, the affinity of PapX for DNA may be altered under varying 
temperatures, and indeed, I observed that PapX had higher affinity for E coli CFT073 
genomic DNA during SELEX at 37
o
C as compared to 30
o
C and 23
o
C (unpublished 
observation) as reflected in a larger portion of the library fragments recovered in outputs 
at higher temperatures than in the lower temperatures in the presence of PapX-His6 
compared to the input libraries. Though single papX knockout mutants showed no effect 
on urovirulence of mutant strains, it could be productive to repeat the study using double 
focX papX knockout strains of E. coli strain CFT073. Additionally, transcriptional 
profiling of flhD and flhC could be repeated in the double-kockout background to 
eliminate any lingering background effect of focX on expression. This experiment has not 
yet been repeated and so preliminary data on that subject are unreliable. 
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That the relationship between papX and swarming motility may be temperature-
sensitive may be used to further characterize and investigate the downstream effects of 
PapX binding. The swarming assay may provide an ideal system in which to examine the 
Lys
54
Asn mutant of PapX. Swarming assays should be performed as described in 
Appendix A comparing the effects of pPxWT, pVector, and pK54N on E. coli strains 
CFT073 and K12, with a careful eye to the effects of pK54N on the papX focX mutant 
strain of E. coli CFT073. Transcriptional data (microarray and qPCR) were both gathered 
at 37
o
C, but if PapX activity is influenced by temperature, as indicated by the preliminary 
swarming data, then transcriptional analysis should be repeated, varying conditions that 
are known to influence swarming motility. These might include temperature at which 
samples are collected, the type of broth in which samples are prepared (LB or tryptone 
broth), the salt concentration under which samples are collected, and potential samples 
should be taken directly from swarming plates (center and edge portions of a swarm). 
These types of transcriptional profiling experiments could be performed using wild-type 
PapX as well as the Lys
54
Asn mutant. Other mutants also had an influence on PapX 
activity (FIGURE 2-4C), and these, too, might be illuminating when scrutinized under 
variable temperatures and conditions in swarming assays. 
Though the expression of papX did not appear to vary under conditions of Type 1 
fimbrial L-ON and L-OFF state, further work should be done to formally characterize the 
expression levels of papX under various environmental conditions. Using a focX 
knockout background of E. coli strain CFT073, transcript levels of papX should be 
scrutinized under variable temperatures and conditions known to affect both swimming 
and swarming motility, as above. It will be important to establish to our satisfaction the 
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precise mechanism and role for papX expression before considering and experimentally 
investigating alternative mechanisms of papX regulation. The work presented here 
provides strong initial data upon which to base continued studies of PapX mechanism. 
Many questions of the action of PapX have been resolved, and investigation of the 
remaining unknowns is likely to bear scientifically valuable dividends.  
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APPENDIX A 
Material and Methods 
Materials and methods 
 
Bacterial strains and plasmid 
For bacterial strains and plasmids used in this study, refer to Table 2-2.  E. coli 
CFT073, a fully-sequenced [32] strain of UPEC, was cultured from the blood and urine 
of a hospitalized patient with acute pyelonephritis and urosepsis [219].  E. coli 
BL21(DE3) was used for over-expression of PapX-His6.  All E. coli strains were cultured 
overnight at 37C in Luria broth with aeration or on Luria agar plates containing either 
ampicillin (100 g/ml), chloramphenicol (20 g/ml), kanamycin (25 g/ml or no 
antibiotic.  For western blots, PapX was expressed from the isopropyl -D-1-
thiogalactopyranoside (IPTG) -inducible plasmid pPxWT in E. coli K12 strain MG1655 
in the presence or absence of 300 M IPTG.  Growth curves were generated in triplicate 
using a Microbiology Reader Bioscreen C (Oy Growth Curves AB, Ltd.) in 0.2 ml 
volumes; OD600 was recorded every 15 min for 24 h. 
 
Motility assay 
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Flagellum-mediated swimming motility was measured as described previously 
[169].  Briefly, soft Luria agar [0.25% (w/v)] plates containing ampicillin (100 µg/ml) 
were stabbed in the center of the plate using an inoculating needle with either Luria broth 
cultures normalized to OD600=0.9-1.0 or from colonies struck onto plates the day prior.  
Care was taken not to touch the bottom of the plate during inoculation to ensure only 
swimming motility was assessed.  Plates were incubated at 30C for 16 h and swimming 
diameter was measured.  Results were analyzed using a paired t-test. 
Swarming assays were performed on Eiken agar as described previously  [220] 
with minor modiciation. Briefly, Eiken agar was composed of 3.5 g yeast extract, 7 g 
tryptone, 3.5 g NaCl, 10.5 g Eiken agar, autoclaved, and 0.5% glucose added per liter. 
Plates were allowed to cool for 1 day before use. 5 l of overnight culture of E. coli 
normalized to the culture with the lowest OD600 was inoculated onto the center of the 
plate and allowed to fully absorb into the agar. Plates were then incubated at 23
o
C, 30
o
C 
or 37
o
C for 48-72 hrs after which images of swarming were recorded. 
 
Construction of promoter-lacZ fusions and -galactosidase assays 
Nested deletions of the flhDC promoter and the intergenic regions between papG 
and papX as well as between papB and papI were fused to lacZ using a promoterless 
lacZ-containing plasmid, pRS551, using previously described methodology [151].  
Briefly, primers containing flanking BamHI or EcoRI overhangs were designed to 
amplify DNA fragments that were -130, -215, -360, -501, -597 and -718 -bp upstream of 
the translational start site of flhD of E. coli CFT073, the 262 bases between the end of 
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papG and the start of papX, and the 330 bases preceding papB which includes the pap 
operon’s promoter (Table 2-1).  Fragments and the pRS551 vector were digested with 
EcoRI and BamHI and ligated to form constructs pRS551(a-f, GX and BA) (Table 2-2).  
Electrocompetent E. coli DH5α was electroporated with pRS551(a-f), incubated for 1 h in 
500-800 µl Super Optimal broth with Catabolite repression (SOC), and plated onto Luria 
agar plates containing kanamycin (25 µg/ml).  Plasmids were extracted from Kan
R
 
colonies using a Miniprep kit (Qiagen) and sequenced to confirm the proper fusion 
constructs.  Plasmid constructs were transformed into E. coli CFT073 papXlacZ 
(Cam
R
) or E. coli CFT073 lacZ (CamR).  β-galactosidase activities of the constructs 
were measured using the modified Miller assay as described [195].  Briefly, overnight 
cultures of each construct were diluted 1:100 in LB broth and incubated at 37C with 
aeration.  OD600 was measured after 2.5 h and samples (5 µl) were added to 95 l 100 
mM Na2HPO4, 20 mM KCl, 2mM MgSO4, 0.8 mg/ml CTAB, 0.4mg/ml Na-
deoxycholate, 5.4 µl/ml β-mercaptoethanol to lyse bacterial cells.  Lysates (100 l) were 
mixed with 600 l 60 mM Na2HPO4, 40 mM NaH2PO4, 1 mg/ml ONPG, 2.7 µl/ml -
mercaptoethanol reaction buffer and incubated at 30C.  Reactions were stopped after 5-
25 min with 700 l 1 M sodium carbonate.  Bacterial cells were pelleted by 
centrifugation (10,000 x g, 10 min, 23C) and OD420 of the supernatant was measured.  
Miller units were computed using the formula: 1000 X (Abs420)/(Abs600*0.05*time in 
min).  Results were compared using a paired t-test. 
 
Construction of E. coli mutants 
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Deletion mutants were constructed using the -red recombinase system [221].  
Briefly, flanking homologous primers were designed (Table 2-1) and used to generate 
amplicons from plasmids pKD3 or pKD4 to generate kanamycin- or chloramphenicol-
resistance cassettes.  Amplicons were treated with DpnI for 3 h at 37C to remove 
parental DNA and transformed into electrocompetent CFT073 bacteria expressing 
pKD46 induced in 10 mM (final concentration) arabinose.  Resistance cassettes were 
removed by transforming resultant constructs with pCP20 and leaving cultures to 
incubate at 37C overnight.   
Site-directed mutants were constructed in pPxWT using the QuikChange II kit 
(Strategene) according to the manufacturer’s instructions.  Briefly, overlapping primers 
were designed to contain nucleotide substitutions and used for rolling PCR of pPxWT.  
PCR products were treated for 3 h with DpnI at 37C to remove parental DNA.  
Amplicons were transformed into electrocompetent CFT073, recovered for 1 h in 500-
800 l SOC and then 200 l plated onto LB agar containing ampicillin (100 g/ml).  
Resistant colonies were cultured overnight in LB broth at 37C and plasmid DNA was 
extracted and sequenced as described above. 
 
PapX purification 
Nucleotides encoding amino acids 13-183 of PapX were cloned into pMCSG7 in 
front of a His6-TEV cleavage site by ligation-independent cloning.  pMCSG7 was 
transformed into E. coli BL21 (DE3).  Bacteria were cultured in 500 ml terrific broth in a 
2 L flask at 250 rpm at 37C to OD600  1.0, then cooled to room temperature for 1 h.  
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Bacteria were induced overnight with 300 M IPTG.  After induction, cells were 
centrifuged (13,000 x g, 20 min, 4C) and pellets were frozen at -80C.  Frozen pellets 
were suspended in 20 mM Tris-HCl, pH 8.0, 10% glycerol, 1 mM DTT, 300 mM NaCl 
and ruptured by sonication using a blunt-tip probe for 7 cycles of 60% maximum energy 
for 30-sec bursts with 1 min intervals to cool (GENEQ, 500 watt Ultrasonic Processor).  
The lysate was centrifuged (112,000 x g, 1 h, 4C) and the supernatant was passed 
through 0.22 m pore size filter (MillexGP, Millipore) and incubated for 1 h at 4C with 
5-10 ml Ni-NTA resin (Invitrogen).  Resin was washed 3 times in 20 mM Tris-HCl, pH 
8.0, 10% glycerol, 1 mM DTT, 300 mM NaCl, 20 mM imidazole and protein was eluted 
with 20 mM Tris-HCl, pH 8.0, 10% glycerol, 1 mM DTT, 300 mM NaCl, 500 mM 
imidazole.  Protein was concentrated to 2 mg/ml and 50 l aliquots were frozen at -80oC.  
The presence of PapX was confirmed as the predominant species on a 12% acrylamide 
gel.  Bands were analyzed using tandem mass spectroscopy (LC-MS/MS) by the 
Michigan State University Proteomics Core Facility. 
 
Co-precipitation 
PapX-His6 was purified as above, with minor modification. Starting culture 
volume in TB was set to 250 ml, and the culture was not induced. Recombinant PapX-
His6 was bound to Ni-NTA resin and incubated with 1 l wildtype E. coli strain CFT073 
lysate for 30 minutes at 37
o
C. Purification proceeded as above from that point onward, 
and eluate was analyzed using tandem mass spectroscopy (LC-MS/MS) as above. 
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Electrophoretic motility shift assays 
Gel shift assays were performed as described [169] with the following 
modifications.  Recombinant PapX-His6, expressed from pMCGS7, was purified as 
described above and used for gel shift assays.  The DNA fragment used was the -345 
through -501 bp region upstream of the flhD translational start site in E. coli CFT073.  
Poly-d(I-C) and poly-L-lysine were substituted with TEN buffer in the binding reaction.  
Competition was performed using four unlabeled fragments Three fragments, 
TTACGGTGAGTTATTTTAACTGTGCGCAA, TTACGGTGAGTTATTTTAAC and 
GTTATTTTAAC, were derived from the predicted PapX binding site from SELEX (see 
Results).  The fourth fragment, ACTCCACTCACGGCCGTTTCGACGGTACCG, was 
derived from the gapA promoter, which has previously been demonstrated not to shift in 
the presence of PapX [169]. 
 
Genomic SELEX 
A library of 80-100-bp sequences was generated from CFT073 genomic DNA and 
paired-end ligated as described [196] at the University of Michigan DNA Sequencing 
Core.  PapX-His6 was purified as described above; however, before eluting bound 
protein, 200 l samples of the resin were incubated with gentle agitation for 30 min at 
37C in the presence of 150 ng of library DNA.  The resin was washed with 20 mM Tris-
HCl, pH 8.0, 10% glycerol, 1 mM DTT, 300 mM NaCl, 20 mM imidazole to remove 
unbound library fragments, and bound DNA-PapX complexes were eluted using the same 
buffer but containing 500 mM imidazole.  DNA was isolated from the eluted complexes 
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by two phenol:chloroform extractions.  DNA was subjected to 12-15 rounds of PCR 
using primers specific to the ligated paired-ends to ensure no contaminating DNA was 
amplified.  Libraries were quantified using quantitative PCR.  The resultant library (150 
ng) was run again over a fresh 200 l sample of PapX-His6 bound to Ni-NTA resin and 
the process was repeated four times.  The unselected library, as well as enriched rounds 
two, three and four, were sequenced using Illumina high-throughput sequencing.  A local 
BLAST comparison to the CFT073 genome was done for each short read per run and the 
number of reads at each chromosomal position in CFT073 was recorded.  Matlab 
(Student version 7.12.0) was used to identify peaks that had enriched competitively 
throughout the cycles of amplification to identify relevant peaks.  60-bp regions, centered 
on each relevant peak, were analyzed using the MEME suite [192] to generate most 
likely motifs. 
 
Protein structural predictions 
PHYRE (version 0.2) [172] and I-TASSER (version 1.1) [173, 174] were 
employed to predict the most likely structure of the PapX protein.  The model predicted 
by I-TASSER was rendered using PyMOL Molecular Graphics System (version 1.3, 
Schrödinger, LLC).  Recombinant purified PapX-His6 was also analyzed by size-
exclusion chromatography on a Sephacryl S-200 size-exclusion column (GE Healthcare) 
and semi-native gel electrophoresis in 12% SDS-polyacrylamide gel. 
 
Antiserum production 
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Antiserum to PapX was commercially generated in rabbits using a polyclonal 
antibody fast production protocol (Rockland Immunochemicals Custom Antibody 
Services) from a single-protein peak eluted from a Sephacryl S-200 size-exclusion 
column (GE Healthcare) of nickel affinity purified recombinant PapX-His6. 
 
Transcriptional profiling 
Quantitative real-time PCR was performed as described [169].  Briefly, total 
RNA, extracted from 200 l of bacterial culture, was reverse-transcribed to generate 
cDNA, and analyzed using Sybr Green and primers for 100-bp fragments of genes of 
interest (Table 2-1).  gapA was used as a normalizer for all conditions. 
 
DNase footprinting 
Primers, end-labeled with 6-carboxyfluorescein, were used to generate fluorescent 
probes from the first 130-, 215-, 360-, and 500-bp-fragments of the flhDC promoter as 
well as a 300-bp fragment of the gapA promoter.  Fragments were incubated with 
purified recombinant PapX-His6 and exposed to low-levels of DNase I for 1-10 min.  
Sheared fragments were processed by electrophoresis (as for DNA sequencing) to 
produce chromatograms representing all sheared fragments and examined for stretches of 
troughs between peaks. 
 
Multiplex PCR 
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Multiplex PCR was performed using methods and a 294-member subset of a 315-
member strain collection as described [194, 222]. Primers were designed to unique 
flanking sequences of papX, focX and common regions of both (Table 2-1). 
 
Semi-native gel electrophoresis 
Non-reducing/semi-native gel electrophoresis was performed as described 
previously [31]. Briefly, protein was isolated as described above.  SDS-PAGE loading 
buffer lacking dithiothreitol was added to samples, which were electrophoresed in the 
presence of 0.1% SDS on a 12% acrylamide gel (3.75% stacking gel) at 200V for 1 h at 
room temperature.  Gels were stained using Coomassie Brilliant Blue R-250 dissolved in 
a buffer composed of 10% acetic acid, 40% methanol, and 50% water.  Gels were de-
stained in a buffer composed of 10% acetic acid, 40% methanol, and 50% water. 
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APPENDIX B 
TFAST Instructions for use 
Overview of TFAST 
 
TFAST was originally adapted from a series of algorithms used to analyze 
SELEX with high-throughput sequencing data. To make optimal use of TFAST, first the 
initial (unselected) library used for SELEX must be sequenced, as well as selected 
subsequent cycles. Once sequence data has been procured, they can be processed using 
TFAST. Alternatively, the user may process files as she or he wishes and enter completed 
files into the TFAST workflow, so long as files are properly formatted. Included here are 
instructions for the use of TFAST and the file format used at each stage, so that the user 
can integrate features as they see fit. 
Dependencies: TFAST is written in Java. Java must be installed to execute the .jar 
files. 
 
Terms 
“Probe length” or “fragment length” refer to the average size of fragment 
submitted for sequencing in each round of SELEX sequenced. 
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“Upper limit of reads” refers to the number of reads aligned in the cycle of 
SELEX in which the greatest number of reads was aligned to the target sequence. 
“N” and “#” are placeholders for integer values. 
“Power” refers to the area under peaks and is a surrogate for representation of a 
peak in the final cycle of SELEX sequenced 
“Weight” is an indicator of how well a given peak enriched. Weights per cycle of 
SELEX are determined by the user, and should reflect the bulk binding characteristics of 
the library (ie, should increase with stringency as cycles are iteratively enriched). 
 
 
Quick use guide 
1. Run fileconversion.jar on Illumina _fastq.txt formatted sequence folder 
2. Run folder blast.jar on the resulting /fasta directory from step “1” 
3. Run freq counter.jar on the resulting /blast directory from step “2” 
3. Alternatively, run sam freq counter.jar on .SAM files generated by the user 
using another aligner. 
4. Run peak finder.jar on the resulting freq_n.txt files generated in either step “3” 
5. Run evaluation.jar on the resulting peak.txt or spoof.txt files generated in step 
“4” 
116 
 
 
 
Instructions for use 
The first step in analyzing aptamer-free SELEX-seq data is to align the reads 
generated by next-generation sequencing (NGS) to a target sequence (eg, a chromosome). 
TFAST can accept alignment in the form of BLASTn output or .SAM files. BLASTn 
tends to generate a very complete alignment of NGS reads to a target sequence, but tends 
to be computationally heavy and may take some time. To align sequences using BLASTn 
follow the steps as outlined. TFAST can also accept .SAM alignment files, which can be 
generated very quickly using programs such as BOWTIE. To use .SAM files, enter the 
workflow at step “alternate step 3 sam freq counter”. 
 
Step 1   fileconversion.jar 
BLASTn requires that sequences are in FASTA format, so the first program in the 
TFAST workflow, fileconversion.jar, converts Illumina high-throughput sequence data 
(typically in a form similar to “s_#_1_0#_qseq.txt”, ie “s_5_1_0001_qseq.txt” or 
“s_1_1_0120_qseq.txt”) into FASTA format. Fileconversion currently only supports 
Illumina’s _qseq.txt format. Fileconversion.jar only coverts uninterrupted reads from 
_qseq.txt files into FASTA format; partial, degenerate or incomplete reads will not be 
converted. Fileconversion.jar does not take read quality (PHRED score) into account 
when converting sequences. For files in fastq format, existing open-source resources exist 
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for converting sequences to FASTA (such as the Galaxy suite of tools, 
http://usegalaxy.org) 
To use fileconversion.jar, execute the application. This will open the command 
window and prompt the user to enter the directory that contains _qseq.txt files. 
Input: Directory of _qseq.txt files, each line of the format:   
HWUSI-EAS1707 1 6 1 1871 1088 0
 1AAACAATTGACAATGATTATCATTTGCATTAAAAAGACTACGTAGTA
TTTTTATTTCATGAGGAACTATACCCGCCAGCA
 fffaWd`ff]ffd^_SaYa^fffdfcdRccacc\^[]`dccW^ccRb^bbccccccccfccacc_cc[WWd
bb````BBB 
1 
Output: /fasta subdirectory of the original directory, with a file corresponding to 
each _qseq.txt file (naming in line with fasta_ s_#_1_000#_qseq.txt), with lines from the 
_qseq.txt files formatted as follows (corresponding to the above input line):      
>18711088 
AAACAATTGACAATGATTATCATTTGCATTAAAAAGACTACGTAGTAT
TTTTATTTCATGAGGAACTATACCCGCCAGCA 
Notes: If the raw sequence was not determinable at one point (indicated by one or 
more '.' characters instead of A/C/G/T), the read will be discarded. 
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Step 2   Folder blast.jar 
Requirements: Download and install the appropriate version of BLASTn for your 
operating system. BLASTn is a utility provided by the NCBI at no cost at 
(http://www.ncbi.nlm.nih.gov/books/NBK1762). 
Folder blast.jar uses FASTA formatted sequences, provided by the user or 
generated by fileconversion.jar in Step 1. The user will also have to provide a sequence 
file of the genome of the organism being investigated, in .fna format. .fna files can be 
found on the NCBI website (http://www.ncbi.nlm.nih.gov/pubmed/). 
Folder blast.jar uses a shell script to run BLASTn on the FASTA formatted 
sequences against the appropriate .fna file of interest. To use folder blast.jar, execute the 
application. This will open the command window and prompt the user to enter the 
directory containing the FASTA formatted sequence files as well as the .fna genome 
sequence file. The result of folder blast.jar are BLAST-formatted .txt files (naming in line 
with blast_fasta_ s_#_1_000#_qseq.txt). Check the NCBI website for tips on streamlining 
very large BLAST sets (http://www.ncbi.nlm.nih.gov/books/NBK1762). 
 
Input: Directory of FASTA formatted sequences, as described above. Each .txt 
file in the directory will be run with BLAST - be sure to include only FASTA sequence 
files. 
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Output: /blast subdirectory of the /fasta, with a file corresponding to each 
FASTA_ s_#_1_000#_qseq.txt file. Output is a series of BLAST files corresponding to 
each FASTA sequence read. Also requires a plain sequence .fna file. 
       
Step 3    freq counter.jar 
Freq counter.jar uses results of local BLAST files to generate a position-
frequency table, provided by the user or by running folder blast.jar. Frequency tables can 
be generated by the user using other utilities or program packages (see description of 
_freq.txt format, below). Freq counter.jar takes the aligned sequences from folder 
blast.jar and counts the number of sequence reads that overlap at each nucleotide within 
the chromosome of interest. This results in a frequency table (displayed freq_#.txt), 
which is a tab-delimited single column table the length of the target sequence (sequence 
aligned to, ie chromosome or genome) that indicates frequencies at each position. 
To use freq counter.jar, execute the application. This will open the command 
window and prompt the user to enter the directory containing the files produced in the 
local BLAST of sequences, the genome’s .fna file, the estimated upper bound on the 
number of aligned reads and the cycle number. Cycle number is “1” for the control cycle 
(the unselected cycle, i.e. the starting library of sequences), “2” for the second cycle to be 
analyzed, etc. The estimated upper bound for the number of aligned reads allows freq 
counter.jar to normalize the number of reads processed. This ensures that freq counter.jar 
will not bias frequency files due to variation in raw number of reads between or within 
lanes during sequencing. Blast sample counter.jar can estimate the number of aligned 
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reads for BLASTn aligned files. To use it, execute the program, select the directory 
containing the blast_ files and run. The fields will populate automatically. 
 
Input: Directory of BLAST results, as described above. Each .txt file in the 
directory will be included in the frequency table generation so be sure to include only 
relevant BLAST results. Also requires a plain sequence .fna file. 
 
Output: /freq subdirectory of the /blast directory, with a freq_n.txt file which is a 
list of integers, with the nth integer corresponding to the frequency of the nth location in 
the genome. 
 
Alternate step 3  sam freq counter.jar 
A user may choose to use a different method of aligning their NGS data to a target 
sequence. The easiest way to incorporate alternative (non-BLASTn) alignments into the 
TFAST workflow is to generate .SAM files (such as by using BOWTIE). There are 
several good, freely available NGS alignment tools. Many tools of this type require 
FASTQ formatted sequences (instead of Illumina’s _qseq.txt format). An easy way to 
convert _qseq.txt to FASTQ is to use Bash (the command line in Cygwin and Unix-based 
systems, i.e., Linux, OSX, etc). 
Once the user has generated .SAM files using their alignment tool of choice, 
execute sam freq counter.jar. This will open the command window and prompt the user to 
121 
 
enter the directory containing .SAM files for a particular cycle, the genome .fna file, the 
upper bound on number of aligned reads (usually given in aligner reports), the cycle 
number, the fragment length subjected to sequencing, and the read length (number of 
bases sequenced/read per fragment). Sam freq counter.jar will then generate freq_n.txt 
files as described in step 3. 
 
Step 4 – peak finder.jar 
Peak finder.jar uses the frequency tables of the control library and the final round 
of SELEX (that is, the most enriched round that was sequenced). Frequency tables can be 
generated using TFAST or generated by the user. Peak finder.jar determines local 
maxima, and rejects peaks that are less than two standard deviations above the mean of 
an n-bp window (set by the user) around that peak position in the control library. Peak 
finder.jar also rejects peaks that were two standard deviations above the mean in the 
control library, to reduce bias from aberrant variation in the control cycle being counted 
as peaks. Peak finder.jar examines the sequence within a fragment length (probe length) 
of each peak to determine whether or not a given peak is an aberration or represents a 
true maxima for that region. 
To use peak finder.jar, execute the application. This will open the command 
window and prompt the user to enter the frequency file of the most enriched SELEX 
cycle, the frequency file of the control library, the .fna file of the genome of interest, a 
manually set threshold for peaks in the final cycle (optional), the threshold window (we 
suggest a value equal to or greater than probe length) and the estimated fragment length 
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(probe length). Probe length can be determined empirically by running the library on a 
high-resolution gel, or when the initial library is selected for SELEX analysis. 
Peak finder.jar produces two files – Peak.txt and Spoof.txt. Peak.txt is a .txt file 
containing a single column of chromosomal positions corresponding to predicted peaks. 
The user may elect to use his/her own peak finding algorithms, in which case, format the 
output similarly to proceed to Step 5. Spoof.txt is a similarly formatted file that contains 
chromosomal positions generated randomly. Spoof.txt can be used as a control file to 
validate results and improve downstream data analysis when using motif finding software 
and to generate background models of genome sequence behavior and nucleotide 
representation. 
TFAST can also find minima instead of maxima if the user desires. In most 
SELEX experiments, this will result in a vast number of minima as SELEX tends to 
produce zero frequency between peaks. This option is useful for knockout experiments, 
such as transposon mutagenesis studies coupled with high-throughput sequencing. When 
selecting minima, TFAST subtracts the final cycle from the control cycle and counts 
regions that are two standard deviations of the control cycle (within the set window) 
above zero as peaks. 
 
Input: freq_n.txt (where n is the number of cycles), freq_1.txt (the control library), 
a plain sequence .fna file, a set threshold if necessary, threshold window and the average 
probe (fragment) length. 
       
123 
 
Output: /peak subdirectory, with a peak.txt file and a spoof.txt file. 
 
Step 5 – Evaluaton.jar 
Evaluaton.jar uses peak positions determined in Step 4 or provided by the user to 
grade peaks. Before using evaluaton.jar, place all freq_#.txt files of interest (including the 
control) into a single directory. To use evaluator.jar, execute the application. This will 
open the command window and prompt the user to enter the directory containing all 
freq_#.txt files, the .fna file of the genome of interest, the peak.txt file, weights for every 
round, average probe length (fragment length) and the length of sequence around each 
peak to be included in the output. 
Weights for every round should be delimited with commas. Every cycle of 
SELEX selects for the most strongly binding species in a pool. Thus, as cycles continue, 
the requirements for binding increase. Therefore, we advise the user to use a scheme that 
weighs enrichment in later rounds higher than enrichment in earlier rounds. For example, 
for a SELEX with three rounds of enrichment (control library, enriched1, enriched2 and 
enriched3), one scoring schema could be “1, 1.5, 2”. “1,1,1” will result in equal weights 
in every round, which does not reflect the increasing stringency of competitive binding in 
the DNA fragment libraries. Ideally, a scoring scheme for weights between rounds will 
be based on the fraction of input species that are recovered after each round in the 
SELEX experiment, reflecting the bulk affinity of the library for the protein of interest. 
These considerations are less of a concern if the user performs “fixed stringency 
SELEX”. 
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Once completed, evaluaton.jar will produce a tab-delimited table called 
“output.txt”, including data on each peak. 
-The first (left-most) column describes the peak number, which for most users can 
be disregarded (useful for testing the program internally). 
-The second column describes the location of the peak within the chromosome, 
based on the .fna file provided. 
-The third through nth columns describe the frequency at that chromosomal 
position for each SELEX cycle amplified, where “n” is the cycle number (1 = the control 
library, 2 = first enrichment entered, etc). 
-The (n+1)th column describes the weight of a peak. Weight is determined by 
adding the “weight” values when the frequency at a position increased between cycles, 
and by adding 0 when the frequency at a position remained unchanged or declined. High 
weights correspond to strongly enriching sequences. 
-The (n+2)th column describes the power of a peak. Power represents the area 
under a peak as compared to the total area under peaks for the final cycle sequence. 
Power is another way to grade how strongly a fragment has enriched relative to every 
other fragment. 
-the (n+3)th column describes an estimated binding site length. This is determined 
by finding the bounds under a peak that includes 99% of the peak area, and subtracting 
that distance from twice the probe length. Because probe length will vary slightly for 
technical reasons, it is best to use an average of several peaks to assess the theoretical 
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binding length for a site. This can be useful for determining cases of multiple adjacent 
binding sites as well as for discarding large repeated regions. 
-The (n+4)th column describes The chromosomal sequence that falls under a 
given peak, with the amount of sequence included determined by the user. The length 
included should conform to the standards of any downstream analysis planned. 
 
Evaluation.jar can also analyze the quality of minima (valleys) instead of peaks. 
This utility is useful for knockout experiments that incorporate NGS, but is unlikely to 
yield results in SELEX data. 
  
Input: A folder containing only the freq_1.txt through freq_n.txt files, with every 
file from 1 to n included. Also, a plain sequence .fna file, average probe length, length of 
flanking sequence to be printed, and a list of weights.       
 
Output: /output subdirectory, with a output.txt file as referenced above. 
 
 
A dataset of SELEX data using high-throughput sequencing is provided in 
supplemental data. Feel free to make use of them as a practice set. The files are from an 
actual experiment that used the algorithms found in TFAST to determine and 
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experimentally validate a novel, unique binding site for a transcription factor (PapX) in 
E. coli. 
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APPENDIX C 
TFAST availability 
TFAST is implemented in Java and supported on MS Windows and Mac OSX. 
TFAST was designed in compliance with the GNU GPL. TFAST, documentation, source 
code, instructions for use, sample data and example output are freely available for 
download at http://www-personal.umich.edu/~hmobley/ or 
http://sourceforge.net/projects/tfast/files/. 
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APPENDIX D 
Supplemental data 
 
Supplementary Figure 2-1. papX linker-insertional mutants do not have 
impaired growth rate.  Thirty 15-bp insertional mutants of papX in pDRM001, as well 
as WT papX in pDRM001, were electroporated into strain CFT073 papX.  Strains were 
diluted 1:100 in LB broth containing 100 g/ml ampicillin and not IPTG and OD600 was 
automatically recorded every 15 min by a bioanalyzer.  No significant difference in 
growth rate was detected among the constructs. Name of transforming plasmid is shown 
on right. 
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Supplementary Figure 2-2. PapX is a dimer. (A) Recombinant purified PapX-
His6 and molecular-weight standards were run through a Sephacryl S-200 size-exclusion 
column at 1 ml/min and OD280 was measured in mAU over a 300 ml volume.  Traces of 
each were superimposed by aligning the void-volumes. PapX-His6 peak appears at 
approximately twice the predicted molecular weight of the monomer.  (B) SDS-PAGE 
was performed on non-denatured recombinant PapX-His6.  A major band appears at 
twice the molecular weight of the monomer (the minor band).  
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Supplementary Figure 2-3. Non-radiolabeled fluorescent DNase protect assay 
(A) 0.5 g of recombinant purified PapX-His6 was incubated with a 6-carboxyfluorescein 
end-labeled fragment derived from the first 360 bases of the flhD promoter and exposed 
to low-levels of DNase I for 1-20 minutes.  Sheared fragments were processed by 
electrophoresis as for DNA sequencing to produce chromatograms representing all 
sheared fragments. Fluorescence of the 6-carbosyfluorescein is shown on the y-axis. 
Position of the fragment is shown on the x-asis. (A) Representative chromatogram of a 
fragment exposed to DNase I for 1 minute in the absence of PapX protein (B) 
Representative chromatogram of a fragment exposed to DNase I for 1 minute in the 
presence of 0.5 g of PapX. (C) Representative chromatogram of a fragment exposed to 
DNase I for 20 minutes in the presence of 0.5 g of PapX. Ratios of peak heights 
remained the same between conditions. 
131 
 
 
REFERENCES 
 
 
 
 
1. Moore, K.L., A.F. Dalley, and A.M.R. Agur, Clinically oriented anatomy. 6th 
ed2010, Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. xxix, 1134 
p. 
2. Czaja, C.A., et al., Prospective cohort study of microbial and inflammatory events 
immediately preceding Escherichia coli recurrent urinary tract infection in 
women. J Infect Dis, 2009. 200(4): p. 528-36. 
3. Schilling, J.D., R.G. Lorenz, and S.J. Hultgren, Effect of trimethoprim-
sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice 
infected with uropathogenic Escherichia coli. Infection and Immunity, 2002. 
70(12): p. 7042-9. 
4. Hooton, T.M., Recurrent urinary tract infection in women. Int J Antimicrob 
Agents, 2001. 17(4): p. 259-68. 
5. Bacheller, C.D. and J.M. Bernstein, Urinary tract infections. Med Clin North Am, 
1997. 81(3): p. 719-30. 
6. Gupta, K., et al., International clinical practice guidelines for the treatment of 
acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the 
Infectious Diseases Society of America and the European Society for 
Microbiology and Infectious Diseases. Clin Infect Dis, 2011. 52(5): p. e103-20. 
7. Faro, S. and D.E. Fenner, Urinary tract infections. Clin Obstet Gynecol, 1998. 
41(3): p. 744-54. 
8. Ikaheimo, R., et al., Community-acquired pyelonephritis in adults: characteristics 
of E. coli isolates in bacteremic and non-bacteremic patients. Scand J Infect Dis, 
1994. 26(3): p. 289-96. 
9. Litwin, M., C.S. Saigal, and E.M. Beerbohm, The burden of urologic diseases in 
America. Journal of Urology, 2005. 173(4): p. 1065-1066. 
10. DeFrances, C.J., et al., 2006 National Hospital Discharge Survey. Natl Health 
Stat Report, 2008(5): p. 1-20. 
11. Bent, S., et al., Does this woman have an acute uncomplicated urinary tract 
infection? JAMA, 2002. 287(20): p. 2701-10. 
12. Warren, J.W., et al., Guidelines for antimicrobial treatment of uncomplicated 
acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases 
Society of America (IDSA). Clin Infect Dis, 1999. 29(4): p. 745-58. 
13. Fairley, K.F., et al., Site of infection in acute urinary-tract infection in general 
practice. Lancet, 1971. 2(7725): p. 615-8. 
14. Stamm, W.E., Measurement of pyuria and its relation to bacteriuria. Am J Med, 
1983. 75(1B): p. 53-8. 
15. Kunin, C.M., Urinary tract infections : detection, prevention, and management. 
5th ed1997, Baltimore: Williams & Wilkins. ix, 419 p. 
16. Heptinstall, R.H., Pathology of the kidney. 3rd ed1983, Boston: Little, Brown. 3 
v. (xi, 1695, 42 p.). 
132 
 
17. Svanborg, C. and G. Godaly, Bacterial virulence in urinary tract infection. 
Infectious Disease Clinics of North America, 1997. 11(3): p. 513-&. 
18. Raz, R., R. Colodner, and C.M. Kunin, Who are you--Staphylococcus 
saprophyticus? Clin Infect Dis, 2005. 40(6): p. 896-8. 
19. Wallmark, G., I. Arremark, and B. Telander, Staphylococcus saprophyticus: a 
frequent cause of acute urinary tract infection among female outpatients. J Infect 
Dis, 1978. 138(6): p. 791-7. 
20. Gupta, K., et al., The prevalence of antimicrobial resistance among uropathogens 
causing acute uncomplicated cystitis in young women. Int J Antimicrob Agents, 
1999. 11(3-4): p. 305-8. 
21. Gillespie, W.A., et al., Urinary tract infection in young women, with special 
reference to Staphylococcus saprophyticus. J Clin Pathol, 1978. 31(4): p. 348-50. 
22. Jordan, P.A., et al., Urinary tract infection caused by Staphylococcus 
saprophyticus. J Infect Dis, 1980. 142(4): p. 510-5. 
23. Czaja, C.A., et al., Population-based epidemiologic analysis of acute 
pyelonephritis. Clin Infect Dis, 2007. 45(3): p. 273-80. 
24. Echols, R.M., et al., Demographic, clinical, and treatment parameters influencing 
the outcome of acute cystitis. Clin Infect Dis, 1999. 29(1): p. 113-9. 
25. Podschun, R. and U. Ullmann, Klebsiella spp. as nosocomial pathogens: 
epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin 
Microbiol Rev, 1998. 11(4): p. 589-603. 
26. Lin, W.H., et al., Clinical and microbiological characteristics of Klebsiella 
pneumoniae isolates causing community-acquired urinary tract infections. 
Infection, 2010. 38(6): p. 459-64. 
27. Ronald, A., The etiology of urinary tract infection: traditional and emerging 
pathogens. Dis Mon, 2003. 49(2): p. 71-82. 
28. Johnson, D.E. and R.G. Russell, Animal Models of urinary tract infection, in 
Urinary Tract Infections: Molecular Pathogenesis and Clinical Management, 
H.L. Mobley and J.W. Warren, Editors. 1996, ASM Press: Washington, DC. p. 
377-403. 
29. Dlugaszek, M., M. Kaszczuk, and M. Mularczyk-Oliwa, Magnesium, calcium, 
and trace elements excretion in 24-h urine. Biol Trace Elem Res, 2011. 142(1): p. 
1-10. 
30. Wandersman, C. and P. Delepelaire, Bacterial iron sources: from siderophores to 
hemophores. Annu Rev Microbiol, 2004. 58: p. 611-47. 
31. Hagan, E.C. and H.L. Mobley, Haem acquisition is facilitated by a novel receptor 
Hma and required by uropathogenic Escherichia coli for kidney infection. 
Molecular Microbiology, 2009. 71(1): p. 79-91. 
32. Welch, R.A., et al., Extensive mosaic structure revealed by the complete genome 
sequence of uropathogenic Escherichia coli. Proc Natl Acad Sci U S A, 2002. 
99(26): p. 17020-4. 
33. Horwitz, M.A. and S.C. Silverstein, Influence of the Escherichia coli capsule on 
complement fixation and on phagocytosis and killing by human phagocytes. J Clin 
Invest, 1980. 65(1): p. 82-94. 
133 
 
34. Burns, S.M. and S.I. Hull, Loss of resistance to ingestion and phagocytic killing 
by O(-) and K(-) mutants of a uropathogenic Escherichia coli O75:K5 strain. 
Infection and Immunity, 1999. 67(8): p. 3757-62. 
35. Russo, T., et al., The O4 specific antigen moiety of lipopolysaccharide but not the 
K54 group 2 capsule is important for urovirulence of an extraintestinal isolate of 
Escherichia coli. Infection and Immunity, 1996. 64(6): p. 2343-8. 
36. Russo, T.A., et al., The construction and characterization of colanic acid deficient 
mutants in an extraintestinal isolate of Escherichia coli (O4/K54/H5). Microb 
Pathog, 1995. 18(4): p. 269-78. 
37. Smith, S.N., et al., Dissemination and systemic colonization of uropathogenic 
Escherichia coli in a murine model of bacteremia. MBio, 2010. 1(5). 
38. Snyder, J.A., et al., Transcriptome of uropathogenic Escherichia coli during 
urinary tract infection. Infection and Immunity, 2004. 72(11): p. 6373-81. 
39. Welch, R.A., et al., Haemolysin contributes to virulence of extra-intestinal E. coli 
infections. Nature, 1981. 294(5842): p. 665-7. 
40. Welch, R.A., R. Hull, and S. Falkow, Molecular cloning and physical 
characterization of a chromosomal hemolysin from Escherichia coli. Infect 
Immun, 1983. 42(1): p. 178-86. 
41. Smith, Y.C., et al., Hemolysin of uropathogenic Escherichia coli evokes extensive 
shedding of the uroepithelium and hemorrhage in bladder tissue within the first 
24 hours after intraurethral inoculation of mice. Infect Immun, 2008. 76(7): p. 
2978-90. 
42. Vigil, P.D., C.J. Alteri, and H.L. Mobley, Identification of in vivo-induced 
antigens including an RTX family exoprotein required for uropathogenic 
Escherichia coli virulence. Infect Immun, 2011. 79(6): p. 2335-44. 
43. Vigil, P.D., et al., Presence of putative repeat-in-toxin gene tosA in Escherichia 
coli predicts successful colonization of the urinary tract. MBio, 2011. 2(3): p. 
e00066-11. 
44. Hofman, P., et al., Escherichia coli cytotoxic necrotizing factor-1 (CNF-1) 
increases the adherence to epithelia and the oxidative burst of human 
polymorphonuclear leukocytes but decreases bacteria phagocytosis. J Leukoc 
Biol, 2000. 68(4): p. 522-8. 
45. Davis, J.M., et al., Cytotoxic necrotizing factor type 1 delivered by outer 
membrane vesicles of uropathogenic Escherichia coli attenuates 
polymorphonuclear leukocyte antimicrobial activity and chemotaxis. Infect 
Immun, 2006. 74(8): p. 4401-8. 
46. Blum, G., et al., Gene clusters encoding the cytotoxic necrotizing factor type 1, 
Prs-fimbriae and alpha-hemolysin form the pathogenicity island II of the 
uropathogenic Escherichia coli strain J96. Fems Microbiology Letters, 1995. 
126(2): p. 189-95. 
47. Lloyd, A.L., D.A. Rasko, and H.L. Mobley, Defining genomic islands and 
uropathogen-specific genes in uropathogenic Escherichia coli. Journal of 
Bacteriology, 2007. 189(9): p. 3532-46. 
48. Smith, T.G. and T.R. Hoover, Deciphering bacterial flagellar gene regulatory 
networks in the genomic era. Adv Appl Microbiol, 2009. 67: p. 257-95. 
134 
 
49. Lane, M.C., et al., Role of motility in the colonization of uropathogenic 
Escherichia coli in the urinary tract. Infection and Immunity, 2005. 73(11): p. 
7644-56. 
50. Wright, K.J., P.C. Seed, and S.J. Hultgren, Uropathogenic Escherichia coli 
flagella aid in efficient urinary tract colonization. Infection and Immunity, 2005. 
73(11): p. 7657-68. 
51. Bahrani-Mougeot, F.K., et al., Type 1 fimbriae and extracellular polysaccharides 
are preeminent uropathogenic Escherichia coli virulence determinants in the 
murine urinary tract. Molecular Microbiology, 2002. 45(4): p. 1079-93. 
52. Connell, I., et al., Type 1 fimbrial expression enhances Escherichia coli virulence 
for the urinary tract. Proc Natl Acad Sci U S A, 1996. 93(18): p. 9827-32. 
53. Gunther, N.W.t., et al., Assessment of virulence of uropathogenic Escherichia coli 
type 1 fimbrial mutants in which the invertible element is phase-locked on or off. 
Infection and Immunity, 2002. 70(7): p. 3344-54. 
54. Snyder, J.A., et al., Role of phase variation of type 1 fimbriae in a uropathogenic 
Escherichia coli cystitis isolate during urinary tract infection. Infection and 
Immunity, 2006. 74(2): p. 1387-93. 
55. Eden, C.S. and H.A. Hansson, Escherichia coli pili as possible mediators of 
attachment to human urinary tract epithelial cells. Infection and Immunity, 1978. 
21(1): p. 229-37. 
56. Eden, C.S., et al., Variable adherence to normal human urinary-tract epithelial 
cells of Escherichia coli strains associated with various forms of urinary-tract 
infection. Lancet, 1976. 1(7984): p. 490-2. 
57. Kallenius, G., et al., Identification of a carbohydrate receptor recognized by 
uropathogenic Escherichia coli. Infection, 1980. 8 Suppl 3: p. 288-93. 
58. Kallenius, G., et al., Structure of carbohydrate part of receptor on human 
uroepithelial cells for pyelonephritogenic Escherichia coli. Lancet, 1981. 
2(8247): p. 604-6. 
59. Lane, M.C., et al., Expression of flagella is coincident with uropathogenic 
Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci U S A, 
2007. 104(42): p. 16669-74. 
60. Simms, A.N. and H.L. Mobley, Multiple genes repress motility in uropathogenic 
Escherichia coli constitutively expressing type 1 fimbriae. Journal of 
Bacteriology, 2008. 190(10): p. 3747-56. 
61. Spurbeck, R.R., et al., Fimbrial profiles predict virulence of uropathogenic 
Escherichia coli strains: contribution of Ygi and Yad Fimbriae. Infection and 
Immunity, 2011. 79(12): p. 4753-63. 
62. Langermann, S., et al., Prevention of mucosal Escherichia coli infection by FimH-
adhesin-based systemic vaccination. Science, 1997. 276(5312): p. 607-11. 
63. Langermann, S., et al., Vaccination with FimH adhesin protects cynomolgus 
monkeys from colonization and infection by uropathogenic Escherichia coli. J 
Infect Dis, 2000. 181(2): p. 774-8. 
64. Brinton, C.C., Jr., The structure, function, synthesis and genetic control of 
bacterial pili and a molecular model for DNA and RNA transport in gram 
negative bacteria. Trans N Y Acad Sci, 1965. 27(8): p. 1003-54. 
135 
 
65. Brinton, C.C., Jr., A. Buzzell, and M.A. Lauffer, Electrophoresis and phage 
susceptibility studies on a filament-producing variant of the E. coli B bacterium. 
Biochimica et biophysica acta, 1954. 15(4): p. 533-42. 
66. Norgren, M., et al., Mutations in E coli cistrons affecting adhesion to human cells 
do not abolish Pap pili fiber formation. EMBO J, 1984. 3(5): p. 1159-65. 
67. O'Hanley, P., et al., Gal-Gal binding and hemolysin phenotypes and genotypes 
associated with uropathogenic Escherichia coli. N Engl J Med, 1985. 313(7): p. 
414-20. 
68. Hultgren, S.J., et al., Regulation of production of type 1 pili among urinary tract 
isolates of Escherichia coli. Infection and Immunity, 1986. 54(3): p. 613-20. 
69. Lawn, A.M., Morphological features of the pili associated with Escherichia coli 
K 12 carrying R factors or the F factor. Journal of general microbiology, 1966. 
45(2): p. 377-83. 
70. Brinton, C.C., Jr., Non-flagellar appendages of bacteria. Nature, 1959. 
183(4664): p. 782-6. 
71. Korhonen, T.K., R. Virkola, and H. Holthofer, Localization of binding sites for 
purified Escherichia coli P fimbriae in the human kidney. Infection and 
Immunity, 1986. 54(2): p. 328-32. 
72. Vaisanen, V., et al., Mannose-resistant haemagglutination and P antigen 
recognition are characteristic of Escherichia coli causing primary pyelonephritis. 
Lancet, 1981. 2(8260-61): p. 1366-9. 
73. Korhonen, T.K., et al., P-antigen-recognizing fimbriae from human 
uropathogenic Escherichia coli strains. Infection and Immunity, 1982. 37(1): p. 
286-91. 
74. Uhlin, B.E., et al., Adhesion to human cells by Escherichia coli lacking the major 
subunit of a digalactoside-specific pilus-adhesin. Proc Natl Acad Sci U S A, 
1985. 82(6): p. 1800-4. 
75. Mulholland, S.G., M. Mooreville, and C.L. Parsons, Urinary tract infections and 
P blood group antigens. Urology, 1984. 24(3): p. 232-5. 
76. Lomberg, H., et al., Correlation of P blood group, vesicoureteral reflux, and 
bacterial attachment in patients with recurrent pyelonephritis. The New England 
journal of medicine, 1983. 308(20): p. 1189-92. 
77. Vaisanen-Rhen, V., et al., P-fimbriated clones among uropathogenic Escherichia 
coli strains. Infection and Immunity, 1984. 43(1): p. 149-55. 
78. Dowling, K.J., J.A. Roberts, and M.B. Kaack, P-fimbriated Escherichia coli 
urinary tract infection: a clinical correlation. South Med J, 1987. 80(12): p. 
1533-6. 
79. Hagberg, L., et al., Adhesion, hemagglutination, and virulence of Escherichia coli 
causing urinary tract infections. Infection and Immunity, 1981. 31(2): p. 564-70. 
80. Jacobsen, S.H., et al., P fimbriated Escherichia coli in adults with acute 
pyelonephritis. J Infect Dis, 1985. 152(2): p. 426-7. 
81. Johnson, J.R., et al., Association of carboxylesterase B electrophoretic pattern 
with presence and expression of urovirulence factor determinants and 
antimicrobial resistance among strains of Escherichia coli that cause urosepsis. 
Infection and Immunity, 1991. 59(7): p. 2311-5. 
136 
 
82. Johnson, J.R., P.L. Roberts, and W.E. Stamm, P fimbriae and other virulence 
factors in Escherichia coli urosepsis: association with patients' characteristics. J 
Infect Dis, 1987. 156(1): p. 225-9. 
83. Kallenius, G., et al., Occurrence of P-fimbriated Escherichia coli in urinary tract 
infections. Lancet, 1981. 2(8260-61): p. 1369-72. 
84. Latham, R.H. and W.E. Stamm, Role of fimbriated Escherichia coli in urinary 
tract infections in adult women: correlation with localization studies. J Infect Dis, 
1984. 149(6): p. 835-40. 
85. Sandberg, T., et al., Virulence of Escherichia coli in relation to host factors in 
women with symptomatic urinary tract infection. J Clin Microbiol, 1988. 26(8): p. 
1471-6. 
86. Ulleryd, P., et al., Virulence characteristics of Escherichia coli in relation to host 
response in men with symptomatic urinary tract infection. Clin Infect Dis, 1994. 
18(4): p. 579-84. 
87. Kisielius, P.V., et al., In vivo expression and variation of Escherichia coli type 1 
and P pili in the urine of adults with acute urinary tract infections. Infection and 
Immunity, 1989. 57(6): p. 1656-62. 
88. de Ree, J.M. and J.F. van den Bosch, Serological response to the P fimbriae of 
uropathogenic Escherichia coli in pyelonephritis. Infection and Immunity, 1987. 
55(9): p. 2204-7. 
89. Hull, R.A., et al., Construction and expression of recombinant plasmids encoding 
type 1 or D-mannose-resistant pili from a urinary tract infection Escherichia coli 
isolate. Infection and Immunity, 1981. 33(3): p. 933-8. 
90. Dodson, K.W., et al., Outer-membrane PapC molecular usher discriminately 
recognizes periplasmic chaperone-pilus subunit complexes. Proc Natl Acad Sci U 
S A, 1993. 90(8): p. 3670-4. 
91. Hultgren, S.J., et al., Pilus and nonpilus bacterial adhesins: assembly and 
function in cell recognition. Cell, 1993. 73(5): p. 887-901. 
92. Kuehn, M.J., et al., P pili in uropathogenic E. coli are composite fibres with 
distinct fibrillar adhesive tips. Nature, 1992. 356(6366): p. 252-5. 
93. Kuehn, M.J., S. Normark, and S.J. Hultgren, Immunoglobulin-like PapD 
chaperone caps and uncaps interactive surfaces of nascently translocated pilus 
subunits. Proc Natl Acad Sci U S A, 1991. 88(23): p. 10586-90. 
94. Lund, B., et al., The PapG protein is the alpha-D-galactopyranosyl-(1----4)-beta-
D-galactopyranose-binding adhesin of uropathogenic Escherichia coli. Proc Natl 
Acad Sci U S A, 1987. 84(16): p. 5898-902. 
95. Normark, S., et al., Genetics of digalactoside-binding adhesin from a 
uropathogenic Escherichia coli strain. Infection and Immunity, 1983. 41(3): p. 
942-9. 
96. Remaut, H., et al., Fiber formation across the bacterial outer membrane by the 
chaperone/usher pathway. Cell, 2008. 133(4): p. 640-52. 
97. Kline, K.A., et al., A tale of two pili: assembly and function of pili in bacteria. 
Trends in microbiology, 2010. 18(5): p. 224-32. 
98. Larsson, A., et al., Quantitative studies of the binding of the class II PapG 
adhesin from uropathogenic Escherichia coli to oligosaccharides. Bioorg Med 
Chem, 2003. 11(10): p. 2255-61. 
137 
 
99. Ohlsson, J., et al., Discovery of potent inhibitors of PapG adhesins from 
uropathogenic Escherichia coli through synthesis and evaluation of galabiose 
derivatives. Chembiochem, 2002. 3(8): p. 772-9. 
100. Dodson, K.W., et al., Structural basis of the interaction of the pyelonephritic E. 
coli adhesin to its human kidney receptor. Cell, 2001. 105(6): p. 733-43. 
101. Lund, B., et al., Uropathogenic Escherichia coli can express serologically 
identical pili of different receptor binding specificities. Molecular Microbiology, 
1988. 2(2): p. 255-63. 
102. Baga, M., et al., Transcriptional activation of a pap pilus virulence operon from 
uropathogenic Escherichia coli. EMBO J, 1985. 4(13B): p. 3887-93. 
103. Braaten, B.A., et al., Methylation patterns in pap regulatory DNA control 
pyelonephritis-associated pili phase variation in E. coli. Cell, 1994. 76(3): p. 577-
88. 
104. Peterson, S.N. and N.O. Reich, Competitive Lrp and Dam assembly at the pap 
regulatory region: implications for mechanisms of epigenetic regulation. Journal 
of molecular biology, 2008. 383(1): p. 92-105. 
105. Hintsche-Kilger, B.B., et al., [Benign liver tumors and oral contraceptives--
difficulties in diagnosis]. Zeitschrift fur arztliche Fortbildung, 1991. 85(11): p. 
513-5. 
106. Hagan, E.C., et al., Escherichia coli global gene expression in urine from women 
with urinary tract infection. PLoS Pathog, 2010. 6(11): p. e1001187. 
107. Holden, N., et al., Regulation of P-fimbrial phase variation frequencies in 
Escherichia coli CFT073. Infection and Immunity, 2007. 75(7): p. 3325-34. 
108. Mobley, H.L., et al., Isogenic P-fimbrial deletion mutants of pyelonephritogenic 
Escherichia coli: the role of alpha Gal(1-4) beta Gal binding in virulence of a 
wild-type strain. Molecular Microbiology, 1993. 10(1): p. 143-55. 
109. Roberts, J.A., et al., The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia 
coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract. 
Proc Natl Acad Sci U S A, 1994. 91(25): p. 11889-93. 
110. Roberts, J.A., et al., Receptors for pyelonephritogenic Escherichia coli in 
primates. J Urol, 1984. 131(1): p. 163-8. 
111. Melican, K., et al., Uropathogenic Escherichia coli P and Type 1 fimbriae act in 
synergy in a living host to facilitate renal colonization leading to nephron 
obstruction. PLoS pathogens, 2011. 7(2): p. e1001298. 
112. Melican, K., et al., Uropathogenic Escherichia coli P and Type 1 fimbriae act in 
synergy in a living host to facilitate renal colonization leading to nephron 
obstruction. PLoS Pathog, 2011. 7(2): p. e1001298. 
113. Snyder, J.A., et al., Coordinate expression of fimbriae in uropathogenic 
Escherichia coli. Infection and Immunity, 2005. 73(11): p. 7588-96. 
114. Duguid, J.P., S. Clegg, and M.I. Wilson, The fimbrial and non-fimbrial 
haemagglutinins of Escherichia coli. J Med Microbiol, 1979. 12(2): p. 213-27. 
115. Orndorff, P.E. and C.A. Bloch, The role of type 1 pili in the pathogenesis of 
Escherichia coli infections: a short review and some new ideas. Microb Pathog, 
1990. 9(2): p. 75-9. 
138 
 
116. Hultgren, S.J., S. Normark, and S.N. Abraham, Chaperone-assisted assembly and 
molecular architecture of adhesive pili. Annu Rev Microbiol, 1991. 45: p. 383-
415. 
117. Schilling, J.D., M.A. Mulvey, and S.J. Hultgren, Structure and function of 
Escherichia coli type 1 pili: new insight into the pathogenesis of urinary tract 
infections. J Infect Dis, 2001. 183 Suppl 1: p. S36-40. 
118. Johnson, J.R., Virulence factors in Escherichia coli urinary tract infection. Clin 
Microbiol Rev, 1991. 4(1): p. 80-128. 
119. Jones, C.H., et al., FimH adhesin of type 1 pili is assembled into a fibrillar tip 
structure in the Enterobacteriaceae. Proc Natl Acad Sci U S A, 1995. 92(6): p. 
2081-5. 
120. Abraham, S.N. and E.H. Beachey, Assembly of a chemically synthesized peptide 
of Escherichia coli type 1 fimbriae into fimbria-like antigenic structures. Journal 
of Bacteriology, 1987. 169(6): p. 2460-5. 
121. Abraham, S.N., J.D. Goguen, and E.H. Beachey, Hyperadhesive mutant of type 1-
fimbriated Escherichia coli associated with formation of FimH organelles 
(fimbriosomes). Infection and Immunity, 1988. 56(5): p. 1023-9. 
122. Hacker, J., et al., Deletions of chromosomal regions coding for fimbriae and 
hemolysins occur in vitro and in vivo in various extraintestinal Escherichia coli 
isolates. Microb Pathog, 1990. 8(3): p. 213-25. 
123. Hung, C.S., et al., Structural basis of tropism of Escherichia coli to the bladder 
during urinary tract infection. Molecular Microbiology, 2002. 44(4): p. 903-15. 
124. Krogfelt, K.A., H. Bergmans, and P. Klemm, Direct evidence that the FimH 
protein is the mannose-specific adhesin of Escherichia coli type 1 fimbriae. 
Infection and Immunity, 1990. 58(6): p. 1995-8. 
125. Wu, X.R., T.T. Sun, and J.J. Medina, In vitro binding of type 1-fimbriated 
Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc 
Natl Acad Sci U S A, 1996. 93(18): p. 9630-5. 
126. Min, G., et al., Localization of uroplakin Ia, the urothelial receptor for bacterial 
adhesin FimH, on the six inner domains of the 16 nm urothelial plaque particle. J 
Mol Biol, 2002. 317(5): p. 697-706. 
127. Min, G., et al., Structural basis of urothelial permeability barrier function as 
revealed by Cryo-EM studies of the 16 nm uroplakin particle. J Cell Sci, 2003. 
116(Pt 20): p. 4087-94. 
128. Zhou, G., et al., Uroplakin Ia is the urothelial receptor for uropathogenic 
Escherichia coli: evidence from in vitro FimH binding. J Cell Sci, 2001. 114(Pt 
22): p. 4095-103. 
129. Sokurenko, E.V., et al., Pathogenic adaptation of Escherichia coli by natural 
variation of the FimH adhesin. Proc Natl Acad Sci U S A, 1998. 95(15): p. 8922-
6. 
130. Donnenberg, M.S. and R.A. Welch, Virulence determinants of uropathogenic 
Escherichia coli., in Urinary Tract Infections: Molecular Pathogenesis and 
Clinical Management, H.L. Mobley and J.W. Warren, Editors. 1996, ASM Press: 
Washington DC. 
139 
 
131. Pere, A., et al., Occurrence of type-1C fimbriae on Escherichia coli strains 
isolated from human extraintestinal infections. J Gen Microbiol, 1985. 131(7): p. 
1705-11. 
132. Zingler, G., et al., Clonal differentiation of uropathogenic Escherichia coli 
isolates of serotype O6:K5 by fimbrial antigen typing and DNA long-range 
mapping techniques. Med Microbiol Immunol, 1993. 182(1): p. 13-24. 
133. Zingler, G., et al., Clonal analysis of Escherichia coli serotype O6 strains from 
urinary tract infections. Microb Pathog, 1992. 12(4): p. 299-310. 
134. Lindberg, S., et al., Regulatory Interactions among adhesin gene systems of 
uropathogenic Escherichia coli. Infection and Immunity, 2008. 76(2): p. 771-80. 
135. Korhonen, T.K., et al., Tissue tropism of Escherichia coli adhesins in human 
extraintestinal infections. Curr Top Microbiol Immunol, 1990. 151: p. 115-27. 
136. Pere, A., et al., Expression of P, type-1, and type-1C fimbriae of Escherichia coli 
in the urine of patients with acute urinary tract infection. J Infect Dis, 1987. 
156(4): p. 567-74. 
137. Castelain, M., et al., Fast uncoiling kinetics of F1C pili expressed by 
uropathogenic Escherichia coli are revealed on a single pilus level using force-
measuring optical tweezers. Eur Biophys J, 2011. 40(3): p. 305-16. 
138. Backhed, F., et al., Identification of target tissue glycosphingolipid receptors for 
uropathogenic, F1C-fimbriated Escherichia coli and its role in mucosal 
inflammation. J Biol Chem, 2002. 277(20): p. 18198-205. 
139. Autar, R., et al., Adhesion inhibition of F1C-fimbriated Escherichia coli and 
Pseudomonas aeruginosa PAK and PAO by multivalent carbohydrate ligands. 
Chembiochem, 2003. 4(12): p. 1317-25. 
140. Harshey, R.M. and A. Toguchi, Spinning tails: homologies among bacterial 
flagellar systems. Trends Microbiol, 1996. 4(6): p. 226-31. 
141. Chilcott, G.S. and K.T. Hughes, Coupling of flagellar gene expression to flagellar 
assembly in Salmonella enterica serovar typhimurium and Escherichia coli. 
Microbiol Mol Biol Rev, 2000. 64(4): p. 694-708. 
142. Kalir, S., et al., Ordering genes in a flagella pathway by analysis of expression 
kinetics from living bacteria. Science, 2001. 292(5524): p. 2080-3. 
143. Komeda, Y., Fusions of flagellar operons to lactose genes on a mu lac 
bacteriophage. Journal of Bacteriology, 1982. 150(1): p. 16-26. 
144. Komeda, Y., Transcriptional control of flagellar genes in Escherichia coli K-12. 
Journal of Bacteriology, 1986. 168(3): p. 1315-8. 
145. Kutsukake, K., Y. Ohya, and T. Iino, Transcriptional analysis of the flagellar 
regulon of Salmonella typhimurium. Journal of Bacteriology, 1990. 172(2): p. 
741-7. 
146. Macnab, R.M., Flagella and motility, in Escherichia coli and Salmonella 
typhimurium: Cellular and Molecular Biology, F.C. Neidhardt, et al., Editors. 
1996, ASM Press: Washington, DC. p. 123-145. 
147. Soutourina, O.A. and P.N. Bertin, Regulation cascade of flagellar expression in 
Gram-negative bacteria. FEMS Microbiol Rev, 2003. 27(4): p. 505-23. 
148. Mizushima, T., et al., Decrease in expression of the master operon of flagellin 
synthesis in a dnaA46 mutant of Escherichia coli. Biological & pharmaceutical 
bulletin, 1997. 20(4): p. 327-31. 
140 
 
149. Soutourina, O., et al., Multiple control of flagellum biosynthesis in Escherichia 
coli: role of H-NS protein and the cyclic AMP-catabolite activator protein 
complex in transcription of the flhDC master operon. Journal of Bacteriology, 
1999. 181(24): p. 7500-8. 
150. Shin, S. and C. Park, Modulation of flagellar expression in Escherichia coli by 
acetyl phosphate and the osmoregulator OmpR. Journal of Bacteriology, 1995. 
177(16): p. 4696-702. 
151. Clarke, M.B. and V. Sperandio, Transcriptional regulation of flhDC by QseBC 
and sigma (FliA) in enterohaemorrhagic Escherichia coli. Molecular 
Microbiology, 2005. 57(6): p. 1734-49. 
152. Krin, E., A. Danchin, and O. Soutourina, RcsB plays a central role in H-NS-
dependent regulation of motility and acid stress resistance in Escherichia coli. 
Research in microbiology, 2010. 161(5): p. 363-71. 
153. Shi, W., et al., DnaK, DnaJ, and GrpE are required for flagellum synthesis in 
Escherichia coli. Journal of Bacteriology, 1992. 174(19): p. 6256-63. 
154. Takaya, A., et al., The DnaK chaperone machinery converts the native FlhD2C2 
hetero-tetramer into a functional transcriptional regulator of flagellar regulon 
expression in Salmonella. Molecular Microbiology, 2006. 59(4): p. 1327-40. 
155. Hughes, K.T., et al., Sensing structural intermediates in bacterial flagellar 
assembly by export of a negative regulator. Science, 1993. 262(5137): p. 1277-80. 
156. Kutsukake, K. and T. Iino, Role of the FliA-FlgM regulatory system on the 
transcriptional control of the flagellar regulon and flagellar formation in 
Salmonella typhimurium. Journal of Bacteriology, 1994. 176(12): p. 3598-605. 
157. Ohnishi, K., et al., Gene fliA encodes an alternative sigma factor specific for 
flagellar operons in Salmonella typhimurium. Mol Gen Genet, 1990. 221(2): p. 
139-47. 
158. Donnelly, M.A. and T.S. Steiner, Two nonadjacent regions in enteroaggregative 
Escherichia coli flagellin are required for activation of toll-like receptor 5. J Biol 
Chem, 2002. 277(43): p. 40456-61. 
159. Bahrani, F.K., et al., Proteus mirabilis flagella and MR/P fimbriae: isolation, 
purification, N-terminal analysis, and serum antibody response following 
experimental urinary tract infection. Infection and Immunity, 1991. 59(10): p. 
3574-80. 
160. Rocha, S.P., J.S. Pelayo, and W.P. Elias, Fimbriae of uropathogenic Proteus 
mirabilis. FEMS Immunol Med Microbiol, 2007. 51(1): p. 1-7. 
161. Li, X., et al., Identification of MrpI as the sole recombinase that regulates the 
phase variation of MR/P fimbria, a bladder colonization factor of uropathogenic 
Proteus mirabilis. Molecular Microbiology, 2002. 45(3): p. 865-74. 
162. Mobley, H.L. and G.R. Chippendale, Hemagglutinin, urease, and hemolysin 
production by Proteus mirabilis from clinical sources. J Infect Dis, 1990. 161(3): 
p. 525-30. 
163. Bahrani, F.K., et al., Construction of an MR/P fimbrial mutant of Proteus 
mirabilis: role in virulence in a mouse model of ascending urinary tract infection. 
Infection and Immunity, 1994. 62(8): p. 3363-71. 
141 
 
164. Zunino, P., et al., Mannose-resistant Proteus-like and P. mirabilis fimbriae have 
specific and additive roles in P. mirabilis urinary tract infections. FEMS 
Immunol Med Microbiol, 2007. 51(1): p. 125-33. 
165. Li, X., et al., Use of translational fusion of the MrpH fimbrial adhesin-binding 
domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B 
subunit, as an intranasal vaccine to prevent experimental urinary tract infection 
by Proteus mirabilis. Infection and Immunity, 2004. 72(12): p. 7306-10. 
166. Scavone, P., et al., Nasal immunization with attenuated Salmonella Typhimurium 
expressing an MrpA-TetC fusion protein significantly reduces Proteus mirabilis 
colonization in the mouse urinary tract. J Med Microbiol, 2011. 60(Pt 7): p. 899-
904. 
167. Scavone, P., et al., Effects of the administration of cholera toxin as a mucosal 
adjuvant on the immune and protective response induced by Proteus mirabilis 
MrpA fimbrial protein in the urinary tract. Microbiol Immunol, 2009. 53(4): p. 
233-40. 
168. Pearson, M.M. and H.L. Mobley, Repression of motility during fimbrial 
expression: identification of 14 mrpJ gene paralogues in Proteus mirabilis. 
Molecular Microbiology, 2008. 69(2): p. 548-58. 
169. Simms, A.N. and H.L. Mobley, PapX, a P fimbrial operon-encoded inhibitor of 
motility in uropathogenic Escherichia coli. Infection and Immunity, 2008. 76(11): 
p. 4833-41. 
170. Li, X., et al., Repression of bacterial motility by a novel fimbrial gene product. 
EMBO J, 2001. 20(17): p. 4854-62. 
171. Mobley, H.L.T. and A.N. Simms, Multiple genes repress motility in 
uropathogenic Escherichia coli constitutively expressing type 1 fimbriae. Journal 
of Bacteriology, 2008. 190(10): p. 3747-3756. 
172. Kelley, L.A. and M.J.E. Sternberg, Protein structure prediction on the Web: a 
case study using the Phyre server. Nature Protocols, 2009. 4(3): p. 363-371. 
173. Roy, A., A. Kucukural, and Y. Zhang, I-TASSER: a unified platform for 
automated protein structure and function prediction. Nat Protoc, 2010. 5(4): p. 
725-38. 
174. Zhang, Y., Template-based modeling and free modeling by I-TASSER in CASP7. 
Proteins, 2007. 69 Suppl 8: p. 108-17. 
175. Owens, R.J., et al., The structure of NMB1585, a MarR-family regulator from 
Neisseria meningitidis. Acta Crystallographica Section F-Structural Biology and 
Crystallization Communications, 2009. 65: p. 204-209. 
176. Alekshun, M.N., et al., The crystal structure of MarR, a regulator of multiple 
antibiotic resistance, at 2.3 angstrom resolution. Nature Structural Biology, 2001. 
8(8): p. 710-714. 
177. Hong, M., et al., Structure of an OhrR-ohrA operator complex reveals the DNA 
binding mechanism of the MarR family. Molecular Cell, 2005. 20(1): p. 131-141. 
178. Kumarevel, T., et al., Crystal structure of the MarR family regulatory protein, ST 
1710, from Sulfolobus tokodaii strain 7. Journal of Structural Biology, 2008. 
161(1): p. 9-17. 
142 
 
179. Saito, K., et al., Mutations affecting DNA-binding activity of the MexR repressor 
of mexR-mexA-mexB-oprM operon expression. Journal of Bacteriology, 2003. 
185(20): p. 6195-8. 
180. Wilkinson, S.P. and A. Grove, Ligand-responsive transcriptional regulation by 
members of the MarR family of winged helix proteins. Curr Issues Mol Biol, 2006. 
8(1): p. 51-62. 
181. Park, P.J., ChIP-seq: advantages and challenges of a maturing technology. Nat 
Rev Genet, 2009. 10(10): p. 669-80. 
182. MacBeath, G. and S.L. Schreiber, Printing proteins as microarrays for high-
throughput function determination. Science, 2000. 289(5485): p. 1760-3. 
183. Tuerk, C. and L. Gold, Systematic evolution of ligands by exponential 
enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990. 
249(4968): p. 505-10. 
184. Ellington, A.D. and J.W. Szostak, In vitro selection of RNA molecules that bind 
specific ligands. Nature, 1990. 346(6287): p. 818-22. 
185. Djordjevic, M., SELEX experiments: new prospects, applications and data 
analysis in inferring regulatory pathways. Biomol Eng, 2007. 24(2): p. 179-89. 
186. Zhao, Y., D. Granas, and G.D. Stormo, Inferring binding energies from selected 
binding sites. PLoS Comput Biol, 2009. 5(12): p. e1000590. 
187. Jolma, A., et al., Multiplexed massively parallel SELEX for characterization of 
human transcription factor binding specificities. Genome Res, 2010. 20(6): p. 
861-73. 
188. Reiss, D.J. and H.L. Mobley, Determination of the target sequence bound by 
PapX, a repressor of bacterial motility, in the flhD promoter using SELEX and 
high-throughput sequencing. J Biol Chem, 2011. 
189. Roulet, E., et al., High-throughput SELEX SAGE method for quantitative 
modeling of transcription-factor binding sites. Nature Biotechnology, 2002. 
20(8): p. 831-5. 
190. Bulyk, M.L., Discovering DNA regulatory elements with bacteria. Nature 
Biotechnology, 2005. 23(8): p. 942-4. 
191. Zhang, Y., et al., Model-based analysis of ChIP-Seq (MACS). Genome Biol, 
2008. 9(9): p. R137. 
192. Bailey, T.L. and C. Elkan, Fitting a mixture model by expectation maximization to 
discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol, 1994. 2: p. 28-
36. 
193. Ott, M., et al., Analysis of the genetic determinants coding for the S-fimbrial 
adhesin (sfa) in different Escherichia coli strains causing meningitis or urinary 
tract infections. Infection and Immunity, 1986. 54(3): p. 646-53. 
194. Spurbeck, R.R., et al., Fimbrial Profiles Predict Virulence of Uropathogenic E. 
coli Strains: Contribution of Ygi and Yad Fimbriae. Infection and Immunity, 
2011. 
195. Zhang, X. and H. Bremer, Control of the Escherichia coli rrnB P1 promoter 
strength by ppGpp. J Biol Chem, 1995. 270(19): p. 11181-9. 
196. Kozarewa, I., et al., Amplification-free Illumina sequencing-library preparation 
facilitates improved mapping and assembly of (G+C)-biased genomes. Nat 
Methods, 2009. 6(4): p. 291-5. 
143 
 
197. Imai, M., et al., Uncoupling of the Cytochrome P-450cam Monooxygenase 
Reaction by a Single Mutation, Threonine-252 to Alanine or Valine - a Possible 
Role of the Hydroxy Amino-Acid in Oxygen Activation. Proceedings of the 
National Academy of Sciences of the United States of America, 1989. 86(20): p. 
7823-7827. 
198. McCarter, L.L., MotY, a component of the sodium-type flagellar motor. Journal of 
Bacteriology, 1994. 176(14): p. 4219-25. 
199. Rowbury, R.J., Regulatory components, including integration host factor, CysB 
and H-NS, that influence pH responses in Escherichia coli. Letters in applied 
microbiology, 1997. 24(5): p. 319-28. 
200. Slattery, M., et al., Cofactor binding evokes latent differences in DNA binding 
specificity between Hox proteins. Cell, 2011. 147(6): p. 1270-82. 
201. Wang, L., et al., Selection of DNA aptamers that bind to four organophosphorus 
pesticides. Biotechnology letters, 2012. 
202. Feng, H., et al., A SELEX-screened aptamer of human hepatitis B virus RNA 
encapsidation signal suppresses viral replication. PLoS One, 2011. 6(11): p. 
e27862. 
203. Zhang, K., et al., A novel aptamer developed for breast cancer cell 
internalization. ChemMedChem, 2012. 7(1): p. 79-84. 
204. Schutze, T., et al., Probing the SELEX process with next-generation sequencing. 
PLoS One. 6(12): p. e29604. 
205. Altschul, S.F., et al., Basic local alignment search tool. J Mol Biol, 1990. 215(3): 
p. 403-10. 
206. Langmead, B., et al., Ultrafast and memory-efficient alignment of short DNA 
sequences to the human genome. Genome biology, 2009. 10(3): p. R25. 
207. Wilbanks, E.G. and M.T. Facciotti, Evaluation of algorithm performance in 
ChIP-seq peak detection. PLoS One, 2010. 5(7): p. e11471. 
208. Djordjevic, M. and A.M. Sengupta, Quantitative modeling and data analysis of 
SELEX experiments. Phys Biol, 2006. 3(1): p. 13-28. 
209. Zimmermann, B., et al., Genomic SELEX: a discovery tool for genomic aptamers. 
Methods, 2010. 52(2): p. 125-32. 
210. Sampson, T., Aptamers and SELEX: the technology. World Patent Information, 
2003. 25(2): p. 123. 
211. McClure, W.R., Mechanism and control of transcription initiation in prokaryotes. 
Annu Rev Biochem, 1985. 54: p. 171-204. 
212. Gabanyi, M.J., et al., The Structural Biology Knowledgebase: a portal to protein 
structures, sequences, functions, and methods. J Struct Funct Genomics, 2011. 
12(2): p. 45-54. 
213. Sjostrom, A.E., et al., The SfaXII protein from newborn meningitis E. coli is 
involved in regulation of motility and type 1 fimbriae expression. Microbial 
pathogenesis, 2009. 46(5): p. 243-52. 
214. Hultdin, U.W., et al., Structure of FocB--a member of a family of transcription 
factors regulating fimbrial adhesin expression in uropathogenic Escherichia coli. 
The FEBS journal, 2010. 277(16): p. 3368-81. 
144 
 
215. Svensson, A., et al., Design and evaluation of pilicides: potential novel 
antibacterial agents directed against uropathogenic Escherichia coli. 
Chembiochem : a European journal of chemical biology, 2001. 2(12): p. 915-8. 
216. Nicholson, T.F., K.M. Watts, and D.A. Hunstad, OmpA of uropathogenic 
Escherichia coli promotes postinvasion pathogenesis of cystitis. Infection and 
Immunity, 2009. 77(12): p. 5245-51. 
217. Bonacorsi, S., V. Houdoin, and E. Bingen, [Virulence factors associated with E. 
coli neonatal meningitis]. Archives de pediatrie : organe officiel de la Societe 
francaise de pediatrie, 2001. 8 Suppl 4: p. 726s-731s. 
218. Mobley, H.L.T. and M.M. Pearson, Repression of motility during fimbrial 
expression: identification of 14 mrpJ gene paralogues in Proteus mirabilis. 
Molecular Microbiology, 2008. 69(2): p. 548-558. 
219. Mobley, H.L., et al., Pyelonephritogenic Escherichia coli and killing of cultured 
human renal proximal tubular epithelial cells: role of hemolysin in some strains. 
Infection and Immunity, 1990. 58(5): p. 1281-9. 
220. Harshey, R.M. and T. Matsuyama, Dimorphic transition in Escherichia coli and 
Salmonella typhimurium: surface-induced differentiation into hyperflagellate 
swarmer cells. Proceedings of the National Academy of Sciences of the United 
States of America, 1994. 91(18): p. 8631-5. 
221. Datsenko, K.A. and B.L. Wanner, One-step inactivation of chromosomal genes in 
Escherichia coli K-12 using PCR products. Proceedings of the National Academy 
of Sciences of the United States of America, 2000. 97(12): p. 6640-6645. 
222. Vigil, P.D., et al., Presence of Putative Repeat-in-Toxin Gene tosA in Escherichia 
coli Predicts Successful Colonization of the Urinary Tract. MBio, 2011. 2(3). 
 
 
